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SUMMARY
The risk of human immunodeficiency virus type-1 (HIV-1) infection and rate of progression
towards development of the acquired immunodeficiency syndrome (AIDS) is determined
by a combination of viral characteristics, immune function and host genetic variation.
Although mutations of the chemokine and chemokine co-receptor genes and allelic
variation of the major histocompatibility complex (MHC) have been studied extensively,
variation in these host genetic factors does not explain the differences in HIV/AIDS
susceptibility in all cases. This study represents the first analysis of new candidate genes
implicated in iron metabolism and immune function in relation to HIV-1 disease in the
African context. Both case-control association studies and genotype-phenotype
correlations were performed to determine the potential functional significance of genetic
variants that may be involved, either directly or indirectly, in susceptibility to HIV-1 disease
in the South African population.
Genotyping was performed to identify potentially important polymorphisms in the solute
carrier family 11 member 1 (SLC11A 1), haemochromatosis (HFE) and protein-tyrosine
phosphatase receptor-type C (PTPRC/CD45) genes in HIV-seropositive versus HIV-
seronegative individuals. This was followed by HLA-B27 genotyping in HIV-1 infected
individuals with known disease status to determine the potential impact of combined
genotypes for different mutations identified in the same study cohort. Preferential
association with any of the mutations screened for in the CCR5, SLC 11A1, HFE or CD45
genes were not detected in HLA-B27 positive individuals identified. These findings were in
accordance with the independent protective role of HLA-B27 in relation to disease
progression in HIV-1 infected individuals.
Although differences in allelic distribution were not significant between the study groups,
an apparently African-specific mutation 32A~G, identified in an exonic splicing silencer
element (ESS-1) of the CD45 gene, appeared to predominate in HIV-1 infected subjects
with WHO Class I disease status and slow progression to AIDS. This mutation was
present in 35.7% (5/14) of HIV-seropositive individuals with WHO Class I disease status,
whilst absent in 22 HIV-seropositive patients with rapid disease progression. This finding
may be related to differences in proportions of both CD4+ and CD8+ subsets observed
following flow cytometry (FACs) analys.s in two HIV-seropositive individuals with mutation
32A~G, compared with an HIV-seropositive individual without this mutation.
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Analysis of the iron-related SLC11A1 and HFE genes did not reveal significant
associations with modified risk of HIV-1 infection or progression to AIDS in our
predominantly African study population. However, the effect of the virus on iron
metabolism was demonstrated for the first time at the DNA level. Haemoglobin levels were
significantly reduced in both HIV-seropositive (P=O.004) and HIV-seronegative (P=O.02)
Black Africans with mutation IVS3-48c~g in the HFE gene, compared with mutation-
negative individuals in both groups. Since this effect was more pronounced in HIV-infected
individuals compared with controls, presence of the HFE mutation seems to result in an
even stronger effect on haemoglobin levels, which may be related to the acute phase
response following virus infection. This effect possibly results from genetic variation in a
nearby gene involved in innate immunity, most likely in the HLA region on chromosome 6.
It therefore seems possible that genetic variation in any of the host molecules involved in
response to infection could contribute to clinical outcome.
The significance of the multitude of host genetic factors investigated in this study, or
previously implicated in susceptibility to HIV-1 infection and disease progression, revealed
a complex interrelationship between the host and HIV-1. In some instances the disease
process following HIV-1 infection depends on combined effects of different mutations
occurring in the same individual, while independent effects of specific genes in conjunction
with environmental influences may explain diverse clinical outcomes in others.
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OPSOMMING
Die risiko vir menslike immuniteitsgebrek virus tipe-1 (MIV-1) infeksie en die progressie-
tempo vir ontwikkeling van die verworwe immuniteits gebrek sindroom (VIGS) word
hoofsaaklik deur fn kombinasie van virale eienskappe, immuunfunksie en gasheer
genetiese variasie bepaal. Alhoewel mutasies van die chemokien en chemokien ko-
reseptor gene en alleliese variasie van die major weefsel-verenigbaarheidskompleks
(MWVK) reeds omvattend bestudeer is, verklaar variasie van hierdie gasheer genetiese
faktore nie noodwendig verskille in vatbaarheid vir MIVNIGS in alle gevalle nie. Hierdie
studie verteenwoordig die eerste analise van nuwe kandidaatgene, geïmpliseer in yster
metabolisme en immuunfunksie in die konteks van MIV-1 siekte in Swart
bevolkingsgroepe. Beide gevalle-kontrole assosiasie-studies en genotipe-fenotipe
korrelasies is uitgevoer om moontlik betekenisvolle verwantskappe met genetiese variante
te bepaal, wat moontlik direk of indirek betrokke mag wees in vatbaarheid vir MIV-1 siekte
in die Suid Afrikaanse populasie.
Genotipering van die solute draer familie 11 lid 1 (SLC11A1), hemochromatose (HFE) en
protein-tirosien fosfatase reseptor-tipe C (PTFRC/CD45) gene is uitgevoer in beide MIV-
seropositiewe en MIV-seronegatiewe individue. Daaropvolgend is genotipering van die
menslike leukosien antigeen-B27 (MLA-B27) uitgevoer in MIV-1 geïnfekteerde individue
met bekende siekte-status, om die potensiële impak van gekombineerde genotipes te
bepaal vir verskillende mutasies wat in dieselfde studie populasie geïdentifiseer is.
Voorkeur-assosiasie is nie waargeneem vir enige van die mutasies waarvoor geanaliseer
is in die CCR5, SLC11A1, HFE of CD45 gene nie. Hierdie bevinding is in ooreenstemming
met die onafhanklike rol van MLA-B27 in verwantskap met siekte progressie in MIV-1
geïnfekteerde individue.
Alhoewel die alleelverspreiding van In Afrika-spesifieke mutasie 32A~GI wat in In
eksoniese splytingsdemper-element (ESS-1) van die CD45 geen geïdentifiseer is, nie
statisties betekenisvolle verskille getoon het tussen studiegroepe nie, is die mutasie
oorheersend waargeneem in MIV-1 geïnfekteerde individue met WGO Klas I siekte-
status en stadige progressie na VIGS. Hierdie mutasie was teenwoordig in 35.7% (5/14)
van HIV-seropositiewe individue met WGO Klas I siekte-status, terwyl dit afwesig was in
22 HIV-seropositiewe pasiënte met vinnige siekteprogressie.
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Hierdie bevinding mag moontlik verband hou met verskille in verhoudings van beide die
CD4+ en CD8+ substelle, soos waargeneem gedurende vloei sitometriese (VAS, FACs)
analise in twee HIV-seropositiewe individue met mutasie 32A---+G, in vergelyking met en
HIV-seropositiewe individu sonder hierdie mutasie.
Analise van die yster-verwante SLC11A 1 en HFE gene het nie betekenisvolle assosiasies
opgelewer met gemodifiseerde risiko vir MIV-1 siekte of progressie na VIGS in die
hoofsaaklik Swart studie-populasie nie. Die effek van die virus op ystermetabolisme is wel
vir die eerste keer op DNS vlak gedemonstreer. Hemoglobien vlakke was betekenisvol
verlaag in beide MIV-seropositiewe (P=O.004) en MIV-seronegatiewe (P=O.02) Swart
individue met die HFE geen IVS3-48C---+G mutasie, in vergelyking met mutasie-negatiewe
individue in beide groepe. Aangesien hierdie effek meer uitgesproke was in MIV-
geïnfekteerde individue as in kontroles, blyk dit dat die teenwoordigheid van die HFE
mutasie die hemoglobienvlakke tot engroter mate beïnvloed weens die akute fase respons
wat verband hou met die virusinfeksie. Hierdie effek kan moontlik toegeskryf word aan
genetiese variasie in ennaasliggende geen wat in aangebore immuniteit betrokke is, heel
moontlik in die MLA gebied van chromosoom 6. Dit wil dus voorkom asof genetiese
variasie in enige van die gasheer molekules betrokke by respons op infeksie kan bydra tot
die kliniese uitkoms.
Die belangrike rol van die veelvuldige gasheer genetiese faktore wat in hierdie studie
bestudeer is, of wat voorheen geïmpliseer is in vatbaarheid vir MIV-1 infeksie en siekte
progressie, het enkomplekse inter-verwantskap tussen gasheer en MIV-1 geopenbaar. In
sommige gevalle is die siekte-proses na MIV-1 infeksie afhanklik van gekombineerde
effekte van verskillende mutasies in dieselfde individu, terwylonafhanklike effekte van
spesifieke gene tesame met omgewings-invloede uiteenlopende kliniese uitkomste in
ander mag verklaar.
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CHAPTER I
INTRODUCTION
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1Chapter 1 INTRODUCTION
1. HIV/AIDS on the African continent
The human immunodeficiency virus (HIV) epidemic has recently passed its twentieth
anniversary, whilst investigation of the complexity of the virus, the mode of infection and
pathology of disease progression is continuing. Acquired immunodeficiency syndrome
(AIDS) is amongst the primary causes of mortality on the African continent
(http://www.who.intlinfectious-disease-reportlpages/ch1text.html). More than fifty million
people worldwide are presently infected with HIV, and more than fifteen thousand new
infections occur daily. The majority of individuals are from developing countries, with more
than thirty million HIV-infected people living in sub-Saharan Africa. Data from a survey in
2000 and annual data available since the beginning of the epidemic in South Africa,
indicated South African HIV prevalence rates rising from 0.7% in 1990 to 24.5% in 2000
(SA Dept. of Health 2001). The continuously increasing rates of HIV infection and
prevalence of AIDS in Sub-Saharan Africa are causing a rapid decline in life expectancy -
from seventy years of age to less than forty years of age. Although recent government
data indicated a stabilising HIV/AIDS prevalence rate in South Africa based on 2001
infection data, the most concerning is the projected drop in life expectancy to about 30
years of age for the continent by 2010.
The increased vulnerability to HIVand sexually transmitted infections has been proposed
to be directly associated with poverty, mainly due to urbanisation, modernisation and
privatisation. The situation is further exacerbated by factors such as poor nutritional status,
lack of health and social services, inadequate education, slow economic growth, and
devastating drought conditions. A direct consequence is the risk of tuberculosis infection,
causing about one-third of all AIDS-related deaths in developing countries. Activation of
latent tuberculosis infection is believed to be due to a weakened immune system, as the
risk of initial infection with tuberculosis is amplified by HIV-1 infection.
Whilst more than fifteen antiretroviral therapies have been accessible to most westernised
populations, the cost may still be too high for many in developing countries. The
continuously rising resistance rates of the virus towards treatment are also a major
concern, highlighting the importance of novel strategies in combating the disease.
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2Up to one in seven reported cases of HIV infection (14%) during 1999 and 2000 revealed
HIV strains with tenfold reduction in susceptibility to at least one class of antiretroviral
drug. This is compared to 3.5% of individuals infected with HIV strains with comparable
resistance levels between 1995 and 1998. The rising rates of therapeutic resistance would
result in a narrowing of the range of available therapeutic options in the continuous battle
with HIV infection. These resistance rates have been suggested to be due to the rapid
mutation potential of HIV, resulting in new quassispecies of HIV.
In addition to the relative inaccessibility of treatment to developing populations, the rapidly
rising rate of resistance to antiretroviral therapy, the absence of a preventative vaccine,
and the lack of proper education targeting behaviour appear to be major contributing
factors in the spread of HIV. Therefore, a possible intervention in the pandemic would be
prevention efforts targeting education and behaviours that put individuals at risk for
infection. Some African countries have maintained relatively low rates of infection because
of early preventative efforts in educating people about the disease and reducing the risk of
infection via low-cost interventions. These include voluntary testing to determine HIV
status and counselling.
Since the beginning of the HIV/AIDS epidemic, fresh insights have been provided
regarding the variation in risk towards infection, as well as development of resistance by
the virus to current therapies and development of complications by the host to the existing
therapies. This has been substantiated by studies involving pharmacogenetic approaches,
the molecular functioning of the virus, as well as case-control studies investigating the risk
towards susceptibility to HIV-infection and progression to full-blown AIDS. It is of great
importance to investigate novel approaches to HIV/AIDS, especially determining the risk of
susceptibility to HIVand the progression to full-blown AIDS. Application of such
information for development of new means or therapies to combat infection, or at least to
prolong life expectancy, has become a priority.
The basic mechanisms of disease pathology will be discussed, with particular focus on
relevant cells and molecules involved in the pathogenesis of HIV/AIDS. These molecules
in their respective ways are directly or indirectly involved in susceptibility and/or resistance
patterns to disease, and all form part of the complex pathology. It has further been
established that various genetic components involved in certain of these pathways are
crucial in resistance or susceptibility to infection and/or progression of disease.
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3This chapter serves as a background to the consecutive discussions investigating
involvement of certain host genetic components in HIV/AIDS disease pathology in South
African ethnic populations.
2. Human Immune Virus type 1 (HIV-1) Pathogenesis and Human Immune
Function - An Overview
The pathogenesis of human immune virus type 1 (HIV-1) infection is highly variable, and
factors that influence susceptibility to infection and rate of disease progression involve a
combination of viral, host, and environmental factors (Fauci 1996). The multifactorial
nature of HIV disease pathogenesis is reflected by the highly variable rates of disease
progression observed in HIV-infected individuals.
Whilst most individuals infected with HIV develop AIDS symptoms within 10 years, about
1-5% remains relatively healthy for 15 years or more (long-term non-progressors, LTNP),
and others progress to AIDS within the first 2-3 years after infection (fast or rapid
progressors). Resistance to infection have been observed in a limited number of
individuals, and some appear to even eliminate the virus.
Host factors that play an important role during modulation of the rates of disease
progression facilitate widely varying clinical outcomes, even in individuals who were
apparently infected from a common source (Liu et al. 1997). The complexity of host
genetic effects is characterised by the involvement of variants with very subtle, although
significant consequences on gene expression or protein function. Although significant
advancement had been made in terms of the proper understanding of the roles of potential
host factors involved in disease acquisition and progression, this represents only a limited
understanding of the complexity of the disease and progression thereof.
Currently no standard practice exists that takes into account the genetic profile of
individuals (i.e. genotypes at loci known to be associated with rate of disease progression).
Assessment of such factors should be a priority to properly understand disease
mechanisms in light of the pandemic. Prediction of disease outcome on an individual basis
will only be possible by a better understanding of the gene-environment interactions in HIV
disease.
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42.1. HIV Infection and Host Cellular Response
Initial cellular target cells of HIV-1 infection are the Langerhans cells, which are tissue
dendritic cells found in the lamina propia subjacent to the cervicovaginal epithelium (Spira
et al. 1996) or the nasopharyngeal tonsil and adenoid tissues (Goldberg et al. 1998), rich
in cells of dendritic origin. These cells fuse with cells involved in the cellular immune
response, and spread to deeper tissues. Viral particles can be detected from draining the
iliac lymph nodes within two days after infection.
2.1.1. HIV Fusion and Cell Entry: Mediated by its own Envelope Structure and Host
Receptor Molecules
Fusion and entry of HIV-1 into target cells (primarily T-cells and macrophages) is mediated
by both determinants of the viral envelope (reviewed by Wyatt and Sodroski 1998) and
host proteins expressed on the surface of CD4+ lymphocytes or macrophages attracted to
areas of inflammation caused by HIV-1 infection. It has been established that primarily
CD4+ and chemokine co-receptors are involved in this mode of entry. Infection by HIV-1
takes place by direct fusion of virus cell surface molecules and CD4+ molecules expressed
on the target cell membranes (Dalgleish et al. 1984, Klatzmann et al. 1984, Maddon et al.
1986).
The HIV-1 viral envelope (Env) consists of two non-covalently associated subunits after
cleavage of a gp160 precursor protein: a) a heavily glycosylated external gp120 subunit,
derived from the N-terminal portion of gp120 and containing the CD4 binding site, and b)
the membrane-spanning gp41 subunit, derived from the C-terminal portion of the precursor
with an N-terminal hydrophobic fusion peptide which is directly involved in membrane
fusion (Wyatt and Sodroski 1998). Native Env expressed on the surface of the virion or the
infected cell is a trimeric structure containing three gp120/gp41 complexes associated
non covalently via gp41.
Associations between the co-receptor and CD4+ are enhanced in the presence of gp120,
although they occur to some extent in the absence of gp120. Furthermore, soluble gp120
binds weakly to co-receptors expressed on cells, with greatly increased affinity upon CD4
binding. This mechanism is referred to as CD4-dependent entry.
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relatively conserved regions, C1-C5 (Starcich et al. 1986). Fusion specificity is primarily
determined by the V3 loop (Chesebro et al. 1991, Hwang et al. 1992, Shioda et al. 1992),
and dependent on the tropism of the infecting HIV strains. Interaction with CD4+ takes
place via relatively conserved amino acid residues in the V3 loop, which is the outermost
principal neutralising determinant of the envelope. This binding is in concert with V1, V2,
V4 and C4 causing the Env complex to undergo pH-independent CD4-induced
conformational changes (Sattentau et al. 1993), thereby creating high affinity binding with
the CD4+ molecule by exposure of the previously hidden co-receptor binding site. The
hypervariabie loops protrude over the conserved residues (Moore et al. 1996), thus
sheltering this presumably highly immunogenic region from host defences. This probably
accounts partially for the ability of HIV to evade an effective immunological response, and
permitting entry of the retroviral genome into the cytoplasm for viral replication to
commence.
Although cell hybrid studies conducted on HIV-entry supports this proposed mechanism,
binding of the HIV envelope to the target cell requires the presence of a co-receptor on the
surface of the target cell (usually either CCRS and/or CCR4, dependent on stage of
infection), in addition to the CD4+ molecule. Interaction with chemokine co-receptors
CCRS and CCR4 follows the steric changes (conformation or charge) of the conserved
receptor-binding site via the V3 loop (Moore et al. 1998), although the binding of gp120
has been shown to be unrelated to physiological (sensitisation) state of the receptor. This
observation suggested that the underlying transduction pathways are relatively
unimportant in the HIV entry mechanism (Aramori et al. 1997).
After infection with HIV-1 and replication, cells expressing the gp120 proteins attract and
bind other CD4+ expressing primary T-cells, creating a syncythium. A syncythium (plural =
syncythia) is the clumping together of T-cells expressing the viral Env protein, encoded by
the HIV viral RNA after integration into the human genome, and being multinucleated (also
referred to as "giant celis").
Although the CD4-dependent mechanism is the major route for HIV-1 fusion and infection,
Env/co-receptor interactions have however been reported in the absence of CD4+
(referred to as the CD4-independent mechanism). The CD4-independent entry pathways
appear to be relatively inefficient.
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to bind CD4+, which markedly enhances functional interaction between gp120 and co-
receptor. However, the significance of CD4-independent Env/co-receptor interactions in
vivo is questionable.
An intriguing hypothesis deduced from these findings is that the evolutionary predecessor
of HIV-1 strictly used the chemokines for entry, and that the CD4+ requirement evolved
later as a means of conferring greater target cell specificity, as well as protecting the co-
receptor binding region from the humoral immune response system.
2.1.2. HIV-1 tropism and Viral Entry: Specificity of Infection of Different Cell Types via
Specific Receptors
Nomenclature to distinguish between different HIV strains was originally based only on
phenotypic properties, as represented by two classification systems.
As depicted by figure 1, some isolates of HIV-1 show efficient infectivity for continuous
CD4+ T-cell lines, but poor infectivity for macro phages. These isolates are designated T-
cell line tropic (T-tropic), and are generally syncythium-inducing (SI) strains. Some HIV-1
strains show the opposite with preferential infection of macrophages, and are referred to
as macrophage-tropic (M-tropic), which are usually non-syncythium inducing (NSI) strains.
W ¥
M-TrooicINSI) T-TrooiclSI)
; t\ }~:::::._.....-:~ M0 = Macrophage
CCR5 CCR4 CD4+ 1° = Primary
Figure 1. Proposed model for chemokine co-receptor usage and viral entry. M-tropic (NSI) viruses use
the CCRS receptor, expressed in macrophages (M0) and primary (10) T-cells. T-tropic (SI)
viruses use the CCR4 receptor, expressed on primary T-cells. Viruses enter after binding of
both CD4+ receptor and chemokine receptor by fusion with the cell membrane. Cells with the
32 base pair deletion (CCRM32) do not express CCRS, and although M-tropic viruses can
bind CD4+, viral entry is not possible.
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are designated dual-tropic. Viral isolates from peripheral blood, isolated shortly after
infection and during the asymptomatic period, are predominantly M-tropic.
Some shortcomings of these classification systems have however been pointed out.
Primary infections with T-tropic (SI) strains, among others, and failure to confirm any
distinctive tropism for HIV-1 isolates in vitro have been reported (Stent et al. 1997). The
ability of activated T-cells to express both CCR5 as well as CCR4 and allow M-tropic
strains to replicate (Trkola et al. 1997) further complicates the concept of tropism. Also,
macrophages or monocytes show expression of CCR4 in addition to CCR5, although they
do not support replication of T-tropic (SI) strains (Yanjie et al. 1998). T-tropic (SI) strains
typically display higher cytopathic effects in vitro, suggesting that they may have a
particularly important role in the decline of CD4 T-cells in vivo, which is the hallmark of
AIDS. Thus, as the infection progresses towards AIDS, predominantly T-tropic (SI) viruses
can be isolated from patients.
Further investigation of these phenotypic properties indicated close correlation with the
use of specific co-receptors for productive HIV infection. Although all HIV-1 strains infect
and replicate in activated primary CD4+ T lymphocytes, various co-receptors are required
for entry into T-cells and macrophages/monocytes. Transmission studies indicated that
initial infection was almost invariably established by M-tropic (NSI) strains, using the CCR5
co-receptor to gain entry in macrophage/monocyte cell lines (Simmons et al. 1996).
However, strains relying on a broader range of co-receptors may develop during the
course of the infection (Connor et al. 1997). Therefore, highly pathogenic SI strains with a
preference for the CCR4 receptor on the surface of T-cells, can be isolated prior to the
development of AIDS in approximately 50% of all cases (Karlsson et al. 1994). Although
the co-receptor binding residues are highly conserved, the extreme mutation rate of HIV in
combination with the duration of infection allows for strains with other tropisms to develop,
further contribute to the complexity HIV disease pathogenesis.
Supported by these observations, construction of a simplified model of molecular events
during HIV entry was proposed to yield a more simplified HIV-1 nomenclature system
(Berger et al. 1998). This facilitated revision of the HIV-1 phenotype to indicate co-receptor
usage, rather than the less biochemically defined characteristics of target cell tropism or
syncythium-inducing properties (Adopted at the Gordon Research Conference on
Chemotactic Cytokines, June 23-28, 1996).
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receptor and corresponding to M-tropism (NSI), is referred to as R5 variants. For HIV-1
variants specific for CCR4 (or CXCR4) co-receptor binding and corresponding to being T-
tropic (SI), reference is made to as X4 variants. Similarly, variants using both CCR4 and
CCR5 as co-receptors (thus with dual-tropism), are referred to as R5X4 variants.
Development of both the X4 and R5X4 variants is potentially due to the extreme mutation
rate of HIV, in concert with the duration of infection. The latter is responsible in the late
stage of disease, yielding a rapid decline of CD4+ T-cells and the subsequent breakdown
of the immune system, which is indicative of the onset of AIDS.
2.2. Host Mediators of HIV Infection: The Chemokinesand Chemokine Receptors
Discovery of chemokines and their receptors have greatly expanded the knowledge of host
factors that form part of the pathogenesis of HIV-1 and the progression to AIDS. Clues that
chemokine-related events are important in HIV-pathogenesis initially came from work
showing that high levels of chemokines could inhibit HIV replication in vitro (Cocchi et al.
1995), which proposed that chemokines might prevent HIV infection by binding to the
elusive HIV cofactor. The general mechanisms of viral infection and pathogenesis
involving these cofactors will be described, to further the understanding of basic
mechanisms of action of these chemokines and their receptors.
Chemokines (chemotactic cytokines) are small serum protein molecules with molecular
weights ranging between 7 and 15 kDa, and -68-120 amino acids in length. The
chemokines are all related in amino acid sequence. They are produced by a variety of
cells and their function is important in the inflammatory process (Baggiolini et al. 1997),
where they induce migration of leukocytes. Chemokines function primarily as
chemoattractants for leukocytes, recruiting monocytes, neutrophils and other effector cells
from the blood to sites of infection. These biological molecules are released by many
different cell types, and serve to guide cells involved in innate immunity, including
lymphocytes in adaptive immunity. Functioning primarily during inflammation, the
chemokines direct cellular movement in the body from the blood into tissues and to the
appropriate location within each tissue. Activation of circulating cells is facilitated by the
chemokines, causing them to bind to the endothelium and initiating leukocyte migration
across the endothelium. Once a cell has crossed the endothelium, it is capable of
responding to a new set of chemokines, which directs its migration through the tissues.
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9Three major functions exist for the chemokines: they 1) act as biological messengers,
recruiting leukocytes to injured or diseased tissue by chemotactic activity along a
chemokine concentration gradient and activation of leukocytes, 2) playa regulatory role in
leukocyte maturation and development of lymphoid tissues, and 3) have a role in infectious
disease susceptibility or pathogenesis.
Chemokines form part of the seven transmembrane G-protein-coupled receptor super-
family (Murphy 1996), which is the largest receptor superfamily in the human genome and
are intracellularly linked to G-proteins, consist of a major group and a minor group
(reviewed by Rollins 1997), and are sub-divided into four classes, based on cysteine
motifs near the N-terminus (Table 1). Although not certain for all classes, respective
signalling functions are as indicated.
Table 1. Chemokines are divided into two groups and four classes, based on cysteine-motifs near
the N-terminus (adapted from Rollins 1997).
Group & Class Type Characteristics Signalling Function
Major Group
Class I 'a-' or CXC two cysteines, separated by mainly neutrophils
chemokines a single residue
Class /I '~-' or CC two adjacent cysteines signalling other
chemokines leukocytes
Minor Group
Class 11/ C chemokines one single cysteine
Class IV CX3C chemokines first two cysteines, separated
by three residues
Leukocyte populations have specific receptors for appropriate chemokines. Chemokine
receptors are all integral membrane proteins containing seven membrane-spanning
helices. Most chemokines act on more than one receptor, and most receptors will respond
to several chemokines. The receptors are selectively expressed on particular populations
of leukocytes, and this determines which cells can respond to signals coming from the
tissues. The profile of chemokine receptors on a cell depends on its type and state óf
differentiation. For example, all T cells express CCR3, whereas T helper-2 (TH2) cells.
preferentially express CCR3, and T helper-1 (TH1) cells CCRS and CXCR3.
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Further, chemokine receptors are functional during microbial infection, and are referred to
as chemokine co-receptors as it functions in concert with other molecules involved in
microbial entry, for example CD4+.
Why do viruses need co-receptors?
Viral entry into the target cells is critically dependent on the interaction between the
surface proteins of the virus and those on the cell membrane (Feng et al. 1996a, Samson
et al. 1996a). As described earlier, initial adherence of the virus is passive to a receptor
protein on the cell surface, followed by conformational changes to improve binding, and
finally penetration. Entry of the viral genome into the cytoplasm takes place for viral
replication to commence. Inhibition of HIV-entry may however be facilitated by chemokine
receptor blockade, desensitisation, sequestration, or internalisation: either through
alterations in receptor affinity; or by inhibiting postbinding steps (Oravecz et al. 1996), such
as phosphorylation through G-coupled mechanisms. Before the link between HIVand
chemokine receptors had been established, these molecules were known as seven
transmembrane-spanning cell-surface proteins or seven transmembrane (7TM) receptors.
Figure 2 shows the basic chemokine receptor (co-receptor) structure (reviewed in Broder
and Collman 1997).
extracellular
cytoplasm
region
• Phosphate
o Carbon CCCH - -----.....-
Figure 2. Structure of the seven-transmembrane chemokine receptor (co-receptor) proteins, facilitating
viral entry into CD4+ target cells (modified from Broder and Collman 1997).
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Receptors for chemokines comprise a subfamily within the G-protein-coupled receptor
super-family. The receptor is topologically arranged with seven characteristic serpentine-
like transmembrane segments, the N-terminus and three extracellular loops, and the C-
terminus and three intracellular loops tMurphy 1994a,b, 1996, Strader et al. 1994). The
negatively charged acidic extracellular N-terminal domain is proposed to be involved in
ligand binding, while the basic C-terminal domain may be a target for phosphorylation by
G-protein coupled receptor kinases following ligand binding. The membrane-spanning
domain consists of seven a-helices containing three intracellular loops and three
extracellular loops composed of hydrophilic amino acids. Disulfide bonds are formed by
highly conserved cysteine residues between the first and second extracellular loops, and
between the N-terminal domain and third extracellular loop. These bonds are thought to
confer a barrel shape, bringing the extracellular domains into close proximity.
In the assumption that Env probably makes initial contact with the extracellular domains,
most focus has been on these regions (Alkhatib et al. 1997, Doranz et al. 1997, Dragic et
al. 1998, Reeves et al. 1998, Wang et al. 1998 as examples). Each extracellular region
has been implicated in co-receptor function, with the N-terminal segment playing a
particularly important role in ligand binding and leukocyte signalling. The transmembrane
and/or intracellular domains however also critically influence activity, perhaps by affecting
display of the extracellular regions in addition to activation of intracellular signalling
pathways. Although the two major chemokine receptors, CCR5 and CCR4, share only
about 30% amino acid homology (including conserved amino acid sequences), they
probably share similar membrane topology.
Identification of the chemokines and their receptors was preceded by the identification of
soluble factors from CD8+ T-cells that control HIV infection in vitro (Walker et al. 1986).
Although further receptors have been identified, the principal chemokine receptors for
either T-tropic or M-tropic strains of HIV-1, are CCR4 (Feng et al. 1996a) and CCR5
(Alkhatib et al. 1996, Choe et al. 1996, Deng et al. 1996, Doranz et al. 1996, Dragic et al.
1996) respectively. It was recently shown in the HIV-1 subtype C strains, predominating in
South Africa, that some of these strains could use both CCR5 and CCR4 or alternative
receptors (Cilliers et al. 2003). These observations are relevant in understanding the rapid
spread of HIV-1 subtype C in the developing world and for the design of intervention and
treatment strategies.
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eeR5
CCR5 (fifth receptor for the ee chemokines) was identified as a receptor for three p-
chemokines (or CC chemokines) RANTES lregulated on _êctivation, normal t ~xpressed
and secreted), MIP-1a and MIP-1p (macrophage inflammatory 12rotein 1a and 1p,
respectively) (Combadiere et al. 1996a, Deng et al. 1996, Raport et al. 1996, Samson et
al. 1996a). As it appears that the co-receptors merely serve as anchors for HIV on the cell
surface, the suppressive effect in primary T-cells by RANTES, MIP-1a and MIP-1p on HIV
replication stems from their ability to occupy and/or internalise the receptor rather than
from their physiological effect on the cell.
CCR5 is utilised as a co-receptor by M-tropic (NSI) R5 variants of HIV-1 early in the
course of infection. In addition to the involvement of the mentioned p-chemokines,
investigation of the possible involvement of other chemokine receptors in the entry
mechanism of HIV into cells demonstrated the involvement of CCR3 and CCR2b (Doranz
et al. 1996). These p-chemokines were the first chemokines shown to act as soluble
inhibitors of HIV in vitro, are released by CD8+ lymphocytes (Cocchi et al. 1995), and bind
to and block HIV-1 infection by binding putatively to CCR5. Individuals resisting HIV
infection or progression to AIDS had abnormally high levels of these chemokines.
eeR4
CCR4 (fourth receptor for the ee chemokines, CXCR4, or 'fusin' as it was referred to
originally) was shown to be a co-receptor for T-tropic (SI) X4 and R5X4 variants of HIV-1,
which predominate in later stages of infection (Feng et al. 1996a). This phenomenon was
supported by the observation that co-expression with CD4+ rendered human cells
permissive for Env-mediated cell fusion and infection of primary CD4+ T-cells. The CCR4
co-receptor was further shown to be specific for the functional chemokines SDF-1a and
SDF-1p, formed by alternative splicing (Bleul et al. 1996, Oberlin et al. 1996), because of
the ability of SDF-1 (stromal derived factor-1) to inhibit T-tropic (SI) X4 HIV-1 strains
selectively.
The exact mechanisms for the CCR4 and CCR5 chemokines as co-receptors for HIV-1
entry have not been clearly defined together with CD4 binding (Wain-Hobson 1996).
However, it appears to involve interactions of the viral V3 loop and other parts of the outer
envelope protein gp120 with extracellular domains of CCR5 or CCR2b.
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This may involve multistep interactions with CD4+, the chemokine receptor and other cell
surface components (Lapham et al. 1996).
CCR3 and CCR2
Subsequent to several studies reporting on CCR3 being a minor co-receptor and with a
limited number of HIV-1 isolates that can function with CCR3, compared to CCRS, it was
indicated that CCR3 has comparable activity with CCRS and/or CCR4 and function with a
broad range of isolates (Rucker et al. 1997, Barzan et al. 1998). It has further been shown
that some HIV isolates may even use both CCRS and CCR4 co-receptors, in addition to
CCR3 or CCR2b (Doranz et al. 1996).
CCR3 was originally reported to be specific to eosinophils (Combadiere et al. 1995),
although it has been reported that brain microglia express CCR3 along with CCRS. This
suggested that either molecule could mediate HIV-1 entry into microglia (He et al. 1997)
with development of neurological disease (HIV encephalopathy), resulting from HIV
infection in the brain. In contrast, CCR2 is highly expressed on blood monocytes and
macrophages, and exists in two isoforms, CCR2a and CCR2b (Combadiere et al. 1995).
Further studies suggested that alternate pathways could be available for HIV entry by
some strains in primary macrophages (Rana et al. 1997), indicating possible inclusion of
the involvement of CCR2b.
Other major chemokine receptors
Although the relative importance and contribution to HIV replication and cellular pathology
is not fully clear, a wide array of chemokine receptors acting as co-receptors have been
identified. Table 2 shows a summary of these cofactors, along with a brief description of
certain co-receptors that have been identified to play an active role in the inflammatory
process of HIV infection.
From several studies involving chemokine co-receptors, absence of activity in HIV
infection has been noted for some, for example CCR6 and CXC chemokine receptors
other than CXCR4, and several other chemokine receptor-like orphans. Additional to the
mentioned human proteins, certain other HIV co-receptors have been identified with
activity in HIV-1 infection. These include CCR2b, CCR3, CCR8, CCR9, CX3CR1; and the
chemokine receptor-like orphans STRL33/Bonzo, GP1S/BOB and Apj.
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Another CC chemokine co-receptor (US28), encoded by human cytomegalovirus (Rucker
et al. 1997, Pleskoff et al. 1997) has been indicated in active HIV infection. These
observations suggest the possibility of other as yet unidentified, but related seven
transmembrane molecules supporting HIVentry, because of the ability of some isolates to
promiscuously utilise a broad range of co-receptors. Thus, identification of strategies to
block infection via CCRS or CCR4 may result in selection for variants with enhanced ability
to enter by alternative co-receptors.
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Table 2. Summary of chemokine receptors and their ligands: tissue distribution and pathogens
(adapted from McNicholi et al. 1997, with modification)
Chemokine receptors
(Old names)"
Ligands Tissue
distribution
Pathogens b
CC Receptors
CCR1 (CC CKR1)
CCR2A (MCP-1 Ra)
RANTES, MIP-1a, MCP-2, MCP-3 Monocytes, T-cells HIV-1
MCP-1, MCP-3 T-cells, Basophils,
Monocytes
Eotaxin, Eotaxin-2, RANTES,
MCP-2, MCP-3, MCP-4
Eosinophils, Basophils,
Microglial Cells, and
possibly Monocytes;
little expression in
Peripheral Blood
T-lymphocytes or
Dendritic cells
HIV-1(NSI)
HIV-1(NSI)
CCR2B (MCP-1 Rb)
CCR3 (CKR3)
MCP-1, MCP-2, MCP-3, MCP-4
CCR4 (CXCR4) TARC, RANTES, SDF-1
MIP-1a, MCP-1, MDC
Basophils, T-cells HIV-1(SI)
CCRS C (CC CKRS) RANTES, MIP-1a, MIP-1~ Monocytes, Dendritic Cells HIV-1
Microglial Cells, T-cells (SI,NSI)
HIV-2, SIV
CCR-S 1-309,MIP-~ Monocytes, Thymocytes HIV-1
CCR9 Unknown PBMC HIV-1
CXC Receptors
CXCR1 (lL-S RA) IL-S Neutrophils, NK cells
CXCR2 (IL-S RB) IL-S, MGSA, gro-, NAP-2,
IP-10, ENA-7S, Mig
CXCR3 IP-10, Mig Activated T-cells
CXCR4 (Fusin, LESTR, SDF-1 Wide: CD4+ and CD4- HIV-1(SI),
HUMSTR) cells, Monocytes, HIV-2
Macrophages, Dendritic
cells, B cells; other
tissues, e.g. brain,
lung, spleen
CC/CXC Receptor
DARC (Duffy Antigen) RANTES, MCP-1, TARC, Endothelial Cells, Plasmodium
IL-S, MGSA, gro-, etc. Erythrocytes vivax
.... .f(eont..)
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Table 2 (cont..)
Chemoklne receptors
(Old names)"
Ligands Tissue
distribution
Pathogens b
Othersd
STRL33 NO Lymphoid Tissues and HIV-1
activated T-cells
Fibroblasts infected HIV-1
with CMV
T-lymphocytes,
Polymorphonuclear cells
Monocytes, Macrophages
Neutrophils, Monocytes,
Brain, Liver, Lung, Skeletal
Muscles
Thymus, Spleen
Neural and Lymphoid Tissue
Wide: incl. cells of
hemopoietic origin
B-Iymphocytes
B-Iymphocytes
NO
T-cells, monocytes, HIV-1(SI),
placental cells HIV-2, SIV
T-Iymphocytes, colon
PBMC, brain
HCMV-US28 MIP-1, RANTES
ChemR1 NO
Chem R23 Unknown
CMKBRL1 NO
TER1 NO
V28 NO
02S201E NO
BLR1 NO
EBI1 NO
GPR1,2,5 NO
BONZOI STRL33 Unknown
BOB/GPR-15 Lymphotaxin
Apj Unknown
a New nomenclature for CC and CXC chemokine receptors was adopted at the Gordon Research Conference on
Chemotactic Cytokines, June 23-28, 1996.
b Pathogens using this receptor for infection.
c The 32 bp deleted allele of CCR5 has been referred to as CCR5-2, or CCR5t.32.
d Chemokine receptor-like genes whose predicted proteins have 7 transmembrane domains.
Abbreviations: BLR1, Burkitt's lymphoma receptor-1; CMKBRL 1, Chemokine receptor like-1; OARC, duffy anti
genlreceptor for chemokines; EBI1, Epstein-Barr virus-induced receptor; ENA78, epithelial-derived
neutrophil-activating peptide-78; GPR, G protein coupled receptor; gro, growth related gene product;
HCMV, human cytomegalovirus; HUMSTR, human serum transmembrane segment receptor; IL,
interleukin; IP-10, interferon-gamma inducible 10kO protein; LESTR, leukocyte-expressed seven-
transmembrane-domain receptor; MCP, monocyte chemotactic protein; MOC, macrophage-derived
chemokine; Mig, monokine induced by interferon gamma; MIP, macrophage inflammatory protein;
NSI, non-syncythium inducing; N/A, not applicable; NAP-2, neutrophil- activating protein-2; NO, not
determined; RANTES, regulated on activation, normal T-cell expressed and secreted; PBMC,
peripheral blood mononuclear cells; SOF-1, stromal cell-derived factor-1; STRL33, seven
transmembrane-domain receptor from lymphocyte clone 33; TARC, thymus and activation regulated
chemokine.
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3. Host genetics and resistance or susceptibility to microbial infection
A rapid transition in the understanding of the involvement of genetics and genomics in
infectious disease pathology has been achieved over the past decade. Most human
populations are affected by microbial infections, which is especially true for developing
countries where some infections may predominate. Varying clinical outcomes are often
seen between individuals or populations, ranging from asymptomatic to severe disease
pathogenesis. Some pathological disorders may become apparent within days or weeks,
whereas others are detected only after a number of years of infection. For the majority of
infections, only a proportion of individuals exposed to the pathogen become infected with
consecutive development of clinically evident disease.
It has been suggested that the variation between individuals is mainly due to combination
effects of host genes and proteins, controlling the quality and possibly quantity of host-
parasite interaction and human immune responses. Environmental factors, density and
distribution of the infecting organism, as well as differing susceptibilities amongst different
ethnic groups due to genetic differences, may all contribute significantly to the disease
outcome. The phenotypic and/or genetic characteristics of the infecting organism itself
however also play an important role in disease pathogenesis.
Assessment of the importance of host genetics in disease development has been
complicated by the multiplicity of environmental factors. For example, nutritional
requirements can be modulated by genetic mechanisms that might further affect microbial
transmission. Discovery of genetic mechanisms of both host and pathogen associated
with infectious disease pathology, and elucidating the involvement of environmental
factors in the genetic mechanisms that underlie acquisition of infectious disease, may
therefore aid in development of novel therapeutic strategies.
Speculation of polygenic control of infectious disease susceptibility has been confirmed
recently by identification of several genetic regions containing genes that determine
susceptibility to Leishmania major, the agent for cutaneous leishmaniasis in humans
(Roberts et al. 1997a).
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Further, infectious diseases can act as strong selective influences in moulding human
evolution and population structure. It was established that the heterozygous advantage of
mutant alleles compensate for the deleterious effect of homozygotes in the face of malaria
challenge, associated with sickle cell anaemia and thalassemia (Allison 1969, Flint et al.
1986, Hili et al. 1987, Weatherall et al. 1987, Clegg and Weatherall 1999). The high
prevalence of mutated alleles of the j3-globin gene in areas of high malaria endemicity
confirmed that this gene provided protection against severe malaria. Using similar
strategies, it was demonstrated that certain HLA haplotypes and TNFo. alleles (McGuire et
al. 1994, Kroeger et al. 1997, Abraham and Kroeger 1999) could also be responsible for
modified host susceptibility to malaria.
At present no vaccines exist towards therapy of many of these pathogenic diseases.
Preventative therapies in general are often inadequate, mainly because of economic
considerations and toxicity of drugs used in the treatment regimens. The fact that
evolution of the infecting organism also plays an important role in the pathogenesis
suggests proper assessment of the potential host genetic mechanisms that could
contribute to increased susceptibility or resistance to microbial infection.
As with most infections, no standard practice presently exists for HIV/AIDS with regard to
the prediction of disease outcome on an individual basis, taking into account the genetic
profile (i.e. genotypes at loci associated with rate of disease progression) of individuals
subjected to functional studies for immune responsiveness to HIV-1. This would only be
possible with a better understanding of the various effects on HIV disease. Such an
approach was proposed recently by Carrington and co-workers (Carrington et al. 2001),
which may clarify the critical steps required in the disease pathogenesis, thereby providing
novel targets for vaccines or chemotherapy.
Various host genetic mechanisms, which could potentially form integral parts in novel
treatment strategies towards HIV infection and/or disease progression to AIDS, will be
discussed.
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3.1. Host genes and HIV-1 infection and progression to AIDS
Significant differences in the rate of disease progression have been observed in
longitudinally followed HIV-infected persons since the beginning of the HIV epidemic.
Identification of persons who were persistently exposed to HIV but remained uninfected
facilitated studies of the effect of host genes on susceptibility to HIV infection (Rowland-
Jones et al. 1995a,b, Fowke et al. 1996, Huang et al. 1996, Liu et al. 1996, Paxton et al.
1996, Stephens et al. 1996).
Prior to the discovery of the role of chemokine receptor gene polymorphisms in HIV
infection, only genes of the HLA system were thought to protect against HIV infection.
However, as with many infectious diseases, it was suggested that polygenic control might
contribute to the individual risk to susceptibility to HIV-infection. For example, certain
distributions of HLA class I alleles were observed in uninfected female commercial sex
workers (CSWs) in Africa and Thailand, who had been highly exposed to HIV (Fowke et
al. 1993, Plummer et al. 1993, Stephens et al. 1996). Additional class I and II alleles have
been identified, that may be associated with those remaining uninfected (Malkovsky
1996). Mechanisms possibly related to cytotoxic Tvcell function, have been suggested to
explain these findings (Rowland-Jones et al. 1995, Rowland-Jones and McMichael 1995a,
Fowke et al. 1996, Stephens et al. 1996).
Several non-HLA genetic factors appear to influence susceptibility to HIV infection and the
course of HIV disease, for example the presence of certain alleles of the CCR5 co-
receptor gene that provide protection against HIV infection (Dean et al. 1996). This has
led to speculation of evolutionary development of a selective force by maintaining one
such allele to control the virus. The major mechanisms providing resistance or
susceptibility to HIV-1 infection and disease progression are discussed.
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3.1.1. The HLA (human leukocyte antigen) genotype
The human leukocyte antigen (HLA) gene complex forms part of the major
histocompatibility complex (MHC) agglomerate (or antigenic cluster), and is encoded by a
3800 kilo base (kb) segment located on the short arm of chromosome 6, locus 6p23-p21
(Dunham et al. 1987). Other immune-related genes (for example the TNFa and TNFp
genes) are also encoded by this region, as was shown by molecular mapping of the MHC
containing the HLA complex (Spies et al. 1986). Expression of the MHC gene products
(HLA genes) plays a crucial role in activation of the immune response to infectious agents.
This primary function is fulfilled by the binding and presentation of antigens to class 1-
restricted CD8+ cytotoxic T-Iymphocytes (CTLs), thereby recruiting other cells involved in
the immune response.
The MHC consists of three classes, which form part of a large multigene family within the
MHC. Class I contains the HLA-A, Band C genes, which encode a protein that forms a
heteroduplex with P2-microglobulin and is expressed on most body tissues. MHC class I
molecules play an indispensable role in the immune defence against intracellular
infections, including HIV-1 infection (Walker et al. 1987, Nixon et al. 1998). Regulation of
the immune system by these molecules takes place by presentation of antigenic peptide
epitopes to CTL, generated as a result of immune stimulation. Initiation of specific immune
responses is activated through this mechanism in order to control clearance of foreign
material (Shiga et al. 1996, Tomiyama et al. 1997, Weinhold et al. 1998, Rowland-Jones
et al. 1999). Class II molecules, on the other hand, encoded by the HLA-DR, DQ and OP
genes, are essential for initiation and control of elements of the immune system. Located
on the surface of immune cells (for example cells of the macrophage lineage, B cells and
activated T-cells), the class II molecules are responsible for presentation of antigens in the
form of peptides by antigen presenting cells including dendritic cells, macrophages and B
cells, to CD4+ T helper cells (Collins et al. 1986). Although very little is known about class
III molecules, these include the molecules involved in the complement system C2, C4B
and BF and tumour necrosis factor (TNF).
The HLA system is the most polymorphic biological system known in humans, and large
racial and geographical variations of specific alleles have been shown. Further, alleles
identified for the respective classes and types vary in number, and no gender-associated
variation has been observed.
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For example, at the peptide level for class I the HLA-A locus contains approximately 27
allelic variants, 60 for the B locus and 10 for the C locus. In class II, 60 variants for HLA-
DR, 32 for HLA-DQand 40 for HLA-DP have been identified. At the molecular (DNA) level
however, many more variants exist for both classes. These variants are suggested to
have evolved in response to a variety of pathogenic confrontations. They have been
maintained specifically within populations in order to elicit immune responses to given
pathogens, thus yielding protective mechanisms in different populations (Parham and
Ohuta 1996, Hughes and Yeager 1998). Accurate assigning of HLA loci to specific
infections has been complicated by the extremely polymorphic nature of the MHC, and
relatively even distribution of HLA alleles characterising the HLA loci.
Due to the polymorphic nature, the possibility of linkage disequilibrium patterns within the
MHC further complicates the assignment of causative loci to specific diseases and/or
disorders. Because of the complexity of the multiple effects of the host genetic
composition on pathogens, multiple HLA loci may therefore be required to elicit an
effective immune response. Although substantial associations have been made, the
effects of multiple variants in complex gene systems clearly need to be investigated in
considerably large populations and by organized comprehensive approaches.
Current methods for accurate detection of specific HLA loci associated with diseases are
limited. Until recently, serological detection methods were applied almost exclusively.
These detection methods only allowed for the basic subtypes (for example HLA-A, Band
C) to be identified, and were very time consuming. However, since the amino acid
sequences of all but the most rare variants of HLA-A, B, Cw and DR have been
elucidated, molecular typing techniques are being developed. These methods include
polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) typing
(Moribe et al. 1997, Nieto et al. 1997), sequence-specific primer polymerase chain
reaction (SSP-PCR) (Geisthorpe et al. 1999), real-time PCR (Bon et al. 2000), flow
cytometric analysis (Chou et al. 1997), amongst others. The advantage of these
techniques over the more traditional tissue typing techniques is predominated by the
robustness of molecular techniques, as well as relatively high-throughput made possible
by such techniques. Although more typing methods are being evaluated, routine
application of these methods will only be possible after a number of years due to the
complexity of allelic variation in the HLA region.
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To understand the potential mechanisms of the HLA system providing protection from
HIV-1 infection or yielding susceptibility to HIV/AIDS, a review of the complex interaction
of the virus with the host in the context of the immune system is necessary. The following
section provides background to susceptibility and/or resistance mechanisms that could be
ascribed to genetic variation of the host HLA system.
CTL-response and HIV-1 escape from the immune system
Cytotoxic T-Iymphocytes (CTLs) play an indispensable role in control and clearance of
infections. Variation in the epitopes expressed by cells involved in the primary immune
response is crucial for effective immune responses to take place. Such variation in
epitopes recognised by CTL however frequently offers potential escape mechanisms for
infecting organisms, as seen in the case of HIV-1 infection.
The polymorphic nature of HLA determines which cytotoxic T-Iymphocyte (CTL) epitopes
are expressed on the surface of infected cells. The breadth of the immunological response
may therefore be a factor of the genotype of the host, and not necessarily due to variation
in the infecting organism, although phenotypic variation of viruses can also elicit specific
CTL-responses. However, evasion from the CTL response often takes place for survival of
the virus, possibly due to extreme mutation rates known to occur especially in viruses. A
number of examples exist for viral infections other than HIV, in which the virus can escape
from control by the CTL by means of mutation (Pircher et al. 1990, De Campos Lima et al.
1993,1994, Bertoletti et al. 1994a,b, Niewiesk et al. 1995, Weiner et al. 1995).
For HIV-infection, the combination of immunodominant T-cell responses, the integration of
single copies of DNA in infected cells, together with high HIV-1 turnover and accumulation
of mutants during persistent infection, makes it almost inevitable that HIV-1 escapes CTL.
Several reports support the hypothesis of escape (Phillips et al. 1991, Johnson et al.
1993, Couillin et al. 1994,1995, Harrer et al. 1994, Koup 1994a, Nietfield et al. 1995),
whilst others argue against it (Meyerhans et al. 1991, Chen et al. 1992). Although many
examples exist for mutations in the provirus, which could affect recognition by CTL from
the same patient, sufficient evidence that escape has occurred has not been provided
(Johnson et al. 1992, Zhang et al. 1994, Safrit et al. 1994, Meier et al. 1995, Nietfield et al.
1995, Nowak et al. 1995, Wolinsky et al. 1996).
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The CTL response is capable of reducing viral levels by approximately 100-fold, but no
further in the case of HIV-infection (Koup et al. 1994b, Safrit and Koup 1995). In contrast
with other viral infections, T-cell control ultimately fails in HIV-1 pathogenesis, with viral
escape due to the rapid HIV-1 replication rate. Estimates based on decline in HIV-1 virion
levels observed after administration of anti-retroviral drugs, have indicated a daily
generation of 109_1010 virions (Ho et al. 1995, Wei et al. 1995). Further, with the HIV
mutation potential of 10-5 per base (bp) per generation (and genome size of 104 bp), on
average 108 mutant viruses should be generated daily (Coffin 1995). Although the immune
response is challenged with this extreme mutation rate, only a minute portion of the
mutant virions yield viable viruses and most are defective with a slower replication rate.
Inefficient competition with wild type virus thus normally allows for mainly wild type virus to
elicit necessary CTL responses. Best-adapted viruses however predominate distinctly in
different geographical regions, referred to as HIV-1 quassispecies, subtypes or clades
(Louwagie et al. 1993). These are based on strong conservation of consensus sequences
of the virus clades. The tendency to revert to the "mean", with little initial selective
pressure from the immune system at each transmission event, therefore allows eventual
escape of the virus from the immune response due to evolution within the host.
HLA and susceptibility to HIV/AIDS
Numerous HLA loci from both classes I and II have been assigned in susceptibility to HIV-
infection and disease progression patterns between individuals, and also with differing
distributions and effects between populations. The role of the HLA system in determining
the course of infection has been examined by using measures such as the CD4+ cell
count or the length of time between HIV-1 infection and AIDS (Steel et al. 1988, Hill 1996,
Kaslaw et al. 1996, Malkovsky 1996, McNeil et al. 1996). From these and other studies, it
had been established that small contributions of multiple interactive HLA marker
combinations (primarily in class I) could significantly modulate the course of HIV-1
infection. However, similar to the 32 bp deletion mutation occurring in the CCR5 gene
(CCR5~32), it has been suggested that these alleles contribute equally, although
independently to disease acquisition or progression status. Together, these observations
strongly support a genetic component in HIV-1 disease pathogenesis.
Stellenbosch University http://scholar.sun.ac.za
24
Although many associations have been made between alleles of the HLA complex and
HIV disease acquisition or progression, inconsistent results have however not facilitated
delineation of a clear pattem on how HLA influences disease progression (Hendel et al.
1996, Hill 1996, Malkovsky 1996, Roger 1998).
Studies on HIV/AIDS susceptibility indicated that the class I HLA-A26, HLA-827 and HLA-
857 are associated with slow progression (Kaslow et al. 1996), whereas the HLA-835
allele which almost always neighbours HLA-Cw*04, has been consistently associated with
rapid progression (Scorza Smeraldi et al. 1986, Itescu et al. 1992, Sahmoud et al. 1993,
Just 1995, Carrington et al. 1999). The accelerating function of HLA-835,Cw*04 has been
observed only in Caucasian individuals and not in Africans, suggesting this allele may be
operating immunologically or may be associated with another locus accelerating
progression to AIDS (Carrington et al. 1999). It was further shown by these investigators
that HIV-seropositive Caucasian individuals lacking the heterozygous class I AIDS-
associated loci HLA-8*35 and Cw*04, avoided AIDS for 10 or more years. Subtypes of the
HLA-8*35 allele, possibly influencing the rapid progression to AIDS, were assessed by
Gao and co-workers (2001). Progression was shown to be attributable to the HLA-8*35-
Px alleles, and it was also concluded by these authors that the previously observed
association of HLA-Cw*04 with progression to AIDS (Carrington et al. 1999) was due to
linkage disequilibrium with HLA-8*35-Px alleles. The association with 8*35-Px was
observed in Caucasians, and this allele was absent from Africans. The only difference
between 8*35-Px and 8*35-Py was one amino acid substitution, which probably facilitated
association with disease progression. In African individuals from the population
investigated by these authors, the HLA-8*5301 allele was associated with susceptibility to
disease progression. This study supported the hypothesis that HLA-8 alleles exert an
effect on the immune response to HIV-1 infection, which appear to differ between
populations.
Strong association for a number of alleles associated with non-progression (such as 814,
827, 857, C8 and C14, DR11) have been shown (Hendel et al. 1999), whereas others
favoured rapid progression (A29, 822, 835, C16). These observations confirmed previous
associations of the 827, 857, 835 and DR11 alleles with slow HIV disease progression
(Scorza Smeraldi et al. 1986, Cruse et al. 1991, Hendel et al. 1996, Kaslow et al. 1996
Malkovsky 1996, McNeil et al. 1996, Roger 1998).
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It was recently established that homozygosity of B alleles sharing the HLA-Bw4 allele, is
markedly associated with suppression of HIV-1 viremia (Flores-Villanueva et al. 2001).
This association was independent from the CCR5~32 mutant in protection and also from
other HLA alleles that could confound the association. This study further showed
independent association of HLA-B44 and control of viremia. Furthermore, it was shown
that specificity for the HLA-Bw6 allele is associated with a worse disease outcome. The
hypothesis that the ability to control disease progression is multifactorial, and that
additional genetic advantages remain to be discovered, was supported by these results.
Some HLA alleles are in linkage disequilibrium and commonly occur on the same
haplotype. For the study conducted by Hendel and co-workers (1999), such linkage was
observed for A29-C16, B8-C7, B14-C8, B27-C1, B27-C2, B35-C4, B51-C14, B57-C6,
B57-DR7 and A1-B8-C7-DR3, explaining similar association for some A, Band C alleles.
These authors further showed that the DR11 allele is protective and it was present in two
patients with the protective CCR5~32 mutation, supporting the hypothesis of polygenic
control of susceptibility patterns to HIV/AIDS.
Extended haplotype analysis with disease progression established association between a
number of HLA haplotypes and HIV-1 disease progression. In Caucasian individuals, the
haplotypes HLA A1-B8-DR3 (Kaslow et al. 1990, McNeil et al. 1996, Steel et al. 1988),
HLA A1-Cw7-B8 and Cw4-B35 (Steel et al. 1988, Kaslow et al. 1990, Carrington 1999,
Keet et al. 1999) appear to be associated with rapid progression. HLA A1-Cw7 -B8-DR3-
DQ2 and HLA A11-Cw4-B35-DR 1-DQ 1 were also found to be associated with fast
progression to AIDS.
In some studies two subtypes identified from the same allele (for both class I and II) have
shown differences in susceptibility patterns between ethnically different populations.
Costello and co-workers (1999) showed that in the Rwandan population the HLA-B5703
subtype predominated in slow progressors, whereas this allele was not present in
Caucasians. Instead, the HLA-B5701 subtype was present almost exclusively in
Caucasians.
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Haplotypes identified predominantly in the Rwandan population included HLA B57-Cw04,
whereas the HLA B57-Cw06 haplotype predominated in Caucasian individuals, although
neither of the C-antigens alone suggested any progression association (Costello et al.
1999). Similarly, it was shown that HIV-1 infection is affected by differing HLA genotypes
between African Americans and Caucasians (Roe et al. 2000). The HLA-DQB1*0603
subtype was positively associated with HIV-infection, and the HLA-DQB1*03032 subtype
was associated with protection from HIV-1 infection in Caucasians, but not in African
Americans. Presence of HLA-DQB1*0201 to be associated with HIV-1 infection in African
Americans was further demonstrated by these authors, as it occurred more frequently in
HIV-seropositive individuals, whereas HLA-DRB1*04 was positively associated with HIV-1
infection in Caucasians from the study population.
The influence of HLA types on susceptibility to HIV-1 infection in highly exposed
individuals was assessed in a population of CSWs in Kenya (MacDonald et al. 2000).
MHC class I HLA-A2, HLA-A28, and HLA-B18 were associated with decreased risk of
HIV-1 infection in this population, while HLA-A23 was associated with increased risk.
Subtyping of class I alleles identified a supertype, consisting of the HLA-A2 subtypes HLA-
A*0202, -A*0205, and -A*0214 and an HLA-A28 subtype, HLA-A*6802, which appeared to
be associated with a significantly decreased rate of HIV-1 seroconversion. A significantly
decreased risk of HIV-1 seroconversion associated with the HLA-DRB1*0102 allele of the
HLA-DRB1*01 determinant was further observed. Resistance to HIV-1 infection in this
cohort was associated with immunological responses to HIV-1, and not with protective
chemokine receptor polymorphisms (for example CCR2). The HLA-A2/6802 supertype
and the DRB1*01 determinant were proposed to mediate protection through presentation
and restriction of conserved epitopes, although these alleles are neither completely
necessary nor sufficient for resistance.
Other alleles in association with alleles from the HLA complex have been shown to
contribute to progression to AIDS. It was reported that the activating KIR allele KIR3DS1,
in combination with HLA-B alleles (HLA-B Bw4-80Ile), is associated with delayed
progression to AIDS (Martin et al. 2002). In the absence of KIR3DS1, the HLA-B Bw4-
80lle allele was not associated with any of the AIDS outcomes. By contrast, in the
absence of HLA-B Bw4-801le alleles, KIR3DS1 was significantly associated with more
rapid progression to AIDS.
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The KIRs encode the killer immunoglobulin-like [eceptors on natural killer (NK) cells and it
was shown to regulate the inhibition and activation of NK cell responses through
recognition of HLA class I molecules on target cells.
Combined, these observations confirm that disease progression appears to be influenced
by several HLA genes or haplotypes. The effects of the associations are however
complex, and may depend on interactions with other host genes. The observation by
Martin and co-workers (2002) strongly suggested a model involving an epistatic interaction
between 2 loci. Although polygenic control involving the HLA system has been proposed,
it should be noted that the effect of HLA genotypes on survival or disease progression are
independent from other host genes that from part of the pathogenesis of, and protection
from HIV infection (Kaslow et al. 1997).
In the context of polygenic control of susceptibility to HIV/AIDS, some recent studies
investigated the possible contribution of variations in the HLA region with those present in
chemokines. Certain HLA alleles, for example HLA-A32 and A2S, were present at higher
frequencies, whereas others (HLA-B8) were present at reduced frequencies in HIV-
infected individuals in progression groups compared with HIV-seronegative individuals
(Geczy et al. 2000). These differing allele frequencies were not accompanied by HIV-
disease associated variants in either the eeR5 or eeR2 genes in long-term survival
groups. Confounding effects of viral mechanisms (for example in the case of nef-defective
HIV-1) could however be a possible explanation for the association between certain HLA
alleles and long-term survival in HIV-1 infection.
Furthermore, data presented by Magierowska and co-workers (1999) have shown that the
combined host genetic background strongly influences the evolution of HIV-1 disease.
long-term non-progressors (LTNPs) studied shared a particular genotype for both
chemokine receptor and HLA loci, which independently influenced the outcome of their
disease. The odds of subjects heterozygous for the CCRS 32-bp deletion and
homozygous for SDF-1 wild-type of being LTNPs, were increased by 16-fold; by 47-fold
when an HLA-B27 allele is present with HLA-DR6 absent, and by 47-fold also if at least
three of the following alleles are present: HLA-A3, HLA-B14, HLA-B17, HLA-DR7. This
model facilitated the accurate classification of 70% of LTNPs and 18% of progressors,
suggesting that other, as yet undefined host susceptibility factors remain to be
investigated.
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3.1.2. The chemokines and chemokine receptors
The chemokines, also known as chemo-attractant cytokines, are a family of proteins that
playa crucial role in inflammatory and immune reactions and viral infections (reviewed in
Luster 1998). As described earlier, several chemokine receptors have been characterised
and many have multiple ligand specificities. These receptors play a major role in
lymphocyte function, recruiting these molecules to sites of infection or inflammation. In the
case of HIV-1 infection, various chemokines are involved in the inflammatory response.
Supported by epidemiological data, some mechanisms have been shown to be crucial in
susceptibility patterns to HIV-infection and disease progression. This section will
emphasise some of these mechanisms involving chemokine receptors and co-receptors
with host genetic variation to susceptibility for HIV-disease.
cces and ccnz
The main focus in the investigation of chemokine receptors and their influence on HIV-1
disease status has been on the human chemokine eeR5 and eeR2 genes, both located
on the short arm of chromosome 3p22-p21. eeR5 is amongst a group of genes that
encode multiple chemokine receptors, including the eeR2 gene (Liu et al. 1996, Samson
et al. 1996a). These two genes are tightly linked, and separated by less than 20 kb,
suggesting a single promoter(s) may regulate expression of both genes. The respective
coding regions of the two genes share 75% nucleic acid and amino acid identity. Both
gene products can serve as co-receptors with eD4+ for HIV as indicated by several
studies. However, common allelic variants in both genes (which may occur in linkage
disequilibrium) are associated with HIV-1 disease progression and these mechanisms will
be discussed.
eeR5
The eeR5 gene consists of 4 exons spanning 6 kb, and two introns (Mummidi et al.
1997). Exons 2 and 3 are continuous as no intron is present between the two exons, and
the open reading frame and complete 3' untranslated region (UTR) are present in exon 4.
A region upstream of exon 1 was identified with strong sequence homology (-89%) with
sequences in the 3'-flanking region of eeR5.
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Two distinct AT-rich promoters have been identified around exon 1 (one upstream and
one downstream), both lacking TATA and CAAT motifs. Pu, a weak promoter which
resides proximal to exon 1, and PD, a stronger promoterwhich is located upstream of exon
3. It is conceivable that regions further upstream of exon 1, or constructs shorter than
those tested, may support strong promoter activity for Pu.A strong silencer element (nt. -
244 to -80) and enhancer element (nt. -486 to -244) have been located, suggesting the
gene region between nt. -486 and -1 may be regulating the expression of CCR5 in
monocytes/macrophages and T-Iymphocytes (Guignard et al. 1998). Multiple CCR5
transcripts have been identified, which are due to a complex alternative splicing pattern in
the 5' UTR and exon 4. Intact, CCR5 encodes a 352 amino acid protein CCR5, with a
molecular mass of 40,600 kilo Dalton (kDa) and contains a potential N-glycosylation site
(Samson et al. 1996a). The regulatory sequences and non-coding exons have however
been shown to be polymorphic, whereas the amino acid coding sequence appears to be
more conserved.
Independent studies identified the CCR5 protein as a coreceptor for HIV-1 (Deng et al.
1996, Dragic et al. 1996). Some individuals however resisted infection despite repeated
exposure to HIV-1, and a possible mechanism of resistance to HIV-1 infection involving a
homozygous 32 bp deletion in the eeR5 gene (two copies CCR5il32/CCR5il32) was
identified (Liu et al. 1996,Samson et al. 1996a, Biti et al. 1997).
CCR5il32 involves a deletion of the nucleotide sequence between bases 794-825 of the
eeR5 gene, at a site of a repeat motif consisting of 10 bases (Figure 3). The deletion
results in a non-functional truncated protein due to a frame-shift after amino acid 174,
inclusion of 7 novel amino acids and premature a stop-codon at codon 182 (Liu et al.
1996). Loss of three of the seven transmembrane domains (two of the three outer loops,
and the intracellular domain) results from the deletion, and the truncated protein is not
expressed on the surface of immune cells. The predicted structures of the wild-type
protein and the truncated form containing the 32 bp deletion are depicted in Figure 4. The
deletion does not appear to impair immune function, but reduces the risk for HIV-1
infection. This occurs because of the inability of the virus utilising this protein as co-
receptor for attachment to and integration into CD4+ cells.
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Figure 3. Partial CCR5 gene and amino acid sequence with 32 bp deletion (CCR5L'132).Nucleotide
sequence of the CCR5 gene surrounding the deleted region, and translation into the normal
receptor (top lines) or the truncated mutant (CCR5L'132,bottom lines). The 10 bp direct
repeat is represented in bold italics and the deleted nucleotides are non-capitalized
(adapted from Zhang et al. 1996).
A
B
Figure 4. Predicted structures of the CCR5 chemokine co-receptor (Doranz et aI.1996). A. Wild-type
CCR5 protein. The typical serpentine structure is depicted with three extracellular (top) and
three intracellular (bottom) loops and seven transmembrane domains. B. The predicted
CCR5L'132protein structure. The mutant protein lacks the last three transmembrane
segments of CCR5, as well as regions involved in G-protein coupling. The transmembrane
organization is given by analogy with the predicted structure of the wild-type CCR5 protein
(adapted from McNicholl et al. 1997).
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In contrast with the protective effect of the homozygous genotype for the deletion mutant,
heterozygosity for the 32 bp deletion (one copy, eeR5 wild type/CCR5~32) did not show
protection against HIV-1 infection (Samson et al. 1996). Rather, retardation of progression
to AIDS as the result of heterozygosity for CCR5~32 had been noticed predominantly in
Caucasian populations (Dean et al. 1996, Garred 1996, Eugen-Olsen et al. 1997, Meyer
et al. 1997, Michael et al. 1997). Furthermore, prolonged AIDS-free survival has been
associated with a slower decline in CD4+ T-Iymphocytes and a lower viral load
(Katzenstein et al. 1997). At the onset of AIDS however, heterozygosity does not offer
protective advantage over the wild type (Garred et al. 1997a, Michael et al. 1997a,b,
Smith et al. 1997a,b). The effect in heterozygotes appear to be a suppression of wild-type
CCR5 co-receptor function due to an intracellular association of these defective and
normal gene products, which is retained in the endoplasmic reticulum (ER) (Benkirane et
al. 1997). Retention in the ER was shown to result in decreased surface expression of
CCR5 and degradation of the truncated CCR5 protein.
However, although the protective effect of this deletion against HIV-1 infection has been
confirmed, some isolated individuals with the homozygous deletion subsequently became
infected with HIV-1 (Balotta et al. 1997, O'Brien et al. 1997, Theodorou et al. 1997). This
genotype therefore does not confer absolute resistance against HIV infection, and
infection can infrequently be established by T-tropic HIV strains (NSI) which use the CCR4
receptor for infection, as well as strains which can enter via alternative receptors (Balotta
et al. 1997, O'Brien et al. 1997, Rana et al. 1997, Simmons et al. 1997, Theodorou et al.
1997).
Population studies have shown that homozygosity for CCR5~32 occurs at a frequency of
approximately 1% amongst Northern American or European Caucasians, whereas the
homozygous genotype was absent in Africans (Dean et al. 1996, Michael et al. 1997a,
McNicholl et al. 1997). Conversely, these and other studies showed that heterozygosity
occurs in 10-20% of Caucasian populations from North America and the European
continent. In non-Caucasian populations however, heterozygosity has been found in 1.7-
6% of African Americans, 7% of Hispanics, 13% of Native Americans and less than 1% of
Asians.
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Further investigations on non-Caucasian populations, including persons from parts of
Africa (Zaire, Burkina Faso, Cameroon, Senegal, Benin, Uganda, Rwanda, Kenya,
Malawi, Tanzania, Sierra Leone), Haiti, parts of Asia (Thailand, India, China, Korea,
Japan, the Philippines) and Venezuela have not found CCR5~32 among HIV-infected or
HIV-uninfected individuals, including individuals from African ethnic origin (Huang et al.
1996, Liu et al. 1996, Samson et al. 1996b, Zimmerman et al. 1997). Recent
investigations of eeR5 in the South African Black population showed the 32 bp deletion
was virtually absent, whereas it was present in approximately 10% of Caucasians
investigated (Williamson et al. 2000, Petersen et al. 2001).
A north-south gradient (ranging from less than 1% to 16%)was observed in the CCR5~32
allelic distribution in Europe, and indicated a frequency of 11-16% of the mutant in
Scandinavian countries, 9-11% in France and Belgium, 8-10% in central European
countries, 4-9% in Mediterranean countries and as low as 0.9% in Corsicans (Libert et al.
1998, Lucotte and Mercier 1998, Stephens et al. 1998). Furthermore, heterozygosity was
observed to follow a similar pattern in these populations, and homozygosity was less
frequent. These studies did not show presence of CCR5~32 in Middle Eastern, African,
East Asian and American Indian populations, although in Central Asian populations
(Uzbeks and Kazaks, amongst others) the mutant was less frequent. It was concluded
from these observations that the CCR5~32 deletion had a recent origin in North-eastern
Europe.
Several other point mutations in CCR5 have been identified (Dean et al. 1996, Ansari-Lari
et al. 1997, Carrington et al. 1997), either resulting in amino acid transitions or not, and
some of these mutations appear to be associated with HIV-disease. Others are
population-specific occurring in either Caucasian or non-Caucasian populations, or both. It
was pointed out by Carrington and co-workers (1997) that the majority of missense
mutations identified in Caucasians occurred in more conserved regions of the eeR5 gene,
whereas those occurring in African Americans occurred in more variable regions. This
further supported the more recent origin of population-specific mutations in the eeR5
gene that may be protective in Caucasian individuals. It has also been suggested that
some of these mutations may be in linkage disequilibrium with other as yet unknown
mutations that might affect disease acquisition or progression specifically in different
populations.
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In the South African population investigated by Petersen and co-workers (2001), novel
mutations were identified, including an African-specific single nucleotide polymorphism
(SNP) at codon 35, P35. A significant difference in allelic distribution was observed
between HIV-seropositive and HIV-seronegative individuals in the Cape Coloured
population of mixed ancestry. This observation raised the possibility that this sequence
change occurs in linkage disequilibrium with another polymorphism either in the regulatory
promoter region of eeRS, or in the CeR2 gene as these genes are in close proximity on
chromosome 3. A further significant association in this study population was observed for
the A335V SNP with slow disease progression in individuals of African ethnic origin
(Hayes et al. 2002). This is however in contrast with the observation by Carrington and co-
workers (1997), where this SNP was not associated with disease progression in either
Caucasian or African populations. Furthermore, a recent study in which this
polymorphism, amongst others, was included for investigation indicated no significant
association with HIV/AIDS in the Ugandan population (Ramaley et al. 2002a,b).
Another point mutation in the eeRS gene that appears to be of significance in HIV-
infection is the m303 mutation causing a T-+A substitution at position 303. This results in
a premature stop codon, implicating a loss of functional expression of CCR5 (Quillent et
al. 1998). When present together with the heterozygous CCR5~32 mutation, it was shown
to render resistance to HIV-1 infection. The CCR5~32/m303 genotype was shown to be
functionally indistinguishable from eCR5~32 homozygosity. Although present in the
general population described by these authors, the inheritance of the m303 mutation was
studied further in a family of Western European origin. It was present in association with
the heterozygous CCR5~32 mutation in one individual from this family at high risk for HIV-
1 infection, and whom remained HIV-seronegative. The South African study by Williamson
and co-workers (2000) indicated a frequency of 0.9% for m303 in Caucasians, whereas it
was absent in Africans.
Further, mutations in the regulatory region of CeRS have also been shown to be
associated with rate of disease progression (Martin et al. 1998). A significantly higher
presence of the -59353T/C promoter polymorphism (C-allele) was shown to occur in
nonprogressors, where the -59029G/A promoter polymorphism (G-allele) was associated
with disease retardation.
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The effects of mutations in the CCRS regulatory region were shown to be independent of
the protective effects provided by the CCR5~32 and CCR2-641 polymorph isms. Also, a
promoter haplotype was found to be associated with rapid disease progression. This
observation involved the -59353 (allele C) and -50402 (allele A) polymorphisms, but not
the -59029 polymorphism (Martin et al. 1998). Different frequencies were reported for
these alleles, which could possibly be explained by ethnic admixture in the respective
populations investigated. Also, in a recent study in CSWs in Thailand, highly exposed
persistent seronegative (HEPS) women had higher frequencies of the CCRS -59402
promoter mutation (homozygous for the G allele), compared with controls (Sriwanthana et
al. 2001). This suggested a potential reduction in disease progression amongst these
high-risk individuals.
CCR2
It was recently shown that a mutant allele of the CCR2 gene V641 (CCR2b-641), which is
in strong linkage disequilibrium with CCR5~32, is more frequently found in individuals
whose progression to AIDS was postponed, compared with fast progressors (Smith et al.
1997a, Anzala et al. 1998, Kostrikis et al. 1998, Mummidi et al. 1998, Rizzardi et al. 1998).
It was shown that this point mutation is present in a 1.9 kb intron, which may be
dispensable for optimal promoter activity (Guignard et al. 1998, Mummidi et al. 1998).
However, as both genes are potentially regulated by the same promoter, some studies
have confirmed that CCR5 expression is not influenced in CCR2-641 heterozygotes
(Kostrikis et al. 1998, Rizzardi et al. 1998). Although not associated with HIV-1 infection
per se, CCR2-641 has been shown to contribute to prolonged progression to AIDS (2 to 4
years longer than individuals without the mutation). When in combination with the
heterozygous CCR5~32 genotype, it was however protective against progression for more
than 16 years.
Compared with CCR5~32, the CCR2-641 point mutation was shown to occur in different
ethnic populations and was not only confined to Caucasians. This polymorphism was also
reported recently to be relatively frequent in South African Black individuals (Williamson et
al. 2000). In the population studied by these investigators, CCR2-641 was present in a
significantly higher frequency (13.1 %) in Black Africans, compared with 7.2% of
Caucasians, confirming the higher incidence of this mutation in Africans (Mummidi et al.
1998).
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A subsequent study investigating South African populations (Petersen et al. 2002)
indicated a similar distribution of the CCR2-641 polymorphism in African individuals to that
previously reported by Williamson and co-workers (2000). It was further shown by these
authors that this polymorphism was present more frequently in HIV-seronegative Black
African and Coloured individuals of mixed ancestry (16.9% and 17.4%, respectively) than
in HIV-seronegative Caucasian individuals (9.5%). Further, in HIV-seropositive Black
African individuals from the cohort investigated, the frequency was similar (13.0%) to that
of population-matched healthy individuals (16.9%). The polymorphism however differed
significantly in HIV-seropositive individuals of mixed ancestry compared with healthy
population-matched individuals, whereas it was absent in the low number of HIV-
seropositive Caucasians included in the study cohort. A number of novel mutations and
SNPs in this gene was reported in the population investigated, some with conservative
amino acid transitions, although no association with HIV-infection or disease progression
was found. This study also indicated that for the silent CCR2 C~ T mutation N260,
described by Clark and co-workers (2001), the mutant T allele was present at lower
frequencies in the HIV-seropositive individuals compared with healthy individuals, but this
did not reach statistical significance for the individual populations investigated.
Furthermore, as shown by Anzala and co-workers (1998) in a cohort of CSWs from
Nairobi, Kenya (lacking the CCR5~32 mutation), the CCR2b-641 was present in 33% of
HIV-1 infected individuals asymptomatic for more than 12 years, whereas it was present in
11% in those whose infection progressed to AIDS within 4 years (rapid progressors).
These investigators concluded that this mutation provided a two-fold protection in African
individuals compared with Caucasians towards protection from HIV-disease progression.
Interestingly, a recent investigation indicated a significant association of CCR2b-641 with
mother-to-child transmission of HIV-1, as well as a delay in disease progression
(Mangano et al. 2000). Protection was not confounded by either the SDF1-3'A or
CCR5~32 mutations in this study.
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Other chemokine receptors
Other chemokine receptor polymorphisms include two alleles (coding for a serine or
threonine at amino acid position 276) in the CCR3 gene (Combadiere et al. 1996,
Daugherty et al. 1996, Ponath et al. 1996). The population prevalence of this
polymorphism and role in HIV infection or disease progression have however not been
reported. Furthermore, a recent study showed an association with more rapid disease
progression for a haplotype identified in the CX3CR1 chemokine receptor (Faure et al.
2000). HIV-infected Caucasian individuals homozygous for the CX3CR1 1249-M280
haplotype affecting two amino acids (isoleucine-249 and methionine-280) progressed
more rapidly than those with other haplotypes. In a consecutive study, no associations
with disease progression were found (Kwa et al. 2003). No polymorph isms in the CCR4
gene encoding CCR4 (the entry co-factor for T-tropic HIV virus strains) have been
reported to date.
SDF-1
The SDF-1 gene was additionally identified as a potential marker for HIV-disease
progression. SDF-1 is located on chromosome 10q and encodes the ligand for the CXCR4
chemokine receptor, SDF-1 (Shirozu et al. 1995).
SDF-1 forms part of the family of integrins mainly encoded by genes located on
chromosomes 4q or 17q. The integrins are a class of proteins that link the outside of cells
with their interior, thus integrating a response, for example the mediation of adhesion of
neutrophils to endothelial cells. Strong evolutionary conservation and unique
chromosomal localization of SDF-1 suggested that SDF-1 might have important functions,
distinct from those of other members of the integrin family. Two isoforms due to alternative
splicing, SDF-1a. and SDF-1p, were identified. These proteins share 92% homology, and
consist of 89 and 93 amino acids respectively. The SDF-1 gene encodes both isoforms,
and the isoforms are encoded by 3 and 4 exons respectively.
Homozygosity for the chemokine 3'UTR (untranslated region) SDF-1 gene variant SDF1-
3'A (wild type, GG), was shown to confer a recessive protective effect in long-term
nonprogressors (LTNPs) (Winkler et al. 1998). HIV-1 infected individuals showed a
remarkably slower disease progression compared to wild type individuals.
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It was furthermore shown by these authors that in association with either the CCR5.132
deletion or CCR2b-641 mutations, HIV-seropositive individuals progressed even slower
with the SDF1-3'A polymorphism.
Subsequent to the observation by Winkler and co-workers (1998), it was shown that the
homozygous SDF1-3'A genotype (mutant, AA) had an accelerating effect on progression
to disease although it was shown to yield a subsequent prolonged survival after AIDS
diagnosis (van Rij et al. 1998, Brambilla et al. 2000). This polymorphism is present in 1%
of Africans from South Africa, compared with 19.8% of Caucasian individuals, as shown
by Williamson and co-workers (2000). This was in line with previous investigations
(O'Brien 1998), indicating that the mutation was present at a much lower frequency in
African individuals. It was proposed by O'Brien (1998) that SDF1-3'A can up-regulate
biosynthesis of SDF-1, making the protein highly available to compete with HIV for binding
to CCR4 and thereby blocking the emergence of T-tropic HIV isolates.
In the study by Sriwanthana and co-workers (2001) in CSWs in Thailand, highly exposed
persistent seronegative (HEPS) women had higher frequencies of the SDF-1 3'A mutation,
in addition to the eeR5 promoter -59402GG genotype known to influence HIV
transmission or course of disease. This appeared to potentially yield a reduced risk for
disease progression in these individuals.
Interestingly, it was shown that the maternal heterozygote genotype (wild type/SDF1 3'A)
is associated with perinatal transmission of HIV-1 (John et al. 2000), and particularly
transmission through breastmilk. The infant genotype however, had no effect on mother-
to-infant transmission.
3.1.3. Mannose-binding lectin, MBL
The mannose binding lectin (MBl), previously known as mannose-binding or mannan-
binding protein, is the most extensively studied human collectin, and is recognised as a
versatile macromolecule with many functional characteristics of the immunoglobulins (lgM,
IgG) and complement factor, Clq. MBl plays an important role in immune defence, and
appears to have functional significance in paediatric infection (Ross and Densen 1984).
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It has been suggested that MBl is particularly important in first line host defence acting
before establishment of an adaptive (protective) immune response by T- and B-cells
(Sastry and Ezekowitz 1993). The ability of MBl to bind a wide spectrum of
oligosaccharides through multiple lectin domains in the presence of calcium, suggested its
role in immune function upon microbial challenge. Furthermore, a range of mannose-rich
organisms appears to activate complement during the immune response, supporting the
functional importance of MBl during infection.
The MBL gene encoding the MBl protein has been mapped to chromosome 10q11.2-q21
(Sastry et al. 1989, Schuffenecker et al. 1991). Three functional alleles were identified in
exon 1 of the MBL gene, present in codons 52, 54, and 57 respectively, and are referred
to as the B, C and D alleles, whereas the normal allele is referred to as A (Madsen et al.
1994), and designation of any of the variant alleles is O. Allele B results in a glycine to
glutamic acid transition (Symiya et al. 1991), C in a glycine to glutamic acid transition
(Lipscombe et al. 1992), and D in an arginine to cysteine transition (Madsen et al. 1994).
Since these mutations are present in the collagen region of the gene, formation of the
collagenous triple helix of the 96 kDa MBl subunits has been suggested to be disrupted
by the mutations. The disrupted subunits are more vulnerable to degradation thereby
reducing the amount of functional MBl subunits in heterozygous individuals approximately
5-8 times (Symiya et al. 1991, Garred et al. 1992, Madsen et al. 1994).
Population studies have shown that the known mutations vary between populations. For
example, the B allele has been shown to be present at higher frequencies in Caucasian
and Asian individuals (17% and 11% respectively), whereas the mutation was very rare in
the Gambians (0.3%). Furthermore, the C allele was observed at a higher frequency in
West Africans, Gambians (23-29%). Earlier studies indicated the D allele occurs at much
reduced frequency in both African and Caucasian individuals (5%), and is absent from
Eskimos (Madsen et al. 1994). A recent population study investigating the origin of the
infectious disease-associated B-allele, suggested that absence of the mutation from the
founder gene pool of Australian indigenous individuals possibly contributed to the
vulnerability to intracellular infections such as tuberculosis in this population (Turner et al.
2000).
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The mutant alleles were further shown to contribute significantly to a number of infections.
low serum MBl concentrations or an increased frequency of mutations have been
observed in individuals with suspected immunodeficiencies and those with frequent
unexplained infections (Turner 1998). It was suggested that the protein serum levels might
be profoundly reduced in individuals both homozygous and heterozygous for the mutant
alleles. This was confirmed to activate complement through the mannose-binding protein-
initiated classical pathway (Lipscombe et al. 1992). Homozygosity for the B allele was
subsequently identified in individuals with recurrent infections (Summerfield et al. 1995),
confirming the association with infectious diseases.
Studies investigating susceptibility to meningococcal disease showed that homozygosity
or compound heterozygosity for the three alleles occurred at significantly higher
frequencies in subjects with meningococcal disease compared to healthy control subjects
(Hibberd et al. 1999, Jack et al. 1997). Furthermore, investigation of the functional role of
genetic variants of the MBL gene in lung infections frequently observed in cystic fibrosis
(CF), which are a primary cause of morbidity and mortality of this immune disorder,
suggested MBL variant alleles are potential risk factors for susceptibility to these infections
(Garred et al. 1999). Variant alleles were especially confined to patients with chronic
Pseudomonas aeruginosa infection, and heterozygotes for the variants were significantly
more at risk to acquire Burkholderia cepacia infection compared with homozygotes.
Follow-up studies confirmed this observation, and showed complement activation upon
binding of MBl to B. cepacia, which was not the case for the more common colonizing
organism in CF, Ps. aeruginosa (Davies et al. 2000). It was suggested that CF patients
with MBl deficiency would be at a particularly high risk of B. cepacia colonization. The
study by Garred and co-workers (1999) also indicated that the predicted survival age was
significantly reduced in heterozygous carriers, compared with individuals with wild-type
alleles. Furthermore, the lack of binding of MBl to P. aeruginosa suggested the effect of
this organism on lung function in patients with MBl-deficient CF, reflecting a role for MBl
possibly involved in inter-current infections with other organisms or in the inflammatory
process.
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MaL and HIV-infecfion
Homozygously inherited MaL genetic variants are associated with a greater risk for
immunodeficiency (Garred et al. 1995, Summerfield et al. 1995). Further, association
studies of HIV-infected individuals showed that homozygosity for any MaL variant allele
was significantly increased compared to high-risk uninfected control individuals or healthy
individuals (Garred et al. 1997b). Disease progression in HIV-infection was however more
rapid when mutations are present in the MaL gene (Maas et al. 1998), accompanied by
reduced serum MBL. The study eonducted by Garred and eo-workers (1997) also showed
that individuals heterozygous for the variant alleles had significantly shorter survival times
compared to the homozygous wild type genotype. These observations supported previous
data by Nielsen and co-workers (1995), although differing from a study by Senaldi and co-
workers (1995), which may possibly be explained due to random events or by differences
in population-distribution of the variant alleles.
Although the exact mechanism for variant MaL alleles facilitating susceptibility to HIV-
infection has not been elucidated, it has been proposed to have a direct role in HIV
infection due to the ability of MBL to selectively bind HIV-infected cells, thereby inhibiting
infection of CD4+ cell lines (Ezekowitz et al. 1989). This takes place by binding of MBL to
oligosaccharides present on the HIV-1 gp120 glycoprotein, which are ligands for MBL
(Larkin et al. 1989), followed by compliment activation (Haurum et al. 1993). Therefore,
low serum MBL concentrations and compliment activation may impair sequestration and
contribute to an increased viral load in HIV-1 infection.
3.1.4. Iron status
Iron is of vital importance for most living organisms. It is involved in many metabolic
processes including oxygen transport, DNA synthesis and electron transport. However,
regulation of iron concentrations in body tissues is essential, as excessive iron often
causes tissue damage as a result of free radicals. Iron metabolic disorders are amongst
the most common human diseases, with diverse clinical manifestations including iron
overload and iron deficiency or anaemia. Numerous environmental determinants affect the
clinical outcome of both iron overload and iron deficiency. These factors include age,
gender and nutrition, in addition to genetic associations. Therefore, even where an iron-
loading allele is highly prevalent, high iron status is not necessarily affected if dietary iron
intake is low and iron deficiency is common in a population.
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Proper understanding of iron regulation, or homeostasis, is therefore important to provide
proper diagnosis and treatment in severe cases. Various studies have assisted in
understanding the regulation and molecular mechanisms of iron homeostasis from the
perspectives of molecular biology, biochemistry and genetics.
Iron and opportunistic infection
Although iron overload has been proposed not to be directly involved in susceptibility to
microbial infection, compared to the mechanisms involved in more central systems, a
number of infections have been reported in individuals with iron overload (Brennan et al.
1983, Capron et al. 1984, Bullen et al. 1991). Some investigations have shown that iron
chelation therapy could be important in controlling infectious diseases related to iron
overload (Boelaert et al. 1988, Rex 1988, Daly et al. 1989), whereas others have indicated
that iron chelators are often more harmful in stimulating microbial growth and enhancing
the risk of severe infection (Robins-Browne and Prpic 1985). The decision to commence
iron chelation therapy should therefore be carefully individualised. The benefits of therapy
to prevent iron-induced organ damage however mostly outweigh the risk of infectious
complications.
Iron overload has been associated with opportunistic infections in HIV-1 disease. It has
been reported that higher levels of iron is associated with both Mycobacterium
tuberculosis and Pneumocystis carinii infections, two of the most common opportunistic
infections associated with HIV (Weinberg 1994, Lounis et al. 2001). These studies showed
that iron chelation therapy inhibits growth of both organisms, suggesting that excess iron
may enhance microbial propagation in humans, thereby worsening the clinical outcome.
Furthermore, the association of excess iron with Kaposi's sarcoma as a result of
herpesvirus-8 (HSV-8) infection was shown in HIV-infected individuals in Uganda (Ziegler
et al. 2001). These investigators pointed out that exposure to wet clay soils in Africa may
be an important risk factor for accumulating iron through skin uptake, contributing to the
pathogenesis of Kaposi's sarcoma caused by an opportunistic infection associated with
HIV/AIDS.
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African Iron overload: a potential risk factor for HIV infection and disease progression
Dietary iron overload is a common condition in sub-Saharan Africa, affecting up to 10% of
individuals in rural populations (Gordeuk 1992a,b). It is characterised by heavy iron
deposits in both parenchymal cells and in macrophages, and these are important in the
defence against many microbial infections including Mycobacterium tuberculosis (Bothwell
et al. 1965, Learmonth et al. 1991, Gordeuk et al. 1996, Lounis et al. 2001).
Iron loading reduces the function of macrophages and other cells of the immune system,
increasing the vulnerability to infection. In Africans, iron overload can be attributed to the
accumulation of iron due to high amounts of bioavailable iron. The principle source of
excessive iron in these populations is home-brewed beer fermented in steel drums
(Bothwell et al. 1964, Gordeuk et al. 1992a,b). In addition to the potential increased risk
for infectious diseases, various other clinical outcomes, including immune disorders for
example Diabetes mellitus, are often associated with iron overload in these populations
(Bothwell and Bradlow 1960, Isaacson et al. 1961, Seftel et al. 1961, Bothwell et al. 1984).
It has further been suggested that Africans may be genetically predisposed to iron loading,
possibly as a result of a gene that differs from the HLA-linked haemochromatosis (HFE)
gene in Caucasians (Gordeuk et al. 1992a,b). It would therefore be of interest to
investigate genes related to iron-metabolism in populations of African descent, to establish
whether genetic mechanisms exist that could facilitate susceptibility to HIV-disease in
these populations.
Iron and HIV infection
Iron metabolic pathways and the immune system both play an important role in
homeostasis. These systems regulate one another, and infectious agents like HIV can
easily break the regulation. The discovery of the HLA genes involved in
haemochromatosis (Simon et al. 1976, Feder et al. 1996) and the haptoglobin phenotype
involved in iron metabolism (Delanghe et al. 1998) supported this mechanism.
The genetic origin of iron overload was initially described for haemochromatosis, or iron
loading disease by possible association of the MHC system (Simon et al. 1976). The
human leukocyte antigen loci HLA-A3 and HLA-B14 were shown to be associated with
haemochromatosis. It was subsequently shown that the underlying genetic mechanism of
haemochromatosis however involved the HFE gene (Feder et al. 1996).
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Identification of disease-associated mutations in this gene facilitated interest in studies of
gene-environment interactions affecting the individual risk of iron overload. Both these
HLA-A3 and HLA-B14 alleles are implicated in slow progression to AIDS (Magierowska et
al. 1999). Further, haptoglobin has been shown to be important in regulating iron levels by
preventing the formation of free radicals (Gutteridge 1995a,b). An increase in iron
accumulation due to the haptoglobin Hp2-2 phenotype was observed, yielding less
efficient haemoglobin-binding capacity and weaker antioxidant function (Delanghe et al.
1998).
Based on theoretical and experimental considerations that excessive iron stores may have
an adverse effect on immunity, it has been suggested that high iron levels may be of
concern in individuals with HIV-infection. As reviewed by Gordeuk and co-workers (2001),
sufficient evidence has been provided to suspect that high iron may adversely affect the
outcome of HIV-1 infection. Optimum HIV replication requires chelatable iron (Ginatl et al.
1997), and the progression of HIV-1 infection towards AIDS is accompanied by increasing
iron stores (Boelaert et al. 1996a,b). Furthermore, excess iron has the potential to
enhance oxidative stress, thereby impairing immune defence mechanisms and directly
promoting the growth of microbial cells (van Asbeck et al. 2001). Iron accumulation occurs
in several tissues as a result of increasing ferritin levels during HIV disease progression
(reviewed by Savarino et al. 1999). Shorter survival in HIV disease therefore appears to
be directly associated with excess iron due to iron-mediated oxidative stress.
Further, many of the activities of the target cells of HIVare iron dependent or modulate
iron metabolism (Bierer and Nathan 1990, Pattanapanyasat et al. 1992, Whitley et al.
1993, Brock 1994). Macrophages are particularly important as they playa central role in
iron metabolism (Brittenham 1994), and these cells form an integral part in primary
immune function. A number of genes involved in iron metabolism express their products to
localise in macrophages. Investigation of the possible effects of mutations in these genes
in HIV pathogenesis is therefore important.
Iron deficiency and anaemia in HIV infection
Iron deficiency occurs frequently among HIV-seropositive individuals, contributing
significantly to morbidity and mortality (Forsyth et al. 1996). A further complication that
accounts for increased morbidity and mortality in HIV disease is anaemia, often as a result
of iron deficiency.
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The overall incidence of anaemia among HIV-seropositive individuals ranges from 10% in
asymptomatic patients to 92% in individuals with full-blown AIDS (Zon et al. 1987, Mir and
Krantz 1992). The multifactorial nature of anaemia however complicates differential
diagnosis and adequate treatment in HIV-infection.
Intestinal malabsorption was shown to be a direct cause of anaemia (Castaldo et al.
1996). Poor nutritional status and even malnutrition often predominate in HIV-infection,
contributing to reduced iron intake. This in turn correlates with poor prognosis in HIV-
infected individuals (Brettler et al. 1990). The typical pre-terminal stage of HIV disease,
cachexia (also referred to as 'wasting'), is related to malnutrition due to intestinal
malabsorption. Moreover, iron deficiency contributes to immune and neurologic
impairment, both common features in HIV-infected children (Falloon et al. 1989).
Assessment of iron status with clinical correlation could therefore provide a better
understanding of the effect of iron in disease pathogenesis.
Genetic determinants of iron-related disorders in HIV-disease outcome
Genetic mechanisms associated with iron metabolism have been proposed to contribute
to the clinical outcome of HIV disease, and the genes involved in HIV pathogenesis are
discussed in the context of association with HIV-infection and disease progression.
The Haptoglobin gene, Hp
Haptoglobin (Hp) is a polymorphic acute phase haemoglobin-binding plasma glycoprotein
with haemoglobin-binding capacity (Langlois and Delanghe 1996), and is present in all
vertebrates (Bowman and Kurowsky 1982). Hp is part of a group of human serum u2-
globulins, so called due to the ability to complex with haemoglobin. Although the function
of the Hp protein is not completely understood, it may function in limiting iron loss during
erythrocyte turnover and haemolysis. The main physiological function of haptoglobin is the
clearance of free haemoglobin from the plasma to facilitate lower free radical formation.
Hp-haemoglobin complexes are formed following haemolysis, which are rapidly taken up
by hepatocytes (Kino et al. 1980). Hp has been proposed to have an antioxidant function
by preventing haem-iron mediated generation of free radicals (Gutteridge 1987, 1995a,b).
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The haptoglobin (Hp) gene is located on chromosome 16q22.1 and consists of 7 exons.
Almost immediately adjacent to the Hp gene is the haptoglobin-related (Hpf) gene,
consisting of 5 exons, sharing high nucleotide sequence homology with the Hp gene
(Maeda et al. 1984, Bensi et al. 1985, Maeda 1985). The two common alleles of the Hp
gene, Hp1 and Hp2, have been reported to result in three phenotypes, Hp1-1, Hp2-1 and
Hp2-2 (Smithies et al. 1962, Langlois and Delanghe 1996). Several functional differences
have been reported between these phenotypes (Langlois and Delanghe 1996, Langlois et
al. 1997a,b). For example, Hp2-2 has been reported to have less efficient haemoglobin-
binding capacity and hence a weaker function than Hp1-1 and Hp2-1. The Hp2-2
phenotype may result in retention of iron, resulting in oxidative stress induced by excess
iron. Also, vitamin C (an antioxidant) is depleted in individuals with Hp2-2, and was shown
to contribute to increased oxidative stress (Sadrzadeh and Eaton 1988, Gordeuk et al.
1994, Livrea et al. 1996, Langlois et al. 1997a,b). Furthermore, Hp polymorph isms may
influence the course of certain infections, for example viral hepatitis, and the Hp2-2 variant
has been shown to also have an adverse effect in tuberculosis infection in Black Africans
(Kasvosve et al. 2000). Earlier studies identified another major phenotype, HpO,
predominantly in West African individuals (Allison et al. 1958). This phenotype is causative
of an absence of Hp, resulting primarily in anhaptoglobinaemia (or anti-haptoglobin
antibody), often characteristic of anaphylactic reactions in blood transfusion individuals.
HpO was shown to be due to a deletion in the Hp cluster (Koda et al. 1998), involving
complete deletion of both the Hp and Hpr genes. Hpdelwas shown to be approximately 28
kb in size, occurring from 5.2 kb upstream of the Hp gene to the 3' region of intron 4 of the
Hpr gene (Koda et al. 2000).
Haptoglobin and HIV-infection
Recently it was shown that the clinical outcome in HIV-infected individuals differs greatly
according to various haptoglobin phenotypes. Determination of haptoglobin phenotypes in
the serum of HIV-infected subjects has demonstrated that HIV-seropositive patients
carrying Hp2-2 show a worse prognosis, compared to the Hp1-1 and Hp1-2 phenotypes
(Delanghe et al. 1998). This was reflected by a more rapid rate of viral replication in the
absence of anti-retroviral treatment. Sufficient evidence was provided by this study, that
the highest HIV-1 viral load was found in Hp2-2 carriers compared with those with other
Hp phenotypes, suggesting a more rapid viral replication rate in Hp2-2 carriers.
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The lowest haptoglobin concentrations were further observed in the Hp 2-2 carriers. As a
consequence, quantitative binding of haemoglobin is lower in Hp2-2 plasma than in Hp1-1
or Hp1-2 plasma, suggesting a less efficient removal of free haemoglobin from the plasma
and ultimately a degree of haem iron accumulation. These patients accumulate more iron
and oxidise more vitamin C, suggesting that less efficient protection against
haemoglobin/iron-driven oxidative stress may be a direct mechanism for stimulating viral
replication. Excess iron induces an iron-driven peroxidation of vitamin C (Langlois et al.
1997a, Stadtman 1991).
Although vitamin C is a powerful antioxidant (free radical 'scavenger'), in the presence of
excess Fe3+ iron it has pro-oxidant activity (Herbert et al. 1996). This facilitates the
conversion of Fe3+ trapped within ferritin to Fe2+, and vitamin C itself becoming oxidized
(Gordeuk et al. 1994). Fe2+ then leaks out of the ferritin protein, generating free radicals by
means of the Fenton reaction (Gutteridge 1995a,b).
Fenton Reaction: OH· + OH-
Oxidative stress caused for example in this manner due to reactive oxygen radicals (for
example OH"), stimulates HIV replication through activation of the nuclear transcription
factor NF-KB, thereby contributing to development of cell damage and immunodeficiency
(Boelaert et al. 1996, Wong et al. 1991, Schreck et al. 1991). It has been suggested that
oxidative stress is increased in HIV infection due to iron excess, which may potentially
activate viral replication (Boelaert 1996a,b). Vitamin C on the other hand suppresses HIV
reverse transcriptase activity and viral replication in chronically HIV-infected cells
(Harakeh et al. 1990). A combination of higher iron-driven oxidative stress and vitamin C
depletion, may therefore contribute to the increased HIV replication rate as observed in
Hp2-2 individuals.
Further, a recent study investigating the contribution of the deletion of the haptoglobin
gene due to Hpdel in HIV disease, suggested a significant association with fewer HIV-
infected patients and with limited destruction of CD4+ cells, which favours an improved
prognosis (Quaye et al. 2000).
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The importance of host receptor molecules in the infection mode of HIV (via for example
CCR5, CCR4, CCR3, and CCR2b) was highlighted by this observation. As haptoglobin
has been shown to be a ligand for some HIV-1 cellular adhesion molecules (Sanchez-
Madrid et al. 1983, Valentin et al. 1990), these investigators postulated that limited
destruction of CD4+ cells in the HpO phenotype might serve as a cofactor in HIV
transmission from cell to cell. Therefore, although not preventing spreading of the virus,
the absence of haptoglobin might limit virus transmission between cells. It was pointed out
via this study that CD4+ cells were diminished in HIV-seropositive individuals with Hp2-2,
and that HIV transmission might be higher in this group of individuals. This could possibly
be ascribed to the weak binding capacity of Hp2-2 to haemoglobin, making unbound iron
available for HIV-1 replication and transmission.
Other genes potentially involved in HIV-pathogenesis due to their role in iron homeostasis
A number of other genes have been proposed to be associated with iron-related
disorders, including genes encoding transferrin, transferrin receptor 1, transferrin receptor
2, ferritin-L, ferritin-H, IRP1, IRP2, f32-microglobulin, mobilferrin/calreticulin, ceruloplasmin,
ferroportin, NRAMP2 (DMT1), heme oxygenase-1, heme oxygenase-2, hepcidin, USF2,
ZIRTL, duodenal cytochrome b ferric reductase (DCYTB), TNFa, keratin 8, and keratin 18
(Lee et al. 2002). The roles of genes involved in iron metabolic pathways therefore need
further investigation to fully understand their possible role in HIV-pathogenesis.
Genes involved in iron metabolism and/or immune function selected for further
investigation in the present study, are discussed in more detail in the context of HIV
disease.
a. The SLC11A 1 (NRAMP1) gene
The NRAMP1 (natural resistance-associated macrophage protein 1) gene, recently
renamed the SLC 11A 1, solute carrier family 11 (proton-coupled divalent ion transporter),
member 1 gene is located on chromosome 2, locus 2q35 (Cellier et al. 1994, Liu et al.
1995). It consists of 15 exons, 14 introns, an upstream 1 kb promoter, and an alternatively
spliced exon encoded by an Alu element within intron 4. Furthermore, the SLC11A 1 gene
is located on a fragment of 220 kb in close proximity to the VIL gene, encoding villin with
the interleukin-8 (IL-8) genes in between (White et al. 1994).
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Prior to the discovery of the SLC11A 1 gene, its murine homologue Nramp1, was mapped
to mouse chromosome 1 (Vidal et al. 1993), which is located close to the murine beg (ity,
Ish) gene. The Beg gene was shown to be important in natural resistance to infection with
unrelated parasites such as Mycobacteria, Salmonella, and Leishmania (Vidal 1995).
Nramp 1 encodes a macrophage-specific polypeptide with predicted features characteristic
of an integral membrane protein. It was suggested that Nramp1 activity may control its
own expression by negative autoregulation, which may be important in iron homeostasis
and maintenance of low cytoplasmic redox active levels in macrophages (Baker et al.
2000).
Exonic polymorphisms of SLC11A1 appear to be rare, possibly due to the functional
nature of the gene. However, some mutations have been identified primarily in the
promoter region of the SLC11A 1 gene. Nine sequence variants associated with the
SLC11A1 gene were identified by Liu and co-workers (1995), in addition to a dinucleotide
repeat in the 3'UTR of the gene, that was deleted in some cases. This mutation was
suggested to be involved in regulating gene expression (Liu et al. 1995, Buu et al. 1995).
Analysis of the promoter region of SLC11A 1 indicated a polymorphism encoding aZ-DNA
forming dinucleotide repeat 5'[Gnn, containing various alleles (Searle and Blackwell 1999,
Graham et al. 2000, Kojima et al. 2001). It was established that the two most commonly
occurring alleles, alleles 2 and 3, occurred at gene frequencies ranging from 0.20-0.25
and 0.75-0.80 respectively in most populations (Table 3). Alleles 1 and 4 were however
less frequent (0.001), and alleles 5 and 6 are very rare.
Table 3. SLC11A1 5'[GT]n DNA repeat alleles, nucleotide sequences and allele frequencies
(Blackwell et al. 1995, Graham et al. 2000, Kojima et al. 2001)
Allele Nucleotide sequence Allele frequency
1 t(gt)5ac(gt)5ac(gt) 11ggcaga (g)6 0.001
2 t(gt)5ac(gt)5ac(gt)10ggcaga(g)6 0.20-0.25
3 t(gt)5ac(gt)5ac(gt)gggcaga(g)6 0.75-0.80
4 t(gt)5ac(gt)gg ggcaga(g)6 0.001
5 t(gt)4ac(gt)5ac(gt)1oggcaga(g)6 rare
6 t(gt)5ac(gt)5ac(gt)4at(gt)4ggcaga(g)7 rare
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Although the ability to drive gene expression differed for all four alleles, alleles 1, 2, and 4
were shown to have poor promoter activity in the absence of exogenous stimuli, whereas
allele 3 was responsible for increased gene expression. It was suggested that chronic
hyperactivation of macrophages associated with allele 3 was functionally linked to
autoimmune disease susceptibility, while the poor level of SLC11A 1 expression promoted
by allele 2 contributed to infectious disease susceptibility (Blackwell and Searle 1999).
This hypothesis was confirmed by the observation that bacterial lipopolysaccharides (LPS)
significantly reduced expression due to allele 2, although expression was enhanced by
allele 3. Conversely, it was shown that allele 3 protects against infectious disease and
allele 2 against autoimmune disease.
From these observations it was speculated that alleles that are detrimental in relation to
autoimmune disease susceptibility, might be maintained in the population because of
improved survival to reproductive age following infectious disease challenge (Searle and
Blackwell 1999). This observationwas recently supported by Kotze and co-workers (2001)
in demonstrating a significantly increased frequency of allele 3 in elderly subjects,
compared with younger individuals.
Susceptibility to Infectious Diseases
Various studies showed associations between the SLC11A 1 gene and infectious
diseases. Polymorphisms in SLC11A 1were typed in a case-control study of tuberculosis
in the Gambia, West Africa (Bellamy et al. 1998), and four polymorphisms were
significantly associated with tuberculosis infection. Heterozygosity for 2 SLC 11A 1
polymorphisms in intron 4 and the 3'UTR were significantly associated with tuberculosis
infection in this population, compared with the most common genotype 3,3. This
observation was confirmed in a study conducted in Guinea-Conakry (Cervino et al. 2000).
It has further been suggested that susceptibility to leprosy might also have a genetic
component involving SLC11A 1and additional genetic loci (Abel et al. 1998). Susceptibility
studies conducted in different geographical regions indicated clear association with
tuberculosis infection with the SLC11A1 gene (Greenwood et al. 2000, Marquet et al.
1999). Other associations with infectious diseases, including viral (HIV), bacterial
(tuberculosis, meningococcal meningitis) and protozoan pathogens have been described
(Shaw et al. 1997, Marquet et al. 1999, Gao et al. 2000, Ryu et al. 2000).
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The study by Marquet and co-workers (1999) indicated that four variants in the SLC11A 1
gene (5'[GT]n, 274CIT, 469+14GIT and 823CIT) are associated with modified risk to HIV
infection. It was pointed out that three of these markers (5'[GT]n, 274CIT, 469+14GIT)
were in linkage disequilibrium. These three markers were furthermore associated with a
reduced risk to infection, whereas the fourth independent marker (823CIT) was associated
with an increased risk to HIV infection. These observations strongly suggested a risk
modifying effect involving the SLC 11A 1 gene.
Localization and functional mechanism of the SLC11A 1 protein
The human SLC11A 1 gene encodes a membrane protein of 550 amino acids, with 85%
homology to the mouse homologue (Blackwell eta/. 1995). The SLC11A1 protein contains
10-12 putative transmembrane domains, 2 N-linked glycosylation sites (Vidal et al. 1993),
and an evolutionarily conserved consensus transport motif (Cellier et al. 1994, Kishi
1994). An N-terminal SH3-binding domain has further been characterised (Feng et al.
1996a). Since discovery of the human SLC11A1 gene, several investigations identified
homologues in other organisms and mammals (Cellier et al. 1995, Hu et al. 1997).
SLC11A 1 is believed to function in iron homeostasis involving the recycling of iron from
effete macrophages (Atkinson and Barton 1998), possibly through lysosomal iron
exocytosis. SLC11A 1 localizes to membranes of late endosomes and Iysosomes in
macrophages (Gruenheid et al. 1997, Searle et al. 1998), but not to early endosomes. It
was shown that SLC11A 1 targets phagosomes (Searle et al. 1998), which are activated
by cytokines after infection and engulfment of the pathogen. As the function of SLC 11A1
is pH-dependent, this mechanism creates an acidic environment for proper functioning of
SLC11A1.
Although the exact mechanistic function of SLC 11A1 has not been clarified, it is believed
to be a divalent cation (Fe2+, Zn2+ and Mn2+) transporter (Goswami et al. 2001). In contrast
with the symporter SLC11A2/DMT1 (Gunshin et al. 1997), SLC11A 1 is an antiporter that
can flux divalent cations in either direction against a proton gradient. In late endosomes,
i.e. after internalisation of pathogens and maturation of endosomes, SLC 11A1 delivers
divalent cations from the cytosol into the acidic compartment. Ferrous iron is utilised in the
Fenton reaction (refer to page 45) in the acidic environment to generate toxic hydroxyl
(OH .) radicals (Zwilling et al. 1999) for destruction of the pathogen.
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b. The haemochromatosis gene, HFE
Haemochromatosis, or iron loading disease (often referred to as iron storage disease), is
one of the most common autosomal recessive disorders in individuals of European
descent. Progressive accumulation of dietary iron by major body organs is a major clinical
feature of haemochromatosis, which has varied consequences for major organs, including
the skin where milder clinical outcomes have been observed. Haemochromatosis can
result in a wide range of clinical complications, including hepatic cirrhosis, diabetes
mellitus, hypermelanotic skin pigmentation, hypergonadism, arthritis and cardiomyopathy
(Bothwell et al. 1995, Adams and Valberg 1996, Niederau et al. 1996). Regulating the
metabolic levels of iron may therefore have significant outcomes where overload is
diagnosed, and this is effectively achieved by periodic phlebotomy (or bloodletting).
The haemochromatosis protein, HFE, has been shown to have a direct link with iron
loading disease, and is often associated with the inability to down-regulate iron absorption.
Although various types of iron overload exist, the term hereditary haemochromatosis (HH)
should however be reserved for the HLA-linked inherited disease, determined by
inappropriately high absorption of iron by the gastrointestinal mucosa.
The HFE gene encoding the HFE protein is located on chromosome 6p21.3. It was
previously named the HLA-H gene and is related to the MHC class I family (Feder et al.
1996, Bodmer et al. 1997, Mercier et al. 1997). HLA-H was renamed to HFE, as HLA-H
was also used for a presumed pseudogene in the HLA class I region. The gene was
identified to be involved in hereditary haemochromatosis (HH), after the identification of
the MHC class I alleles HLA-A3 and HLA-B14 (both located in the MHC region on
chromosome 6) was linked to iron overload (Simon et al. 1976, 1977a,b,c, Ritter et al.
1984). The gene was suggested to be located on chromosome 6 (Stevens et al. 1977),
possibly in linkage disequilibrium with the HLA-A locus. Some investigations suggested
this gene to be located between the HLA-A and HLA-B loci (Edwards et al. 1985, 1986). It
was further suggested that the locus for the haemochromatosis gene was in close
proximity to two ferritin heavy chain genes, one being a pseudogene (Dugast et al. 1990).
However, Calandro and co-workers (1995) established that the gene involved in HH was
telomeric to the 5' end of the HLA-F locus. Subsequent studies confirmed the locus was in
fact 4.6 megabases (Mb) from the HLA-A locus (Lonjou et al. 1998) and co-localised with
the preferred marker D6S105, although this molecular marker is 2 Mb from the HFE gene.
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The HFE gene consists of seven exons covering 12 kb of DNA (Feder et al. 1996), with
the exon/intron structure identical to other MHC class I genes (Malissen et al. 1982). It
comprises an open reading frame of 1 kb encoding 343 amino acids, and encodes an
MHC class I-like molecule that requires J32-microglobulin association for normal
presentation on the cell surface. Unlike other MHC class I genes where promoters are
relatively close to translation start-sites, no promoter or cis-acting elements have been
identified to promote transcription of the HFE gene. It has been suggested that an intron
and/or an additional 5' untranslated exon exists separating the first known exon and actual
transcription start-site, which may be involved in transcriptional activity (Feder 1999a,b).
HFE is expressed in most tissues as a 4.0 kb major transcript (Feder et al. 1996),
although two minor transcripts have been identified at 5.7 and 2.4 kb. It is unknown
whether this derivation may be due to alternative splicing amongst other possible
mechanisms. The only tissue where HFE mRNA has not been identified is the brain. This
expression pattern is suggestive of the involvement of HFE in most if not all tissues
involved in iron homeostasis. HFE is however most notably expressed in the liver and
small intestine, suggesting its role in cellular uptake of iron, although perhaps not an
exclusive role in the regulation of iron absorption from the gut. Further, because HFE
forms part of the MHC class I molecules it connects haemochromatosis with the immune
system, although the mechanism has not yet been elucidated. Specifically T-cells may
have a direct role in iron loading, as certain HLA alleles and haplotypes (A3 or A3B7) and
CD4-CD8 ratios (CD4:CD8 >3) have been associated with a greater degree of iron
overload (De Sousa 1989).
Various molecules related to HFE have been identified to utilise splice variants to regulate
metabolic pathways. For HLA-G, a non-typical MHC class I protein with significant
homology to HFE, it was shown that inclusion of a premature stop codon in intron 4 yields
an alternatively spliced molecule (Moreau et al. 1995). Similarly, a truncated form of HFE
that lacks the transmembrane domain as a result of alternative splicing was recently
identified (Jeffrey et al. 1999). It was suggested by further studies that the HFE gene does
indeed undergo alternative splicing, as different mRNAs have been identified (Rhodes and
Trowsdale 1999, Thenie et al. 2000). A number of these molecules may have biological
significance.
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Furthermore, other metal transport proteins also use alternative splicing pathways to
produce different protein isoforms. These include the iron regulatory element (IRE) and
non-IRE containing mRNA isoforms of the divalent metal transporter 1 (DMT1/SLC11A2),
found to be differentially expressed in different body tissues (Lee et al. 1998). It was
therefore postulated that this mechanism might allow for regulated uptake of iron by the
enterocyte.
Localization and functional mechanism of the HFE protein
Although HFE has structural homology to other class I MHC molecules, comparison of the
HFE sequence with other MHC class I molecules suggested that it is unlikely that HFE
plays a role in peptide presentation to cells of the immune system due to the structure of
its putative peptide-binding groove (Feder et al. 1996, Lebron et al. 1998). MHC class I
molecules are integral membrane molecules with three extracellular loops (a1, a2 and
a3), a transmembrane region and a short cytoplasmic tail. Similarly, the HFE protein
consists of a peptide binding domain, a single transmembrane region and a short
cytoplasmic tail (Figure 5).
Two functional missense genetic alterations C282Y and H63D (figure 5), were identified
by Feder and co-workers (1996). The C282Y (cysteine to tyrosine) mutation resulted from
a G to A transition at nucleotide (nt.) 845, and the H63D (histidine to aspartic acid)
mutation resulted from a C to G substitution at nt. 187. C282Y was predicted to disrupt a
critical disulphide bond in the a3 loop of the HFE protein (the most highly conserved
domain within class I MHC molecules), and to abrogate binding of the mutant HFE protein
to p2-microglobulin and its transport to and presentation on the cell surface. Formation of
a heterodimer between HFE and p2-microglobulin was however shown to be essential for
correct intracellular trafficking and transport of HFE to the cell membrane, confirming the
prediction of disruption by C282Y (Feder et al. 1997).
Various investigations confirmed that both C282Y and H63D were associated with
haemochromatosis in different populations. Approximately 85% (60%-100% in different
populations) of patients with haemochromatosis are homozygous for the C282Y mutation
(Beutler et al. 1996, Jouanolle et al. 1996, Merryweather-Clarke et al. 1997, Boret et al.
1997, Feder et al. 1998, Rochette et al. 1999). In some studies the mutation was
associated homozygously in up to 100% of HH patients (Jazwinska et al. 1995).
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Figure 5. The predicted structure of HFE, including hereditary haemochromatosis-associated
mutations (modified from Feder et al. 1996).
Beutler and co-workers (1996) reported that the mutations at nt. 845 and 187 where the
respective genetic variations exist were in complete linkage disequilibrium: nt. 187 was aC
on all chromosomes with the 845A mutation. This accounted for both the homozygously or
heterozygously inherited mutations. The H63D mutation was thought to occur in a site that
might cause disruption of ligand-receptor interaction in the protein. It was further shown
that H63D, unlike C282Y, had no effect on p2-microglobulin-association. The frequency of
H63D was found to be approximately 17% in the general population, and occurred
homozygously in 2.8% of the population. In individuals with HH however, this mutation was
found heterozygously in -89% (8 out of 9) of HH patients who were compound
heterozygotes for the C282Y mutation (Feder et al. 1996). Thus, on its own H63D did not
appear to cause HH, whereas in combination with C282Y haemochromatosis could result
(Feder et al. 1996, Beutler 1997a,b,c, Risch 1997).
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Although studies indicated that both the C282Y and H63D mutations were present at low
frequencies in Asian populations, where haemochromatosis is not a major health concern,
it was concluded that C282Y is almost always associated with the Caucasian haplotype
(Chang et aJ. 1997, Merryweather-Clarke et aJ. 1997, Cullen et aJ. 1998). This suggested
its presence in these populations to be due to genetic admixture. Conversely, the H63D
mutation has been found on many haplotypes.
Some studies have however shown that approximately 15% of individuals with HH do not
have any mutation of the HFE gene (Feder et aJ. 1996, Carella et aJ. 1997, Beutler et aJ.
1997). In addition, some of those who were heterozygous for C282Y, but not C282Y/H63D
compound-heterozygotes failed to show any consistent haplotype on the non-C282Y
chromosome. This suggested that many different mutations in HFE should be present,
each with a unique haplotype. However, this has not been supported by most
investigations, suggesting that additional disease-causing HFE mutations are probably
rare. Alternatively, for the majority of individuals with iron overload symptoms and no HFE
mutations, this could possibly be due to causes other than mutations of the HFE gene.
The presumed role of the HFE gene product in the regulation of iron homeostasis
suggested that varying iron levels might regulate the gene itself (Feder et aJ. 1999a,b). It
was demonstrated that both wild type and H63D HFE proteins form stable complexes with
the transferrin receptor (TFR), possibly contributing to its function in iron homeostasis
(Feder et aJ. 1998, Parkkila et aJ. 1997). However, the C282Y mutation almost completely
prevented association of the mutant HFE protein with TFR. Overexpression of the wild
type HFE protein could further decrease the affinity of TFR for transferrin. The
overexpressed H63D protein however did not have this effect, providing direct evidence
for a functional consequence of the H63D mutation. These observations established a
molecular link between HFE and a key protein involved in iron transport, and raised the
possibility that alterations in this regulatory mechanism may play a role in the
pathogenesis of HH.
A molecular model for the function of HFE protein and mechanism by which mutations in
HFE may lead to HH has recently been proposed (Townsend and Drakesmith 2002). It
was suggested that HFE has two mutually exclusive activities in cells: inhibition of uptake
or inhibition of release of iron.
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The balance between serum transferrin saturation and serum transferrin-receptor
concentrations determines which of these functions predominates. HFE enables the
intestinal crypt cells and reticuloendothelial system to interpret the body's iron
requirements and regulate iron absorption and distribution. It was further proposed that
HFE mutations might result in overabsorption of dietary iron with consecutive tissue iron
deposition.
HFE and HIV/AIDS disease progression
A possible link between HFE and HIV-disease progression was recently suggested by the
identification of a HIV-seropositive individual with relatively high iron loading due to HH
(Nielsen et al. 1999). It was shown that HH in this individual was positively linked to
homozygous inheritance of the C282Y mutation. Long-term survival (more than 10 years)
was further achieved after regular phlebotomy. Although this was the only case reported
to date with HH, this observation suggested a potential important role of iron in HIV/AIDS
disease progression. It was further suggested that HIV-infection in this individual might
have been protective against iron loading damage, as no clinical symptoms for HH were
observed. However, as iron loading could be disadvantageous in HIV-infection, one might
expect that HIV-seropositive individuals with HH may present with a worse clinical
outcome due to iron-mediated acceleration of HIV infection (Dhople et al. 1996). The
significant observation described by this report, further supported by preliminary data from
poly transfused individuals, suggested that iron chelation therapy might assist in preventing
(or reversing) negative consequences normally associated with both iron overload and
HIV infection.
Does C282Y and H63D affect African iron overload?
From various population studies, an association for the C282Y substitution in the HFE
gene of African individuals and iron overload have not been found, whereas it is highly
prevalent in populations of European ancestry (Merryweather-Clarke et al. 1997, Roth et
al. 1997, Barton and Acton 2001). This supports the previously suggested Celtic origin of
haemochromatosis (Jazwinska et al. 1995). In contrast however, the H63D substitution is
not restricted to European populations, as it has been detected in some African
populations, suggesting the H63D substitution may have occurred earlier than the C282Y
substitution.
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Furthermore, the H63D and C282Y mutations have not been detected in Southern African
individuals diagnosed with African iron overload (McNamara et al. 1998). It has been
suggested that this condition may have a genetic cause, in addition to being directly
related to excess dietary iron intake (Gordeuk et al. 1992b). However, it does not appear
as though the known HFE mutations have an effect on this condition. It was also shown
that African iron overload was not linked to the HLA locus on the short arm of
chromosome 6 (Gordeuk et al. 1992b), suggesting the involvement of another gene(s) in
this condition in Africans. Therefore, if African iron overload had a genetic cause, it
appears as though this differs from that found in the European condition. Alternatively,
different HFE mutations may be responsible for this condition in African individuals.
It has been suggested that individuals with iron overload who do not have the known
H63D or C282Y causative mutations, may have mutations in other genes contributing to
iron loading (McNamara et al. 1998). This suggestion can be supported by the fact that
excess iron accumulates in the macrophages of individuals with African iron overload,
whereas it is not the case in Caucasian individuals (Bothwell and MacPhail 1998). It is
therefore possible that unidentified mutations in other genes may contribute to the
condition of African iron overload.
Other HFE mutations
A number of other mutations have been identified in HFE. Of these, the S65C mutation
(serine to cysteine) is the most commonly occurring mutation affecting the HFE gene, and
resulting in a mild form of HH (Fagan and Payne 1999, Mura et al. 1999). Also, rare HFE
mutations were recently reported by Bradbury and co-workers (1999). These mutations,
E277K and V212, were observed in two isolated individuals (in an Asian and a Caucasian
individual, respectively) with diabetes, but no signs of iron overload.
Recently, a study on South African populations (de Villiers et al. 1999) identified novel
missense and silent mutations in the HFE gene. An exon 2 mutation resulting in a V53M
amino acid substitution was identified in South African Black and Bushman (Khoi-San)
populations, and a second exon 2 mutation resulting in a V59M substitution was identified
in a South African Caucasian. An exon 5 mutation resulting in a R330M substitution was
also identified in South African Caucasian individuals from this study.
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Of note, a mutation occurring in exon 3 (Q127H) was identified, which may disrupt a
critical disulphide-binding area of the HFE protein. This may resemble the reported
situation for the C282Y mutation, which disrupts a critical disulphide bond in the a3
extracellular loop of HFE (Parkkila et al. 1997). Some of these and other mutations
described by these investigators indicated a possible association with porphyria cutanea
tarda (PCT), often associated with hepatic siderosis and iron overload (Roberts et al.
1997b, Bonkovsky et al. 1998, Sampietro et al. 1998). This relationship has recently been
confirmed in South African individuals with PCT (Elder and Dorwood 1998, Hift et al.
1997).
A previously described intron 2 mutation IVS2+4T was recently identified in 70% of PCT
patients from Denmark (Christiansen et al. 1999, Douabain et al. 1999), which almost
always occurred heterozygously or homozygously with the known H63D or S65C mutants.
Further, a splice-site mutation in intron 3 (IVS3+1 GIT) in compound heterozygosity with
C282Y was identified in two Caucasian siblings with iron overload (Wallace et al. 1999).
Although extremely rare, it was shown that this mutation functionally alters RNA splicing
causing obligate skipping of exon 3. The functionality of this mutation highlighted the
possibility of other rare HFE mutations, possibly in compound heterozygosity with C282Y,
causing high iron overload.
African-specific HFE polymorphism
A common polymorphism in intron 3 (IVS3-48C~G) was identified recently, occurring
almost exclusively in African American individuals (Beutler and Gelbart 2000). This
polymorphism was detected after several investigators noted that the binding site for PCR-
amplification primers used in routine diagnosis of HH (described by Feder and co-workers
in 1996) was hampered by a mutation in intron 4 (de Villiers et al. 1999, Beutler et al.
2000, Merryweather-Clarke et al. 1997). It was indicated that presence of both the intron 3
and intron 4 polymorph isms may lead to misdiagnosis of C282Y.
The IVS3-48 C~G polymorphism occurs in a site that closely resembles the splice site
also occurring in intron 3 (Beutler and Gelbart 2000), and this mutation had a greater
effect than one in intron 4, which prevent amplification of the preferred C282Y allele.
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Although this mutation is located in a potential alternative splice site, no evidence has
been reported on alternative splicing of HFE or iron homeostasis. The elevated frequency
in Africans (12.8% compared with 0.6% of Caucasians) is however a notable observation.
Alternatively, this intronic mutation may be causative of alternative splicing in tissues other
than leukocytes, which may be involved in iron homeostasis. This study furthermore
indicated that serum iron parameters were not altered in individuals with the mutation, and
it was concluded that it only affects accurate diagnosis of the C282Y mutation. It might
however be important to investigate the possible significance of this polymorphism in
different population groups, including HIV-infected individuals where viral infection may
affect iron homeostasis.
c. Immune Function: The CD45 (PTPRC) gene
In addition to non-MHC genes that may determine susceptibility to HIV, for example CCR5
and SLC11A1, the modulation of T-cell responses to particular antigens determines
disease severity. T-cell differentiation depends on the availability of iron, and iron
metabolism appears to be regulated by these molecules, possibly through interactions
with the MHC class I-like HFE protein (reviewed by Bowlus 2002). Alterations in iron
metabolism have a potentially hazardous impact on immune-related disorders, including
immunodeficiency. Both iron deficiency and overload have been shown to contribute to T-
cell abnormalities. The role of iron in the pathogenesis of HIV/AIDS can be supported by
the association of the iron transporter gene SLC11A 1with risk to HIV infection (Marquet et
al. 1999) and several other infectious and autoimmune disorders. Additionally, iron can
catalyse the production of cryptic epitopes of several autoantigens, supporting the role in
immunity. It is further possible that the polygenic nature of HIV/AIDS susceptibility could
be attributed by the involvement of molecules involved in immune activation, for example
CD45 (Tchilian et al. 2001a).
The CD45 (or PTPRC, protein tyrosine phosphatase receptor type C) gene is located on
chromosome 1q31-32, and contains 35 exons encoding the CD45 (PTPRC) molecule, a
member of the protein tyrosine phosphatase (PTPase) family (Akao 1987, Ralph et al.
1987, Seldin 1988). It has been estimated to be more than 120 kb in size (Fernandez-
Luna et al. 1991, Hall et al. 1998), and co-localises with marker D1S413 on chromosome
1 (Goff et al. 1999). Further, other genes of immunologic interest have been reported to
cluster in this chromosomal region (Ravetch et al. 1986).
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Although control elements in the CD45 gene has not been detected, analysis of the 5'
flanking region of the human CD45 gene indicated a region with strong promoter activity in
the highly conserved first intron of the gene (Timon and Beverley 2001). The promoter
activity is not tissue-restricted, and is strongest at the 3' end of intron 1, although the
nucleotide sequence lacks similarities with known promoters and initiators. An alternative
exon 1, designated 1a, was further identified which can be spliced to exon 2. Also, due to
the unusually large intron sequence between exons 2 and 3, which appears to be very
conserved, the possibility of control sequences being located within intronic sequences of
the CD45 gene was recently suggested (Virtis and Raschke 2001).
CD45, also known as PTPRC (or T200 glycoprotein or leukocyte common antigen, Lca) is
an integral transmembrane tyrosine phosphatase that is expressed on nucleated
haemopoietic cells where it comprises up to 10% of the cell surface (Charbonneau et aJ.
1988, Tonks et aJ. 1988, 1990, Trowbridge and Thomas 1994).
CD45 functions as a tyrosine phosphatase in leukocyte signalling, regulating both T-cell
receptor-associated kinases and Janus kinases, and is involved in signal transduction
from cytokine receptors. T-cell receptor-mediated activation of B- as well as T-
lymphocytes is facilitated by CD45 after antigen stimulation by dephosphorylation of an
inhibitory site on the Src-family of tyrosine kinases, yielding an enhanced kinase ability of
the substrate essential for initiation of the signalling event (Thomas and Brown 1999).
Efficient lymphocyte antigen receptor signal transduction is dependent on the
phosphatase activity of CD45 (Kishihara et al. 1993, Byth et aJ. 1996, Kung et al. 2000,
Tchilian et aJ. 2001b). A lack of CD45 has been shown to be responsible for severe
immunodeficiency, due to a lack of T-cells in the periphery and impaired Tand B cell
responses. CD45 can further function as a Janus kinase (Jak) phosphatase, negatively
regulating cytokine receptor activation involved in differentiation, proliferation and anti-viral
immunity of haemopoietic cells (Irie-Sasaki et aJ. 2001).
CD45 is a type I transmembrane protein with a large heavily glycosylated extracellular
domain (consisting of 391-552 amino acids), and an extensive cytoplasmic tail (consisting
of 700 amino acids) that contains two domains with phosphatase homology. The proximal
cytoplasmic domain of CD45 is responsible for phosphatase activity, whereas the second
domain is required for proper folding and substrate recruitment.
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Substrates for CD45 include various members of the Src family of tyrosine kinases, which
are operated by CD45 either as a positive or negative regulator (Ostergaard et al. 1989,
Shiroo et al. 1992). Although the cytoplasmic domain is highly conserved, low sequence
similarities have been observed between CD45 extracellular domains of different species
(Okumura et al. 1996, Diaz Del Pozo et al. 2000). This supports the essential role of CD45
as a phosphatase for normal antigen-induced signal transduction.
At least eight different isoforms have been identified for CD45, which are generated by
complex alternative splicing. The alternative spliced isoforms range in molecular weights
from 180 to 220 kDa (Alexander 1997). Alternative splicing of exons 4, 5 and 6 at the N-
terminus of the extracellular domain of the molecule is responsible for the different
isoforms (Saga et al. 1986, Streuli et al. 1987). Exons 4, 5 and 6 are also termed A, 8 and
C respectively. Thus, CD45RA8C refers to an isoform containing all three variable exons
4, 5 and 6, while the CD45RO isoform refers to the null isoform in which exons 4, 5 and 6
have been spliced out.
Expression of the different CD45 isoforms depends on the state of activation and
differentiation of haemopoietic cells (Akbar et al. 1988, Hathcock et al. 1992, Craig et al.
1994), and plays a distinct role in cellular signalling (Chui et al. 1994, Leitenberg et al.
1996). In humans and other mammals differential expression of CD45 isoforms on the cell
surface has been used as a measure to distinguish between subsets of T-cells with
distinct functional properties (Akbar et al. 1988, Lee et al. 1990, Mackay et al. 1990,
Powrie et al. 1990).
8-lymphocytes express the high molecular weight isoform of 220 kDa, CD45RA8C (also
called 8220). Immature CD4+CD8+ thymocytes express mainly low molecular weight
isoforms, whereas mature CD4+ and CD8+ thymocytes and peripheral T-cells can
express multiple isoforms. Expression of different isoforms also changes during T-cell
activation. Two major subsets of T-Iymphocytes have been identified in humans
expressing high molecular weight isoforms containing the A exon (CD45RA cells) or the
180 kDa isoform (CD45RO cells), also termed naïve and memory cells respectively. The
two subsets however have distinct properties (Michie et al. 1992, Pilling et al. 1996,
Hamann et al. 1997, Young et al. 1997, Maini et al. 1999, 2000). It is further known that
HIV preferentially infects CD45RO cells (memory cells), which are lost earlier in HIV
infection than their CD45RA counterparts (Helbert et al. 1997).
Stellenbosch University http://scholar.sun.ac.za
62
Various mutations in the CD45 gene have been linked to the function of CD45 in immune-
related disorders. The phenotypic changes caused by these mutations could alter the
function of CD45 in immune function in humans, suggesting that CD45 is a potential
candidate target for immune intervention, and that its modulation may affect autoimmune-
related disorders, amongst others. Alterations in the respective mutation carriers may lead
to changes in ligand binding, homodimerization of CD45, and altered immune responses,
suggesting the involvement of natural selection in controlling the carrier frequencies of the
mutations.
Recently, a homozygous 6 bp deletion was identified in exon 11 of the CD45 gene, which
results in a lack of surface CD45 expression and severe combined immunodeficiency
(SCID) (Tchilian et al. 2001c). The deletion resulted in a loss of two essential amino acids
of the extracellular domain of CD45. Another study also reported lack of CD45 expression
associated with SCID (Kung et al. 2000).
Additional to the association of SCID, further abnormalities of CD45 splicing have been
reported in humans yielding lack of CD45 surface expression. A C to G transversion in the
fourth exon of CD45 (exon A, C77G) was shown to disrupt normal splicing of the N-
terminal region (Thude et al. 1995, Zilch et al. 1998). Although this silent mutation does
not change the amino acid sequence, it prevents splicing by disrupting a strong exonic
silencer (Lynch et al. 2001). Both high and low molecular weight CD45 isoforms are
expressed by activated or memory T-lymphocytes in affected individuals, in contrast to the
normal pattern of low molecular weight isoform expression. Development of multiple
sclerosis (MS) was recently associated with expression of the C77G polymorphism
(Jacobsen et al. 2000). This association could not be confirmed in subsequent studies
(Barcellos et al. 2001, Vorechovsky et al. 2001). Furthermore, an increased frequency of
the C77G variant G-allele was observed in HIV-1 seropositive individuals, compared to
healthy individuals (Tchilian et al. 2001 a). Further associations involving alternative
splicing of CD45 due to C77G have also been described (Bujan et al. 1993, Wagner et al.
1995). Combined, these studies suggested an association of abnormal CD45 splicing with
impaired viral clearance. It appears that expression of different isoforms of CD45 alters T-
cell related (TCR)-mediated signal transduction, although the exact functions of individual
isoforms are unknown. It is thus likely that abnormal CD45 splicing may be associated
with immunodeficiency, autoimmunity or impaired anti-viral responses.
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Population studies have indicated that the frequency of the C77G transversion varies
considerably in the general population. Reported frequencies were 0.16% in Germany and
0.85% in the United Kingdom, and ranged between 1.4 and 1.8% in North America and
Sweden (Jacobsen et al. 2000, Vorechovsky et al. 2001). Striking differences have been
observed in different African and Asian populations, where it could be as high as 6.7% in
Pamiris from Central Asia (Tchilian et al. 2002). The observation of the highest frequency
in central Asian populations, suggested that the variant might have arisen in Central Asia.
However, the mutation appears to be absent from African individuals (Tchilian et al. 2002).
Altered isoform expression could further be due to a second mutation in exon 4 (C59A)
causing interference with splicing in MS patients (Jacobsen et al. 2002). In addition to a
disruption of the stronger of two CD45 exonic splicing silencer elements, ESS-1, C59A
causes a non-conservative amino acid exchange (H19Q, histidine to glutamine) in the
CD45A antigen, suggesting this mutation may be causative of a structurally altered
protein.
Most recently, a polymorphism in exon 6 (A138G) was detected in the CD45 gene and it
was also shown to interfere with alternative splicing (Stanton et al. 2003). The
polymorphism results in a T47A (threonine to alanine) amino acid substitution, a potential
0- and N-linked glycosylation site. The A138G variant is present at a frequency of 23.7%
in the Japanese population, although absent in Caucasians. Peripheral blood T-cells from
individuals carrying A 138G showed significant reduction in the proportion of cells
expressing the A, B, and C isoforms of CD45 and a high frequency of CD45RO+ cells.
The CD45 locus has furthermore been suggested to be a site of strong natural selection in
other vertebrates (Raschke et al. 1995, Symons 2000, Ballingall et al. 2001), which
appears to be pathogen driven.
As CD45 has an important role in immune function, with association in various immune-
related disorders including HIV-1 infection, predominantly due to alternatively spliced
isoforms expressed in different cell types of the immune system, it is therefore important
to investigate the association of possible genetic variation in the CD45 gene with
HIV/AIDS in the diverse South African population.
Stellenbosch University http://scholar.sun.ac.za
OBJECTIVES AND AIMS
Stellenbosch University http://scholar.sun.ac.za
64
OBJECTIVES AND AIMS
The complexity of interactions between host cells and microorganisms at the molecular
level suggests that genetic variants of any of the host molecules involved in the host
response to infection might alter the fate of the infectious agent within the host. Differing
susceptibility patterns between individuals and between different ethnic populations
furthermore contribute to the complexity of infectious diseases. Most host genetic
investigations have been conducted in Westem and Asian populations. The importance of
investigating African populations is therefore clear, as the majority of HIV-infections occur
in developing countries, specifically from sub-Saharan Africa.
SPECIFIC OBJECTIVES
1) To contribute to a better understanding of the genetic background of HIV-1-infected
subjects in order to eventually increase the predictive ratio of disease evolution.
2) To identify genetic variants involved in HIV/AIDS susceptibility in the South African
population and investigate possible phenotypic effects of relevant mutations studied.
3) To gain knowledge from studying South African subjects at the molecular level which
may ultimately improve treatment strategies and may serve, in addition to viral load
and CD4 cell counts, as decision-making tools for clinical management of HIV-1
infected subjects.
Even if the promise of preventive and therapeutic intervention based on HIV/AIDS
resistance genes is not fulfilled, discovery of relevant genetic factors potentially
contributing to susceptibility to HIV infection or progression to AIDS may have prognostic
value. This may therefore offer an opportunity to refine ongoing evaluation of other
promising therapeutic or preventive measures.
ETHICAL APPROVAL
Ethical approval for the project was obtained from the Research Committee of
Stellenbosch University (project number 2000/C068). All the patient material has been
obtained with informed consent from collaborating clinicians who are responsible for
patient management.
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A. The SLC11A1 gene and modified risk to human immunodeficiency virus
infection susceptibility in South Africa
Objectives: To investigate the likelihood that variation in the SLC11A 1 gene, encoding the
iron modulating solute carrier family 11 member 1 protein, modifies the risk of HIV
infection and/or progression to AIDS in South African individuals of predominantly African
origin. The ultimate aim is to gain insight into the mechanisms underlying host
susceptibility to disease progression.
Design: The functional 5'[GT]n repeat polymorphism in the promoter region of the
SLC11A1 gene and a potentially detrimental9-bp deletion in exon 2, were analysed in 374
HIV-seropositive individuals and 410 HIV-seronegative population-matched controls.
Methods: Mutation detection was performed using polymerase chain reaction (PCR)-
based methods, including restriction enzyme analysis and combined heteroduplex-single
strand conformation polymorphism (Hex-SSCP) analysis, followed by direct sequencing
where appropriate.
Results: Genotype distribution and allele frequencies did not differ significantly between
HIV-seropositive and HIV-seronegative individuals, although genotype 2,3 of the
SLC11A1 5'[GT]n repeat polymorphism appears to predominate in patients attending the
Infectious Diseases Clinic at Tygerberg Hospital compared with population-matched
controls.
Conclusions: The data obtained in this study largely exclude the likelihood that the studied
SLC11A 1 polymorph isms playa major role in HIV/AIDS susceptibility in our predominantly
African population group. Since polymorphic variants may become clinically relevant only
in certain environments or genetic backgrounds, we conclude that SLC11A1 host factors
involved in modified risk of HIV infection may be population-specific.
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Introduction
Host genetic factors have been shown to influence susceptibility to human
immunodeficiency virus type 1 (HIV-1) infection and progression to AIDS (Klein and
Miedema 1995, Bollinger et al. 1996, Haynes et al. 1996), in addition to immunological
factors and viral characteristics. Variation in a number of genes have been found to
completely confer resistance or at least protect against infectious agents, such as
mutations in chemokine co-receptors and the presence of certain alleles of the major
histocompatibility complex (MHC) (Liu et al. 1996, Dean et al. 1996, Laumbacher and
Wank 1998). Magierowska and co-workers (1999) have shown that combined genotypes
of CC chemokine receptor-2 (CCR2) and -5 (CCR5), the chemokine gene SDF-1,
encoding the ligand for the CXCR4 chemokine receptor, together with certain alleles of
both MHC Class I and II, may strongly influence HIV/AIDS disease progression. Accurate
classification of approximately 70% of long-term non-progressors (LTNPs) and 18% of
progressors was possible by applying this proposed model, suggesting that other as yet
unidentified host factors that may provide protection or increase susceptibility to HIV-
infection in some individuals remain to be identified.
Although various susceptibility mechanisms have been proposed for HIV/AIDS, most
models involving host genetics are based on studies performed in Caucasians and Asian
populations, with limited data from African populations. Also, genes included were mainly
those related to chemokines and the histocompatibility antigen (human leukocyte antigen,
HLA). Recent HIV-association studies of chemokine-related genes in South Africa
(Williamson et al. 2000, Petersen et al. 2001) and elsewhere (Ramaley et al. 2002a) have
shown that except for the CCR2b-641 genetic variant, protective genetic variation is
relatively rare in Africans. Since HLA studies have indicated that different alleles are
implicated in HIV/AIDS susceptibility in Africans and Caucasians (Rohowsky-Kochan et al.
1998, Roe et al. 2000), further studies of new candidate genes are warranted in the
African context.
Genetic variation in genes encoding proteins involved in immune defence, expressed in
cells of the monocyte/macrophage lineage, may modify the risk of HIV-1 infection and
progression to AIDS.
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Interest broadened in the family of proton-coupled divalent metal ion-transporter proteins,
specifically the solute carrier family 11 member 1 (SLC11A 1), formerly known as the
natural resistance-associated macrophage protein 1 (NRAMP1), following evidence that
monocytes and macrophages are important in the early phase of HIV infection (Gill et al.
1996). Association of the SLC 11A 1 gene encoding this protein with modified risk to HIV
infection (Marquet et al. 1999, Ramaley et al. 2000) was in accordance with the proposed
role of SLC 11A1 in infectious disease susceptibility (Skamene et al. 1998, Buschman et
al. 1997, Blackwell et al. 1996). Studies performed by Searle and Blackwell (1999)
demonstrated that the poor level of expression of allele 2 [(t(gt)sac(gt)sac(gt)1Qg] of the
5'[GT]n polymorphism in the promoter region of the gene is associated with infectious
disease susceptibility. Furthermore, chronic hyperactivation of macrophages associated
with allele 3 [(t(gt)sac(gt)sac(gt)gg] is functionally linked to autoimmune disease
susceptibility. Whilst this differential effect was mediated by bacterial lipopolysaccharides
in vitro, an extension of these studies including ferric ammonium citrate as an external
stimulus suggested the importance of cellular iron status in differential regulation of
macrophage activation (Kotze et al. 2003). The finding that allele 3 may protect against
infectious disease and allele 2 against autoimmune disease (Searle and Blackwell 1999),
raised the possibility that this phenomenon is related to low expression of allele 2 in the
presence of high cellular iron, thereby exerting protection against autoimmune disease.
Conversely, high expression of allele 3 upon iron loading may be related to the body's
defence mechanism of withholding iron from invading pathogens. It seems likely that such
complex gene-environment interaction might explain the paradoxical observations that
infectious agents can both induce and suppress autoimmune disorders (Bach 2002).
Availability of cellular iron related to dietary iron intake and subsequent biological
processes involved in iron homeostasis could possibly influence the outcome of case-
control studies in diverse populations exposed to different environments. Further,
infrequent occurring alleles of 5'[GT]n have previously been described, and occur at much
reduced (0.1% respectively) frequencies (Graham et al. 2000). These alleles have been
associated with other immune-related disorders, but no association with infection has
been observed.
Marquet and co-workers (1999) studied six different polymorphisms in the SLC11A1 gene
and reported independent association of two gene regions with HIV susceptibility in
Columbians.
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Their data indicated significant association between HIV/AIDS susceptibility and the
functional 5'[GT]n polymorphism, which appeared in strong linkage disequilibrium with two
downstream polymorphisms, 274CIT and 469+14GIT. In the present study the promoter
polymorphism and a potentially detrimental 9 base pair (bp) deletion in exon 2 encoding
the putative SH3 binding domain of SLC11A1, were analysed in 374 HIV-seropositive and
410 HIV-seronegative population-matched individuals from predominantly African origin
from South Africa. The 9-bp deletion removes three amino acids from an SH3-binding
domain of the protein and has been associated with susceptibility to HIV-1 infection in the
Ugandan population (Ramaley et al. 2000). In the mentioned study by Marquet et al.
(1999) allele 2 of the 5'[GT]n promoter polymorphism, occurring at a frequency of 20-25%
in the general population (allele 3, 75-80%) (Searle and Blackwell 1999), was reported to
be protective towards HIV infection in Columbians.
Materials and Methods
Study Population
The study cohort consisted of HIV-seropositive individuals recruited in the Western Cape,
Northwest and Gauteng Provinces of South Africa, and HIV-seronegative population-
matched control individuals (Table 1). Venous blood samples were obtained with informed
consent from these study participants and the Ethics Review Committees of the
Universities of Stellenbosch and Potchefstroom approved the study.
HIV-seropositive study participants from the Western Cape Province (n=219) attended the
Infectious Diseases Clinic at Tygerberg Hospital in Cape Town and included 125 subjects
of African origin (mainly Xhosa) and 94 of mixed ancestry (Cape Coloured population of
San, Khoi, African, Madagascar, Javanese and European origin). Estimated date of
infection and HIV-1 disease-associated complication data were recorded for the majority
of these individuals, and ages were calculated based on date of blood sampling. Data on
disease status were denoted according to WHO clinical disease classification (classes 1-
IV, http://who.int), which was available for 171 individuals. HIV-seropositive individuals
were further classified as normal progressors when progressive loss in CD4 cell counts
were associated with development of AIDS-related symptoms within 10 years after HIV-1
infection, as fast progressors when they progressed to full-blown AIDS within 2-3 years
from seroconversion, and as slow progressors when they remained unaffected after 8-10
years from seroconversion.
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Table 1. Study Cohort
Study Population HIV-seropositive HIV-seronegative
Western Cape Province Male Female Total Male Female Total
African 37 88 125 26 38 64
Age range (years) 21-59 19-56 19-59 19-47 17-49 17-49
Mean Age 33.19 30.61 31.43 27.5 28.6 27.94
Mixed Ancestry 25 69 94 56 10 83 *
Age range (years) 21-56 22-73 21-73 17-52 26-45 17-52
Mean Age 36.20 34.15 34.71 30.14 34.38 30.67
Northwest Province Male Female Total Male Female Total
African 55 91 146 52 99 151
Age range (years) 15-81 17-69 15-81 7-71 17-77 7-77
Mean Age 35.00 33.76 34.28 42.24 36.23 38.08
Gauteng Province Male Female Total Male Female Total
African 8 9 54 58 112
Age range (years) 32-48 44 32-48 22-62 21-59 21-62
Mean Age 38.50 44 39.11 34.19 30.83 32.38
TOTAL 125 249 374 188 205 410
*Ages and gender available for 66 HIV-seronegative individuals of mixed ancestry
Progression status according to these criteria was available for only 72 of the HIV-
seropositive individuals. HIV-seronegative population-matched individuals for the African
individuals from the Cape Province (n=64) were selected from volunteers with no previous
history of HIV-related infectious disease or immune disorders. For the study participants of
mixed ancestry (n=83), HIV-seronegative population-matched individuals were recruited
from healthy individuals attending blood donation clinics in the Western Cape.
For the population recruited from the Gauteng Province blood samples were obtained
anonymously from predominantly healthy individuals, and the population consisted
exclusively of African individuals (9 HIV-seropositive and 112 HIV-seronegative). The
African population from the Northwest Province formed part of a cross-sectional study
previously performed by James et al. (2000), and consisted of 146 HIV-seropositive and
151 HIV-seronegative individuals.
Stellenbosch University http://scholar.sun.ac.za
70
Since these individuals were recruited from a random population sample, HIV status was
unknown at the time of entry and was assessed upon inclusion into the study. These
individuals originate from a more rural setting compared with the study cohort recruited in
the Cape Province and Gauteng Province, and disease progression status was
asymptomatic for the majority of the HIV-seropositive individuals.
DNA Extraction and Amplification
Genomic DNA was extracted from whole blood using a standard method (Miller et al.
1988). Primer sets used for polymerase chain reaction (PCR)-based DNA analysis of the
SLC11A1 genomic regions of interest were as follows: 5'-CCCCAGAACCTTGAGGTCTA-
3' (forward) and 5'-CCCACACCAGTACCCCAT-3' (reverse) for analysis of the 5'[GT]n
promoter polymorphism; 5'-AGGAGGGAAAGGATCAGG-3' (forward) and 5'-
GGATCCTGTCAATCTTGCAAGC-3' (reverse) for analysis of the 9-bp deletion
polymorphism in exon 2. DNA amplification was performed in 25 !-lI reaction volumes
containing -20 ng of genomic DNA, 5 mM each deoxyribonucleoside triphosphates
(dNTPs), 15 pmol of each PCR primer, Mg2+-containing reaction buffer and 0.375 units of
DNA Taq polymerase (Roche Diagnostics, Switzerland). A step-down PCR amplification
procedure was applied with one cycle initial denaturation for 3 minutes at 95°C, ten cycles
of denaturation at 95°C for 45 seconds, annealing at 65°C for 30 seconds and extension
at 72°C for 45 seconds, followed by twenty-five cycles of denaturation at 95°C for 45
seconds, annealing at 60°C for 30 seconds and extension at 72°C for 45 seconds, and
final extension at 72°C for 10 minutes. PCR amplification products were visualised in 2%
agarose (Seakem) by ethidium bromide staining and ultraviolet transillumination.
DNA analysis
A standard combined heteroduplex single-strand conformation polymorphism (HEX-
SSCP) procedure (Kotze et al. 1995) was applied for detection of the 9-bp deletion in exon
2. Polyacrylamide gels were supplemented with 7.5% urea and electrophoresis was
performed at 270 V for 17 hours (overnight) at 4°C. Sequencing analysis confirmed the 9-
bp deletion (not shown). Alleles of the SLC11A 1 5'[GT]n promoter polymorphism were
distinguished by Rsa I (Promega Inc., UK) restriction enzyme analysis (0.5 units per
reaction) as previously described (Graham et al. 2000). Digested PCR products were
electrophoresed at room temperature in 5% cross-linked polyacrylamide gels at 300 V for
2 hours.
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DNA fragments in the respective polyacrylamide gels were visualised by ethidium bromide
staining and ultraviolet transillumination. Genetic variants were confirmed by automated
sequence analysis, where appropriate.
Statistical Analysis
Allele frequencies were determined by genotype count, and the exact test of the Hardy
Weinberg proportion was applied using the Markov Chain algorithm (Guo and Thompson
1992, available from: http://www2.biology.ualberta.ca/brzusto.hwenj.html). Genotype
distribution and allele frequencies were compared among HIV-seropositive and HIV-
seronegative individuals within the same populations and between populations. Where no
differences in genotype distribution were observed, populations were combined to improve
statistical power. Testing for heterogeneity in mutation frequency was based on the
Fischer exact test for 2-sided probability, using GraphPad InStat® Version 3.05 for Win
95/NT, GraphPad Software, San Diego California USA (www.graphpad.com). and a 2-
tailed P-value <0.05 was considered significant. Odds ratios and 95%CI (with Woolf
approximation) were determined for combined homozygous mutant and heterozygous
genotypes as a measure of relative risk for affected genotypes and alleles of interest and
HIV-status. For populations with differing genotypic distribution between HIV-seropositive
and HIV-seronegative individuals, theoretical sample size for significant power (P<0.05)
was calculated according to observed proportions and resulting odds ratios.
Results
Genomic DNA samples of 374 HIV-seropositive and 410 HIV-seronegative South African
individuals (Table 1) were screened for variation in two functionally important regions of
the SLC11A 1 gene. Figure 1 illustrates ethidium bromide stained gels showing the 5'[GT]n
repeat using Rsa I digestion in the SLC11A 1 gene (A) and a 9 bp deletion polymorphism
detected by HEX-SSCP analysis (B), respectively. The 32 bp deletion of the CCRS gene
(CCR5il32), which was also screened for in all study participants in an attempt to exclude
possible confounding effects as a consequence of the known protective effect in relation
to HIV/AIDS, could be readily detected by polyacrylamide gel electrophoresis (Figure 1C).
The deletion mutation was detected in three Cape Coloured males whilst absent in Black
Africans included in the study, and co-existence with allelic variants of the SLC11A 1 gene
did not influence the outcome of the present study.
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Figure 1. Analysis of the SLC11A1 and CCRS genes using PCR-based mutation detection methods and
gel electrophoresis. A. Rsa I restriction enzyme analysis of the SLC11A 1 5'[GT]n promoter polymorphism
showing genotype 2,2 (lane 1), genotype 3,3 (lane 2) and genotype 2,3 (lane 3). B. Detection of the 9-bp
deletion in exon 2 of the SLC11A 1 gene. The wild type allele is shown in lane 1 and a heterozygote for
the 9 bp deletion in lane 2. C. Detection of the CCRS 32 bp deletion. The wild type allele is shown in lane
1 and a heterozygote for mutation CCRS!l32 in lane 2. Sequence analysis confirmed the 9-bp deletion
(not shown).
The 9-bp deletion was present in 1.3% of HIV-seropositive (1/81) and 2.5% of HIV-
seronegative (1/40) Africans in the Western Cape, and in 2.1% of African HIV-seropositive
(2/95) and 3.3% of HIV-seronegative (4/122) individuals from the Northwest Province. A
single HIV-seronegative individual of mixed ancestry (1.7%, n=60) presented with the
deletion mutation, but this sequence change was not detected in the Cape Coloured HIV-
seropositive group. The allelic distribution of the 5'[GT]n repeat polymorphism was also
similar in HIV-seropositive Africans from different geographical regions in South Africa, as
well as in HIV-seronegative Africans recruited as controls in the same areas. Since the
genotype distribution and allele frequencies in these groups did not differ significantly from
that observed in the Cape Coloured population of South Africa (data not shown), all patient
and control groups were pooled for comparative analysis.
The alleles of the 5'[GT]n SLC11A 1 polymorphism were in Hardy-Weinberg equilibrium in
the different population groups studied. A comparison of genotype distribution and allele
frequencies of the SLC11A1 5'[GT]n promoter polymorphism in HIV-seropositive
individuals compared with HIV-seronegative population-matched control individuals, did
not reveal any significant allelic associations (table 2).
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Table 2. Genotype distribution and allele frequencies of the SLC11A1 5'[GT])n repeat polymorphism in HIV-seropositive individuals compared
with HIV-seronegative population-matched controls
Population HIV+ HIV- OR 95%CI P
Genotype n=280 n=326 1.081 0.7697-1.518 0.6657
2,2 5 (0.018) 10 (0.031)
Africans 2,3 90 (0.321) 95 (0.291)
n=606 3,3 185 (0.661) 221 (0.678)
Allele n=560 n=652 0.9935 0.7395-1.335 1.000
2 100 (0.179) 115 (0.176)
3 470 (0.821) 537 (0.823)
Genotype n=94 n=83 1.668 0.8897-3.128 0.1174
2,2 2 (0.021) 3 (0.036)
Mixed Ancestry 2,3 36 (0.383) 21 (0.253)
n=177 3,3 56 (0.596) 59(0.711)
Allele n=188 n=166 1.391 0.8105-2.389 0.2769
2 40 (0.212) 27 (0.163)
3 148 (0.787) 139 (0.837)
Genotype n=374 n=409 1.198 0.8898-1.613 0.2555
2,2 7 (0.019) 13 (0.032)
Total 2,3 126 (0.337) 116 (0.284)
n=783 3,3 241 (0.644) 280 (0.684)
Allele n=748 n=818 1.078 0.8334-1.395 0.5989
2 140 (0.174) 142 (0.174)
3 618 (0.826) 676 (0.826)
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In the Cape Coloured population, the homozygous 2,2 genotype was observed in 3.6% of
HIV-seronegative (3/83) and 2.1% of HIV-seropositive individuals (2/94), and the 2,3
genotype in 38.3% of HIV-seropositive (36/94) compared with 25.3% of HIV-seronegative
individuals (21/83).
An increased risk of 66.8% was calculated in association with genotype 2,3 in the Cape
Coloured population (OR=1.668, 95% Cl 0.8897-3.128, P=0.1174), but statistical
significance was not reached. The sample size required to enable detection of significant
differences was calculated at 188 for HIV-seropositive (2-fold increase) and 108 for HIV-
seronegative (1.3 fold increase) coloured individuals (OR=1.685, 95% Cl 1.013-2.803,
P=0.0454). In a similar assessment of the total group of African HIV-seropositive and HIV-
seronegative individuals, no increased risk in association with genotype 2,3 was detected,
although a predominance of this genotype was detected in African HIV-seropositive
patients attending the infectious Diseases Clinic at Tygerberg Hospital (data not shown).
One HIV-seropositive individual (0.3%) from this population presented with the 1,2
genotype while it was absent from HIV-seronegative individuals, and this observation was
not included for statistical analysis (results not shown).
In African individuals from the Northwest and Gauteng Provinces, the homozygous 2,2
genotype was present at similar frequencies in both HIV-seropositive (3.2%, 5/155) and
HIV-seronegative (2.7%, 7/263) individuals. Genotype 2,2 was not detected in African HIV-
seropositive individuals attending the Infectious Diseases Clinic at Tygerberg Hospital,
whilst present in 4.8% (3/63) of HIV-seronegative individuals.
Possible association of the SLC11A1 functional 5'[GT)n promoter variant with progression
to AIDS was investigated in HIV-seropositive individuals from the Western Cape Province,
divided into clinical subgroups according to the WHO clinical disease classification (Table
3) and according to disease progression (Table 4). No statistically significant associations
were observed. The 2,2 genotype was present in individuals with a class III classification
(4.3%, 2/46), and absent from individuals in classes I, II and IV. The 2,3 genotype
distribution was similar in classes I, II and III (37.0%-42.6%), and much reduced in class IV
(21.7%). Similarly, allele 2 was present at higher frequency in classes I, II and III (20.6%-
22.8%) and reduced in class IV individuals (10.9%). The homozygous 2,2 genotype was
detected in 6.1% of normal progressors (6/24), in 3.4% of asymptomatic individuals
(5/146), and absent in both slow and fast progressors.
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Table 3. Genotype distribution and allele frequencies of the SLC11A 1 5'[GT]n-repeat promoter polymorphism in 171 HIV-seropositive patients atten-
ding the Infectious Diseases Clinic at Tygerberg Hospital, Western Cape, subdivided according to WHO clinical disease classification (Classes I, II, III,
IV), compared with asymptomatic HIV-seropositive individuals.
Population
Progressors (n=171), IOC Asymptomatic, NWP
Class I Class II Class III Class IV
A (n=39) M (n=29) A (n=19) M (n=15) A (n=19) M (n=27) A (n=14) M (n=9) A (n=146)
Genotype n=68 a n=34 n=46 n=23 a n=146
2,2 0 0 2 (0.043) 0 5 (0.034)
2,3 29 (0.426) 14 (0.412) 17 (0.370) 5 (0.217) 39 (0.267)
3,3 39 (0.574) 20 (0.588) 27 (0.587) 18 (0.783) 102 (0.699)
OR 1.724 1.623 1.631 0.6439
95%CI 0.9491-3.131 0.7519-3.502 0.8221-3.237 0.2248-1.844
P 0.0886 0.2268 0.2071 0.4695
Allele n=136 n=68 n=92 n=46 n=292
2 29 (0.213) 14 (0.206) 21 (0.228) 5 (0.109) 49 (0.168)
3 107 (0.787) 54 (0.794) 71 (0.772) 41 (0.891) 243 (0.832)
OR 1.344 1.286 1.467 0.6048
95%CI 0.8051-2.244 0.6623-2.496 0.8248-2.608 0.2274-1.608
P 0.2826 0.4795 0.2155 0.3900
A&M
n=317
IOC, Infectious Diseases Clinic; NWP, Northwest Province; A, African; M, mixed ancestry
Genotypes a class I vs. class IV: OR=2.677, 95% Cl 0.8897-8.054, P=0.0857
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Table 4. Genotype distribution and allele frequencies of the SLC11A 1 5'[GT]n promoter variant in 72 HIV-seropositive patients attending the
Infectious Diseases Clinic at Tygerberg Hospital, Western Cape, subdivided according to disease progression (normal, slow and fast), com-
pared with asymptomatic HIV-seropositive individuals.
Progressors, IOC
Population Normal Slow Fast
A (n=16) M (n=17) A (n=6) M (n=9) A (n=1S) M (n=9)
Genotype n=33 n=15 n=24
A&M 2,2 2 (0.061) 0 0
n=218 2,3 13 (0.394) 6 (0.400) 6 (0.250)
3,3 18 (0.545) 9 (0.600) 18 (0.750)
OR 1.932 1.545 0.7727
95%CI 0.8934-4.177 0.5185-4.606 0.2873-2.079
P 0.1034 0.5583 0.8094
Alleles n=66 n=30 n=48
2 17 (0.258) 6 (0.200) 6 (0.125)
3 49 (0.742) 24 (0.800) 42 (0.875)
OR 1.721 1.240 0.7085
95%CI 0.9150-3.235 0.4814-3.193 0.2854-1.758
P 0.1125 0.6154 0.5322
IOC, Infectious Diseases Clinic; NWP, Northwest Province; A, African; M, mixed ancestry
Asymptomatic, NWP
A (146)
n=146
5 (0.034)
39 (0.267)
102 (0.699)
n=292
49 (0.168)
243 (0.832)
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Distribution of the 2,3 genotype was similar between normal (39.4%, 13/33) and slow
(40.0%, 6/15) progressors, and also between fast (25.0%, 6/25) progressors and
asymptomatic (26.7%, 39/146) individuals. Further, distribution of allele 2 between the
respective progression groups was similar compared to the WHO classification. Allele 2
was present at elevated frequencies in normal and slow progressors (25.8% and 20%
respectively) and reduced in individuals with fast disease progression (12.5%), although
not significant.
Failure to demonstrate an association between polymorphisms in the SLC11A 1 gene and
HIV/AIDS susceptibility could not be ascribed to antiretroviral treatment of patients
attending the Infectious Diseases Clinic, since only 22% of these individuals received
antiviral treatment. No gender-related differences in allelic distribution were furthermore
observed in the South African populations studied (data not shown).
Discussion
The human SLC11A 1 gene studied in 374 HIV-seropositive and 410 HIV-seronegative
South African individuals in relation to susceptibility to HIV-1 infection and progression to
AIDS, has previously been associated with both autoimmune and infectious diseases
(Searle and Blackwell 1999). Chronic hyperactivation of macrophages associated with
allele 3 is functionally linked to autoimmune disease susceptibility, while the poor level of
expression of the SLC11A 1 allele 2 contributes to infectious disease susceptibility. The
likelihood that allele 3 would conversely protect against infectious disease and allele 2
against autoimmune disease, was supported by data from Kotze et al. (2001), by
comparison of allele frequencies of the promoter variant between different age groups. It
appeared that SLC11A 1 alleles considered to be detrimental in relation to autoimmune
disease susceptibility might be maintained in the population as a consequence of
improved survival to reproductive age following infectious disease challenge. These
studies demonstrated the complex interplay between genetic and environmental factors
related to multifactorial conditions, and provided the background for analysis of the
SLC 11A 1gene in the study populations included in the present study.
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The frequency of the 9-bp deletion in exon 2 of the SLC 11A 1 gene, previously associated
with susceptibility to HIV-1 infection in sub-Saharan Africans (Ramaley et al. 2000), was
very low in our study population. It does however not appear to be associated with
modified risk to HIV-1 infection in South African individuals, since allelic distribution was
similar in the patient and control samples.
We therefore focused on the SLC11A1 5'[GT]n promoter variant in an attempt to elucidate
the role of allele 2 as a modifying factor of HIV infection and/or progression to AIDS. While
homozygotes for allele 2 were protected from HIV-1 infection in an earlier study (Marquet
et al. 1999), this genotype was detected at similar frequencies in the South African patient
groups compared with population-matched HIV-seronegative individuals. Our findings,
therefore does not provide evidence that homozygosity for allele 2 is protective in Africans.
This may be explained in part by differences in ethnic background, which may include co-
existence of other important SLC 11A 1 allelic variants or mutations in other genes
occurring in linkage disequilibrium with specific alleles in different populations. The
possible role of the CCR5 32-bp deletion as a confounding factor was excluded in our
study population. Further studies are however warranted to investigate the significance of
the SLC11A 1 promoter polymorphism --237C/T in this context. In vitro studies performed
by M Zaahl (PhD study, submitted) have demonstrated that the presence of the T-allele in
association with allele 3 results in an opposite effect in vitro upon iron loading, similar to
that of allele 2.
We hypothesise that the availability of cellular iron related to dietary iron intake, and
subsequent biological processes involved in iron homeostasis, may have had an influence
on the outcome of the case-control comparisons in this study. Iron homeostasis is of vital
importance for proper cellular function, specifically cells of the phagocytic lineage involved
in modulation of immunological responses to infection (for example macrophages). Iron
dysregulation has been shown to be associated with various human diseases, including
some infectious diseases and autoimmune disorders (Dhople et al. 1996). Recent studies
have shown that the SLC11A 1 protein plays a significant role in iron homeostasis in
macrophages (Blackwell et al. 2000), and is closely associated with another structurally
related divalent cation transporter, DMT1 (Fleming et al. 1997, Gunshin et al. 1997). This
model facilitated explanation of the multiple pleiotropic effects of SLC11A 1 and its complex
roles in infectious and autoimmune disorders.
Stellenbosch University http://scholar.sun.ac.za
79
Analysis of the SLC11A 1 gene in our study cohort has contributed to a better
understanding of the complexity of host genetic factors implicated in modified risk to HIV-1
infection. The proposed effect of the functional SLC11A 1 5'[GT]n promoter polymorphism
on HIV-related infectious disease (Marquet et al. 1999) may be mediated though a
complex gene-environment interaction within the context of the genetic background of an
individual. Multiple low-penetrance host alleles contribute to susceptibility to HIV-1
infection and progression to AIDS, and a combination of these factors together with viral
load and CD4+ counts, could provide a valuable decision-making tool in the management
of HIV-infected individuals in a population-specific manner. We conclude that SLC11A1
host factors involved in modified risk of HIV infection are population-specific.
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B. The African-specific HFE gene polymorphism IVS3-48c~g correlates significantly
with reduced haemoglobin levels in HIV-infected South African individuals
Background: Human immunodeficiency virus (HIV)-infected individuals experience a range
of haematological complications, including anaemia, representing a prognostic marker for
future disease progression or death independent of CD4+ counts or viral load.
Objective: Given the ability of HIV to alter iron metabolism, we aimed to identify host
genetic factors associated with altered iron parameters that may be of prognostic value.
Subjects and Methods: DNA samples of 111 HIV-seropositive and 145 HIV-seronegative
Africans were amplified by the polymerase chain reaction (PCR) method and screened for
an African-specific polymorphism IVS3-48c~g in intron 3 of the haemochromatosis (HFE)
gene. Iron parameters were compared between individuals with and without this point
mutation.
Results: Significantly reduced haemoglobin levels were detected in both HIV-seropositive
(P=0.004) and HIV-seronegative (P=0.02) Africans with the intronic polymorphism IVS3-
48c~g in the HFE gene, in comparison with individuals in these respective study groups
without this point mutation.
Conclusions: Although the g-allele of the IVS3-48c~g polymorphism may occur in linkage
disequilibrium with a functional mutation in the HLA region of chromosome 6, possibly
implicated in HIV infection, our data identified the HFE gene polymorphism as a potentially
useful genetic marker of poor clinical outcome in HIV-infected individuals.
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Introduction
Progression of human immunodeficiency virus (HIV) infection towards advanced disease is
accompanied by alterations in iron metabolism and increased body iron stores (Boelaert et
al. 1996a,b). In the absence of antiviral treatment elevated iron levels cause shorter
survival times (De Monye et al. 1999), promote growth of AIDS-opportunistic pathogens
(Boelaert et al. 1996a,b) and HIV-1 replication (Sappey et al. 1995), and contribute to an
increased risk for cancer, for example Kaposi's Sarcoma (Simonart et al. 1998).
Impairment of immune defence mechanisms is enhanced by oxidative stress due to
excess iron, directly promoting growth of microbial cells (Dhopie et al. 1996). Recently it
was demonstrated that HIV-1 infected individuals carrying the haptoglobin Hp2-2
phenotype show a worse prognosis (Delanghe et al. 1998). An increased oxidization of
vitamin C due to iron accumulation in affected individuals suggests a less efficient
protection mechanism against haemoglobin/iron-driven oxidative stress, which may
stimulate viral replication directly. Iron deficiency or anaemia conversely represents a
prognostic marker of poor clinical outcome in HIV-infected individuals, independent of
CD4+ counts and viral load (Means 1997, Moyle 2002). However, while many of the
activities of HIV target cells (for example polymorphonuclear granulocytes and
macrophages) are iron-dependent and/or modulate iron metabolism (Cantinieaux et al.
1992, van Asbeck et al. 1982), the exact mechanical basis of the associated deleterious
effects is not fully understood.
In addition to the complex interaction between infectious agents and host cells, variation in
genes involved in host response to infection can be expected to alter the clinical outcome
in HIV-seropositive subjects. Reduced haemoglobin levels in HIV-infected patients are
associated with enhanced cellular immune activation, as seen by release of certain
cytokines and changes of iron metabolism (Fuchs et al. 1993). Furthermore, significantly
lower haemoglobin levels in HIV-seropositive compared with HIV-seronegative individuals
most likely result from virus infection (Spada et al. 1998).
Risk of HIV-1 infection and progression to AIDS has been shown to be modified due to
genetic variation in genes encoding chemokine receptors and their ligands, and the major
histocompatibility complex (Liu et al. 1996, Magierowska et al. 1999, Laumbacher and
Wank 1998,Winkler et al. 1998).
Stellenbosch University http://scholar.sun.ac.za
82
The functional linkage between immune function and iron absorption became evident with
the identification of the major histocompatibility complex (MHC)-encoded HFE protein,
underlying the common iron overload condition hereditary haemochromatosis (Feder et al.
1996, 1998). Evidence that MHC-encoded class I molecules might playa role in iron
metabolism (Salter-Cid et al. 2000), led to targeting of the human haemochromatosis gene
(HFE) as a potential candidate gene involved in iron dysregulation related to HIV
infectivity. Prolonged progression status has been reported in an HIV-seropositive patient
treated for iron overload as a consequence of hereditary haemochromatosis caused by
homozygosity for the C282Y mutation in the HFE gene (Nielsen et al. 1999).
In the present investigation the HFE gene (Feder et al. 1996) was studied in 111 HIV-
seropositive and 145 HIV-seronegative Black South African individuals with known iron
status. The previously-documented HFE gene mutations, V53M, V59M, H63, H630, S65C
and C282Y were present at a relatively low frequency in both HIV-seropositive and HIV-
seronegative Africans, or were not detected at all in this study population (0 Pretorius,
unpublished data). This finding was in accordance with the previously reported low
frequencies for these mutations occurring among these populations (de Villiers et al.
1999). The African-specific HFE polymorphism IVS3-48c-)g that does not appear to affect
RNA splicing, nor does it influence serum iron parameters (Beutler and Gelbart 2000), was
therefore investigated by mutation analysis. We investigated the likelihood that
haemoglobin levels and serum iron parameters are differentially affected upon HIV-
infection, in relation to the IVS3-48c-)g polymorphism.
Materials and Methods
The Ethics Review Committees of the Universities of Stellenbosch and Potchefstroom
approved the study.
Study Population
Blood samples were obtained with informed consent from 111 HIV-seropositive (42 males,
69 females) and 145 HIV-seronegative (59 males, 86 females) Black South African
individuals recruited from the Northwest Province of South Africa.
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HIV status and iron parameters of all study participants were determined and previously
described (James et al. 2000), as part of a cross-sectional study performed by these
authors. The study population represents a random sample of individuals unaware of their
HIV status at the time of entry.
DNA Analysis
Genomic DNAwas extracted from whole blood following a standard procedure (Miller et al.
1988). The IVS3-48c~g polymorphism in intron 3 of the HFE gene was analysed
following restriction enzyme analysis of polymerase chain reaction (PCR)-amplified DNA
(Beutler and Gelbart 2000). One PCR cycle of 3 minutes at 95°C was followed by 35
cycles of 95 °C for 45 sec, 55°C for 30 sec and at 72 °C for 45 sec, and a final cycle at 72
°C for 10 min. PCR products (10-15 J.l1) were digested with 0.75 units Bsa J1 restriction
enzyme (New England Biolabs, Beverley, MA, USA) for 2 hours at 60°C, and compared
with DNA from an individual heterozygous for the polymorphism as positive control
(Beutler and Gelbart 2000). Digested products were electrophoresed at room temperature
in a 3.4% cross-linked polyacrylamide gel for two hours and 300 V. DNA fragments were
visualised by ultraviolet transillumination following ethidium bromide staining.
Statistical Analysis
Allele frequencies were determined by genotype count, and the exact test of the Hardy
Weinberg proportion was applied using the Markov Chain algorithm (Guo and Thompson
1992, http://www2.biology.ualberta.ca/jbrzusto/hwenj.html). Genotype distribution and
allele frequencies were compared between HIV-seropositive and HIV-seronegative
individuals within the same population group. Chi-square (x2) statistical analysis was
performed using Simcalc V1.0 (Provalis Research, USA) to test for heterogeneity in
mutation frequencies, with P-values <0.05 considered as significant. For continuous
variables, groups were compared using unpaired t tests. Statistical comparisons of iron
parameters were done after correction for age and gender, where appropriate. Groups
were compared by multivariate analysis, adjusting for age using the GLM (General linear
model) with LSD (least significant differences) procedure. The total means were also
adjusted for gender. Mutation data was provided blindly to the statistician for correlation
with biochemical parameters of iron status.
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Analysis of the IVS3-48c---+g polymorphism in intron 3 of the HFE gene is shown in Figure
1, in an individual homozygous for the wild type c-allele (lane 1), a heterozygote with
genotype cg (lane 2), and a homozygote for the mutant g-allele (lane 3).
123
Figure 1. Detection of the HFE intron 3 polymorphism, IVS3-48c~g, using Bsa J1 restriction
enzyme digestion. Lane 1: homozygous wild type genotype cc, lane 2: heterozygous genotype cg,
lane 3: homozygous mutant genotype QQ.
The genotype distribution and allele frequencies determined in 111 HIV-seropositive and
145 HIV-seronegative South African individuals with known iron status are indicated in
Table 1. Both alleles were in Hardy-Weinberg equilibrium in the respective HIV-
seropositive and HIV-seronegative study groups. Although mutant allele frequencies were
similar in HIV-seropositive individuals (12.6%) compared with those previously reported
(12.8%) for African individuals (Beutler and Gelbart 2000) and lower in HIV-seronegative
individuals (9.6%), the allelic distribution of the IVS3-48c---+g polymorphism did not differ
significantly between these groups. Theoretical estimates indicated that a sample size of
444 HIV-seropositive and 580 HIV-seronegative individuals is required for sufficient
statistical power to confirm or exclude association between HIV infection and the HFE
polymorphism.
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Table 1. Comparison of genotype distribution and allele frequencies of the HFE IVS3-48c~g
polymorphism in HIV-seropositive and HIV-seronegative Africans.
HIV-seropositive
Males Females Total
n=42 n=69 n=111
Genotype
cc 33 (0.786) 52 (0.754) 85 (0.766)
cg 9(0.214) 15 (0.217) 24 (0.216)
gg 0 2 (0.029) 2 (0.018)
Allele
c 75 (0.893) 119 (0.862) 194 (0.874)
9 9 (0.107) 19 (0.138) 28 (0.126)
HIV-seronegative
Males Females Total
n=59 n=86 n=145
47 (0.797)
12 (0.203)
o
70 (0.814)
16 (0.186)
o
117 (0.807)
28 (0.193)
o
106 (0.898) 156 (0.907) 262 (0.903)
12 (0.102) 16 (0.093) 28 (0.097)
Comparison of iron parameters in relation to the IVS3-48c--+g polymorphism revealed
significantly lower haemoglobin levels in individuals with the g-allele (P<0.05) (Table 2).
This association was observed between mutation groups in both the HIV-seropositive
(P=0.004) and HIV-seronegative (P=0.021) individuals. Although haemoglobin levels were
significantly lower in HIV-seropositive compared with HIV-seronegative individuals as
reported previously (HH Vorster et a/., unpublished data), it was consistently lower in the
presence of the IVS3-48c--+g polymorphism.
When males and females were considered separately, the most striking observation was
the significantly reduced haemoglobin levels in HIV-seropositive females (10.95 g/dl) with
the g-allele compared with HIV-seronegative females (13.10 g/dl) without the g-allele
(P=0.01). The two HIV-seropositive individuals from this population homozygous for the g-
allele were both females, and their haemoglobin levels were reported to be 10.70 g/dl and
11.50 g/dl, respectively. Although the numbers are small, the mean haemoglobin value for
these two homozygous female individuals (11.10 g/dl) was below the normal reference
value of 11.5-16.5 g/dl, while that of females heterozygous for the polymorphism (12.47
g/dl) was within the normal range (12-15 g/dl for females; Mahan and Escott-Stump 2000).
In an attempt to determine whether the IVS3-48c--+g polymorphism affects a branch site in
intron 3 that may possibly affect gene splicing in an exonic splice element (ESE), the web-
based ESEfinder release 2.0 computer program (Cartegni et al. 2003,
http://exon.cshl.edu/ESE) was used. It was however indicated that IVS3-48c--+g appears
not to cause a disruption that may result in a splicing defect.
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Table 2. Comparison of mean values for different iron parameters measured in Black African HIV-seropositive and HIV-seronegative
individuals recruited from the Northwest Province of South Africa in relation to the presence of the HFE IVS3-48c~g polymorphism.
HIV seropositive Genotype Total HIV+a 95%CI Males 95%CI Females 95%CI
Parameter (n=111) Lower Upper (n=42) Lower Upper (n=69) Lower Upper
Hb (g/dl) cc 12.77b 12.25 13.28 13.67c 12.85 14.50 12.20d 11.53 12.88
cg/gg 11.21 10.30 12.13 11.38 9.52 13.24 10.95 9.89 12.01
SI (urnolïl) cc 15.11 13.53 16.70 17.86 15.36 20.35 13.44 11.35 15.53
cg/gg 15.40 12.58 18.23 16.99 11.35 22.63 14.15 10.86 17.43
TIBC cc 67.58 64.27 70.89 62.59 59.12 66.06 70.64 65.58 75.69
cg/gg 64.44 58.55 70.34 59.47 51.64 67.30 67.43 59.48 75.37
TS (%) cc 23.92 21.27 26.57 29.57 24.97 34.18 20.48 17.22 23.75
cg/gg 24.56 19.84 29.29 28.79 18.40 39.18 21.62 16.49 26.75
Fe (f.tg/I) cc 112.75 53.82 172.09 195.06 42.45 347.66 61.92 48.90 74.94
cg/gg 64.75 -40.70 170.21 76.72 -267.81 421.24 41.92 21.44 62.39
HIV seronegative Genotype Total HIV+" 95%CI Males 95%CI Females 95%CI
Parameter (n=145) Lower Upper (n=59) Lower Upper (n=86) Lower Upper
Hb (g/dl) cc 13.43e 13.07 13.80 13.89 13.37 14.40 13.10' 12.57 13.63
cg/gg 12.23 11.31 13.16 12.86 10.54 15.18 11.91 10.88 12.94
SI (flIllol/l) cc 15.98 14.58 17.38 18.55 16.51 20.60 13.99 12.10 15.89
cg/gg 18.56 15.05 22.08 11.13 1.92 20.34 18.67 14.98 22.37
TIBC cc 63.32 61.23 65.40 58.51 55.79 61.24 66.99 63.89 70.10
cg/gg 66.22 60.97 71.47 69.72 57.47 81.96 67.76 61.71 73.81
TS (%) cc 26.19 23.85 28.53 31.90 28.40 35.40 21.90 18.76 25.05
cg/gg 29.14 23.25 35.04 19.22 3.47 34.96 27.94 21.81 34.07
Fe (f.tg/I) cc 113.82 80.88 146.47 196.33 126.59 266.08 56.21 36.09 76.33
cg/gg 157.56 74.66 240.47 400.83 87.13 714.52 64.35 25.15 103.55
Hb, haemoglobin: 51, serum iron; TIBC, total iron binding capacity; TS, transferrin saturation; Fe, ferritin
• Means adjusted for age and gender
b HIV-seropositive with (cg/gg) and without (cc) HFE IVS3-48c/g: P=0.OO4
C Males: HIV-seropositive with (cg/gg) and without (cc) HFE IVS3-48c/g: P=O.029
d Females: HIV-seropositive with (cg/gg) and without (cc) HFE IVS3-48c/g: P=0.051
• HIV-seronegative with (cg/gg) and without (cc) HFE IVS3-48c/g: P=O.021
f Females: HIV-seronegative with (cg/gg) and without (cc) HFE IVS3-48c/g: P=O.033
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Although almost identical to the downstream splice-site nucleotide sequence
(ttcctgtcaag) of the same intron, this finding is in accordance with the previously
reported data indicating that the IVS3-48c~g polymorphism (ttcctgggaag, wild type
ttcctgm~aag) does not affect alternative splicing (Beutler and Gelbart 2000).
Discussion
The present investigation was prompted by a previous finding of significantly lower
haemoglobin levels in South African HIV-seropositive individuals compared with
population-matched HIV-seronegative individuals (HH Vorster et aI., unpublished data).
It however was unclear whether variation in genes involved in host response to infection
would influence the acute response upon infection, and possibly alter clinical outcome in
HIV-infected individuals. Since HIV has the ability to affect iron metabolism, we aimed to
identify host genetic factors that may be of prognostic value and could possibly define
potential targets for future therapeutic intervention. HFE is expressed on the cell surface
and it has been speculated that this protein may be a receptor for some infectious
agents (Rochette et al. 1999).
The finding that the presence of the IVS3-48c~g polymorphism correlates significantly
with a reduction in haemoglobin levels, irrespective of HIV status, largely excluded the
possibility that this apparent phenotypic effect is related only to an acute phase response
due to HIV infection. The g-allele shown to possibly be related to this effect most likely
occurs in linkage disequilibrium with a functional sequence variant in a gene in close
proximity to the HFE gene, since only the haemoglobin levels were significantly affected
and not serum iron parameters, for example serum ferritin and transferrin saturation that
are typically altered by deleterious mutations in the HFE gene (Feder et al. 1996). These
findings are in accordance with the genotype-phenotype correlation studies performed
by Beutler and Gelbart (2000), failing to demonstrate any effect of the IVS3-48c~g
polymorphism on serum iron parameters or RNA integrity.
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The HLA-A3 and HLA-B14 loci, associated with slow disease progression in HIV-
infected individuals (Magierowska et al. 1999) were shown to occur in strong linkage
disequilibrium with the HFE gene. It therefore seems likely that our findings may be
explained by the occurrence of other unidentified MHC class I molecules (also encoded
on chromosome 6) in close proximity to HFE that may affect iron status, as speculated
by Salter-Cid et al. (2002).
A limitation of the present study is the fact that disease status was unknown in the study
population, and due to ethical constraints follow-up studies could not be performed for
comparison of clinical outcome between individuals with and without the IVS3-48c~g
polymorphism. Comparison of allelic distribution between the 111 HIV-seropositive and
145 HIV-seronegative individuals did not reveal any significant differences, even after
increasing the sample size to include 233 HIV-infected and 274 population-matched
control individuals (data not shown). The additional samples were however from
populations recruited from the Western Cape and Gauteng Provinces, and from
individuals originating from different ethnic backgrounds.
It is further possible that the polymorphism may have an impact on disease progression
once an individual is infected with the virus, but does not playa role in HIV infection.
Preliminary data from analysis of 165 HIV-infected individuals with disease status
classified according to the WHO criteria (classes I-IV, http://www.who.int) did however
not reveal any significant association with disease status or rate of disease progression.
These HIV-infected subjects with known progression status were recruited from the
population attending the Infectious Diseases Clinic at Tygerberg Hospital. Homozygosity
for the g-allele of the IVS3-48c~g polymorphism was not detected in any of these HIV-
seropositive individuals. A predominance of heterozygotes with a single copy of the g-
allele was noted in HIV-seropositive individuals compared with HIV-seronegative
individuals, but the sample size was too small to obtain conclusive results (data not
shown).
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Detection of significantly reduced haemoglobin levels in association with the IVS3-
48c-)g polymorphism is an important consideration with respect to nutritional status,
since previous studies have indicated that anaemia independently predicts poor clinical
outcome and contributes to morbidity in HIV-infected children and adults (Tovo et al.
1992, Forsyth et al. 1996, Sullivan et al. 1998). Recovery from anaemia reduces the risk
of disease progression to approximately the same level as observed in patients who are
not anaemic. Administration of iron supplementation or blood transfusion to correct this
condition may activate HIVexpression and probably worsen immunosuppression. It
therefore seems likely that our findings may be explained by the close proximity of other
unidentified MHC-encoded class I molecules that affect iron status as speculated
(Salter-Cid et al. 2002). Thus, it is important to identify factors contributing to iron
deficiency, particularly since recombinant human erythropoietin may provide an effective
means of improving haemoglobin and reducing transfusion requirements in patients who
have low endogenous erythropoietin levels (Moyle 2002).
We conclude that a significant association was detected between the IVS3-48c-)g
polymorphism and haemoglobin levels, irrespective of HIV status. This effect was more
pronounced in HIV-seropositive than in HIV-seronegative individuals, which may point to
an added effect with HIV infection. Iron metabolic pathways and the immune system are
regulated by one another, however HIV infection can break this inter-relationship
resulting in disruption of cellular homeostasis. Since a reduction in haemoglobin levels is
associated with poor nutritional status and consequently poor clinical outcome in HIV-
infected individuals, it seems possible that detection of the IVS3-48c-)g polymorphism in
HIV-seropositive individuals may have prognostic value.
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c. Sequence variation in the exonic splicing silencer element (ESS1) of the CD45
gene: a possible role in HIV-disease
Background: The 77C~G polymorphism in the protein tyrosine phosphatase receptor
type C (CD45IPTPRC) gene has previously been associated with increased risk of HIV-
infection in the Caucasian population, but this point mutation is virtually absent in
Africans.
Objective: The aim of this study was to identify possible functional mutations in the
exonic splicing silencer element (ESS-1) and promoter region of the CD45 gene that
may be related to increased risk of HIV-1 infection or progression to AIDS.
Design: DNA analysis was performed in 300 HIV-seropositive individuals and 354 HIV-
seronegative population-matched control individuals, followed by functional studies to
evaluate the possible significance of the mutations identified.
Methods: Polymerase chain reaction (PCR)-based mutation detection methods were
applied, which included combined heteroduplex-single stranded conformation
polymorphism (HEX-SSCP) analysis, restriction enzyme analysis and direct sequencing.
The potential significance of the mutations identified was assessed using the web-based
ESEfinder (ESE - Exonic Splice Element) program and flow cytometry (FACs) analysis.
Results: Although modified risk to HIV infection was not demonstrated for two novel
mutations 32A~G and 54A~G identified in the ESS-1 situated in exon 4 of the CD45
gene, FACs analysis indicated a significantly reduced number of CD45RA- CD45RO+
cells in the CD8+ subset (9.8% and 16.6% versus 40.6% of CD8+ cells) in two HIV-
seropositive individuals with the 32A~G mutation. Application of the ESEfinder program
furthermore indicated that the missense mutation, T18A (54A ~G), potentially results in
alternative splicing due to disruption of important splicing elements.
Conclusions: The 32A-+G mutation in the CD45 gene appears to be predominantly
associated with slow disease progression in the HIV-seropositive individuals studied.
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This finding may be related to differences in proportions of both CD4+ and CD8+
subsets observed following FACs analysis in HIV-seropositive individuals with mutation
32A~G, compared with a control without this mutation. Further studies are however
warranted to exclude the possibility of false positive results due to small sample size and
the effect of HIV disease status on CD45 expression.
Introduction
The protein tyrosine phosphatase receptor type C (PTPRC) gene, also known as CD45,
encodes an abundantly expressed transmembrane protein that is expressed on all
hematopoietic cells (Trowbridge and Thomas 1994). CD45 appears at one of the earliest
stages of hematopoietic development, suggesting a role in the generation of a functional
immune system. Structural heterogeneity of CD45 is facilitated by alternative splicing of
exons 4,5 and 6, giving rise to multiple isoforms (Saga et al. 1986, Streuli et al. 1987). T-
cell receptor (TCR)-mediated activation of both B- and T- lymphocytes is facilitated by
CD45 after antigen stimulation by dephosphorylation of an inhibitory site on the Src-
family of tyrosine kinases, yielding an enhanced kinase ability of the substrate essential
for initiation of the signalling event (Thomas and Brown 1999). This molecule further
functions as a negative regulator of cytokine receptor signalling, due to its function as a
hematopoietic Janus kinase (Jak) phosphatase (Irie-Sasaki et al. 2001).
Recently it was shown that an exon 6 deletion causes a lack of CD45 expression and
appears to be associated with severe combined immunodeficiency (SCID) in humans
(Tchilian et al. 2001c). Loss of CD45 expression with consecutive development of SCID
has also been reported in a child bearing a large deletion in one CD45 allele and a point
mutation in the other (Kung et al. 2000). It therefore became clear that CD45 is essential
for normal immunological functioning. This was further exemplified by the development
of autoimmune disease due to an inactivating point mutation in the CD45 gene in a
murine model (Majeti et al. 2000).
Stellenbosch University http://scholar.sun.ac.za
93
The role of CD45 in autoimmune diseases was highlighted by detection of two point
mutations, 59C-+A and 77C-+G, in patients with multiple sclerosis (MS) (Jacobson et al.
2000, 2002). The 77C-+G mutation may also be associated with an increased risk of
HIV-1 infection (Tchilian et al. 2001a), and appears to be absent in Africans (Tchilian et
al. 2002). Both mutations 59C-+A and 77C-+G cause disruption of the exonic splicing
silencer element-1 (ESS-1) in exon 4 of the CD45 gene, resulting in altered isoform
expression due to interference with exon-intron splicing (Thude et al. 1995, Tchilian et al.
2001b, Jacobson et al. 2002). ESS-1 usually suppresses splicing at a splice site located
at the 5' end of exon 4 (Lynch and Weiss 2001), resulting in continuous expression of
CD45RA isoforms on activated T-Iymphocytes (Zilch et al. 1998). The mutation at
nucleotide position 59 causes a non-conservative amino acid change (H19Q) in the
CD45 antigen, while 77C-+G represents a silent mutation.
Since the CD45 molecule has been implicated in various immune-related disorders, it
seems likely that the CD45 gene may be involved in HIV-1 infection, as reported by
Tchilian and co-workers (2001a). In the present study an attempt was made to identify
functional mutations in the ESS-1 element and promoter regions of the CD45 gene in
non-Caucasian South Africans, which may affect risk for HIV/AIDS in the South African
population. Preliminary data revealed two novel mutations in the CD45 gene, 32A-+G
and 54A-+G, in our predominantly African study population (Jooste et al. 2002). We
have subsequently screened a total of 300 HIV-seropositive individuals and 354 HIV-
seronegative population-matched control individuals for these mutations, to determine
their possible involvement in HIV/AIDS susceptibility. Mutations 32A-+G and 54A-+G
were furthermore assessed using the web-based ESEfinder release 2.0 computer
program (Cartegni et al. 2003) to theoretically determine whether these mutations would
yield alternative splicing patterns. Functional studies using flow cytometry (FACs)
analysis were additionally performed to investigate the possible functional significance of
mutation 32A-+G, occurring most frequently in the local population. This investigation
was deemed important, since the identification of functional CD45 gene variations may
provide molecular targets for immune intervention.
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Methods
Study population
Informed consent was obtained from all study participants following approval of the study
by the Ethics Review Committee of the University of Stellenbosch. The study population
consisted of 300 HIV-seropositive and 354 HIV-seronegative individuals (table 1).
The HIV-seropositive population consisted predominantly of Black African (Xhosa-
speaking) individuals (n=124, 39 males and 85 females) and non-Caucasian individuals
of Mixed Ancestry (n=96, 27 males and 45 females). The estimated date of infection and
HIV-1 disease-associated complication data were recorded for the majority of
individuals, and clinical monitoring was performed for at least 5 years in most individuals.
Ages were calculated based on the date of blood sampling.
Table 1. Study Cohort
Study Population HIV-seropositive HIV-seronegative
Western Cape Province Male Female Total Male Female Total
African 39 85 124 27 45 72
Age range (years) 21-59 22-59 21-59 19-47 17-49 17-49
Mean Age 33.76 31.28 32.76 28.04 26.66 27.18
Mixed Ancestry 27 69 96 52 10 62
Age range (years) 21-55 22-73 21-73 17-52 26-44 17-52
Mean Age 36.30 34.16 34.77 30.38 35.20 31.16
Northwest Province Male Female Total Male Female Total
African 20 50 70 36 59 95
Age range (years) 21-81 17-69 17-81 7-71 17-77 7-77
Mean Age 39.06 33.55 35.39 42.47 37.45 39.16
Gauteng Province Male Female Total Male Female Total
African 7 3 10 61 64 125
Age range (years) 32-47 30-44 32-48 22-62 21-59 21-62
Mean Age 37.14 37 39.11 33.96 31.61 32.66
TOTAL 93 207 300 176 178 354
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Disease status was denoted according to the WHO clinical disease classification
(http://www.who.int), and was available for the majority (n=178) of HIV-seropositive
individuals attending the clinic. HIV-seropositive individuals were further classified as
normal progressors when progressive loss in CD4 cell counts was associated with
development of AIDS-related symptoms within 10 years after HIV-1 infection, as fast
progressors when they progressed to full-blown AIDS within 2-3 years from
seroconversion, and as slow progressors when they remained unaffected after 8-10
years from seroconversion. Progression status according to this classification was
unknown for the majority of individuals and in those with known progression status,
approximately 20% were receiving antiretroviral treatment. Xhosa-speaking HIV-
seronegative control individuals (n=72, 27 males and 45 females) were recruited from
healthy individuals without a previous history of tuberculosis or immune disorders.
Healthy blood donors (n=62, 52 males and 10 females) were included as controls for
HIV-seropositive individuals of MixedAncestry.
Additionally, 70 African HIV-seropositive individuals (20 males and 50 females) and 95
HIV-seronegative population-matched individuals (36 males and 59 females) originating
from the NorthWest Province in South Africa were included in the study. This population
formed part of a cross-sectional study previously performed by James et al. (2000), and
disease progression status was unknown for HIV-seropositive individuals. An
anonymous, predominantly HIV-seronegative population of African origin from the
Gauteng Province of South Africa was also included in the study, consisting of 10 HIV-
seropositive (7 males and 3 females) and 125 HIV-seronegative (61 males and 64
females) individuals.
In this study African (or Black African) refers to individuals of central African descent,
and individuals of Mixed Ancestry (also referred to as Cape Coloured, or Coloured) are
of San, Khoi, African, Madagascan, Javanese as well as European origin.
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Mutation Analysis
EDTA blood samples of the study population were collected for genomic DNA extraction
and mutation screening of exon 4 and the proposed promoter region of the CD45 gene,
described by Timon and Beverley (2001). DNA was isolated from peripheral blood using
a standard procedure (Miller et al. 1988), and amplified by the polymerase chain reaction
(PCR) using CD45-specific primers following a step-down PCR amplification procedure.
Primers used for PCR amplification (Table 2) of exon 4 and the promoter region of the
CD45 gene were designed according to the Genbank gene sequence for CD45
(Accession Numbers AF492459 and M23461).
Table 2. PCR amplification primers for exon 4 and the proposed promoter region of the CD4 gene
Gene fragment peR primer nucleotide sequence (5'~3') Fragment size (bp)
Exon 4 forward ATTTATTTTGTCCTTCTCCCA
reverse GTTAACAACTTTTGTGTGTGCC
260
Promoter forward CCGAATCTGACATCATCACC
reverse CCTTGTACTTACCTGTCACAA
324
PCR amplification conditions consisted of initial denaturation at 95°C for 3 min, followed
by 10 cycles of 95°C for 45 sec, 60°C for 30 sec, 72°C for 30 sec; and 30 cycles of 95
°C for 45 sec, 55°C for 30 sec, 72°C for 45 sec; with final extension at 72 °C for 10 min.
Amplification products were visualized in 2% agarose (Seakem) by ultraviolet
transillumination and ethidium bromide staining. Mutation screening was performed
using a combined heteroduplex single strand conformation polymorphism (Hex-SSCP)
procedure (Kotze et al. 1995). Heat-denatured PCR amplification products were
electrophoresed in 10% cross-linked polyacrylamide gels supplemented with urea as a
mild denaturing agent, for 17 hours at 270V and 4°C, and visualised by ultraviolet
transillumination and ethidium bromide staining. Aberrant fragments detected with Hex-
SSCP analysis were subjected to automated sequencing on an ABI Prism 310 Genetic
Analyser (Applied Biosystems, Foster City, CA, USA).
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Lymphocyte Isolation and FACscan cel/ular assay
For functional analysis of the 32A~G mutation, cellular lymphocyte isolates were
prepared following a standard isolation procedure. Venous blood was collected in
heparinised syringes, diluted in an equal volume of sterile phosphate buffered saline
(PBS) and slowly layered onto Ficoll Paque (Amersham Pharmacia, UK) in 50 ml Falcon
tubes. Blood was centrifuged at 500xg for 30 minutes at room temperature (RT). Cells
were removed from the interface and washed twice in sterile PBS at 350-400xg, and
resuspended in 90% foetal calf serum (FCS), 10% dimethyl sulphoxide (DMSO) (Merck,
UK) before cryopreservation at -BO°C.
Cell viability was tested using the trypan blue exclusion method. Viable cells were
counted using a haemocytometer (improved Neubauer chamber) and light microscopy
(Leiea), after dilution in an equal volume of trypan blue solution (Sigma, UK), and by
exclusion of trypan blue. The number of cells in suspension was calculated by the
formula: number of viable cells in 25 squares x 2 (dilution factor) x 104 = number of
cells/ml.
Flow cytometry (FACS) analysis of CD45 variant splicing was performed as previously
described (Tchilian et al. 2001). Briefly, 2x105 PBMC were stained with either APC-
conjugated CD4 (S3.3, Caltag, Silverstone, UK) or CDB-APC (clone RPAITB,
Pharmingen, San Diego, CA) along with FITC-conjugated CD45RA (clone H110,
Pharmingen) and PE-conjugated CD45RO (clone UCHL 1, Pharmingen) monoclonal
antibodies (mAbs) in a single step at 4°C for 20 minutes and washed with phosphate-
buffered saline (PBS), containing 0.2% BSA. Isotype-matched mAbs were used as
controls. Ten thousand events per sample were collected on a FACSCalibur (Becton
Dickinson, Mountain View, CA), and analysed using Win MDI software.
Statistical analysis
Allele frequencies were determined by genotype count, and the exact test of the Hardy
Weinberg proportion was applied using the Markov Chain algorithm (Guo and Thompson
1992, available from: http://www2.biology.ualberta.ca/jbrzusto/hwenj.html).
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Data was analysed for significance of associations tested using Simcalc V1.0 for
Windows (Provalis Research). Chi-square (x2) analysis was performed, and a two-tailed
P-value <0.05 was considered significant.
Results
Mutation Analysis
No mutations were identified in the proposed promoter region of the CD45 gene, which
is in accordance with the fact that the nucleotide sequence of this gene fragment
appears to be relatively conserved (Timon and Beverley 2001). Aberrant bands detected
in exon 4 by Hex-SSCPwere analysed by direct sequence analysis to characterise the
gene variations. Among individuals attending the Infectious Diseases Clinic in the
Western Cape, only one Coloured HIV-seropositive individual (1.04%, n=96) was
heterozygous for the 77C-tG polymorphism, known to be more common in individuals of
Caucasian origin but absent in Black Africans (Tchilian et al. 2002). This female
individual was classified with class IV disease status according to the WHO criteria.
Although progression status for this individual was unknown, she was diagnosed with
both cryptococcal meningitis and tuberculosis, and no antiretroviral therapy has been
provided.
Mutation 32A-tG was identified heterozygously in 6 of 123 HIV-seropositive Black
Africans (4.9%) and 1 of 95 Coloured HIV-seropositive individuals (1.1%) (Table 3). The
mutation was however absent in the respective HIV-seronegative control groups from
this population, including 72 African and 62 Coloured individuals. This apparent
association between the 32A~G mutation and HIV-1 infection was marginally significant
(P=0.057) in the African individuals. The likelihood that this mutation is associated with
increased risk of HIV-1 infection was however largely excluded by analysis of African
study cohorts including individuals unaware of their HIV status at the time of entry into
the study. The 32A~G mutation was present at a lower frequency in HIV-seropositive
(1.4%, 1/70) compared with HIV-seronegative (3.2%, 3/94) African individuals recruited
from the NorthWest Province.
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Furthermore, 5 of 120 (4.2%) of African HIV-seronegative individuals from the Gauteng
Province population presented with the 32A~G polymorphism, compared with none of
the 10 HIV-seropositive individuals from this population.
Table 3. Allelic distribution of the 32A~G mutation in exon 4 of the CD45 gene in South African
populations of African ethnicity and Mixed Ancestry per geographical region
HIV+ HIV - P
n=298 n=348
Western Cape Province
African Genotype n=123 n=72
n=195 aa 117 (0.951) 72 (1.00) 0.057
ag 6 (0.049) 0
Alleles n=246 n=144
a 240 (0.976) 144 (1.00) 0.059
g 6 (0.024) 0
Mixed Ancestry Genotype n=95 n=62
n=157 aa 94 (0.989) 62 (1.00) 0.418
ag 1 (0.011) 0
Alleles n=190 n=124
a 189 (0.995) 124 (1.0) 0.418
g 1 (0.005) 0
North West Province
African Genotype n=70 n=94
n=164 aa 69 (0.986) 91 (0.968) 0.469
ag 1 (0.014) 3 (0.032)
Alleles n=140 n=188
a 139 (0.993) 185 (0.984) 0.472
g 1 (0.007) 3(0.016)
Gauteng Province
African Genotype n=10 n=120
n=130 aa 10 (1.00) 115 (0.958) 0.510
ag 0 5 (0.042)
Alleles n=20 n=240
a 20 (1.00) 235 (0.979) 0.514
g 0 5 (0.021)
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When genotypes for all African individuals were combined to improve the statistical
power, neither the genotype distribution (P=0.680) or allele frequencies (P=0.683)
differed significantly between HIV-seropositive individuals (n=203) compared with HIV-
seronegative individuals (n=286).
In order to determine a possible relationship between the 32A~G mutation and disease
classification, allele frequencies were determined among patients subdivided according
to the WHO HIV-1 disease classification. No statistically significant differences were
observed between groups, although the are numbers very small and therefore findings
were considered inconclusive (data not shown). The same accounted for comparisons
between rapid and slow progressors. It is however noteworthy that the 5 individuals with
this mutation for whom disease status were known were all classified according to the
WHO criteria as class I. Detection of mutation 32A~G in 35.7% (5/14) of HIV-
seropositive individuals classified as WHO class I and slow progression compared with
its absence in 22 HIV-seropositive patients with rapid disease progression therefore
suggests a positive link with slower disease progression. Table 4 shows a summary of
clinical data of the 5 HIV-seropositive individuals with the 32A~G mutation with known
disease status according to the WHO criteria. Two were classified as LTNPs, two
remained asymptomatic after several years of infection, and progression status was
unknown in the remaining individual.
Table 4. Clinical characteristics of HIV-seropositive individuals heterozygous for the CD45
32A~G mutation
No. Popul.! Age a
Gender (years)
Est. infection WHO Disease
length (years) class. Progress
CD4+ ARV
(x106 cells/I)
HIV-1disease-
assoe. symptoms
HIV118 SF 45 unknown unknown 293 yes unknown
HIV125 CF 43 > 4 normal 980 no asymptomatic
HIV241262 SF 46 >10 LTNP 350, 325 no lymphadenopathy
HIV54 SF 31 - 9 slow 585 no asymptomatic
HIV245 SF 19 - 11 LTNP unknown no HIV-associated
polyadenitis, PTS
a Age at blood sampling; Popul., population; ARV, antiretroviral therapy; BF, Black female; CF, Coloured female;
LTNP, long-term non-progressor; PTB, pulmonary tuberculosis
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The second novel mutation identified in the South African population, 54A~G, causing a
non-conservative amino acid change T18A, was identified in only one African HIV-
seropositive individual (1/118, 0.8%) from the Western Cape whilst absent in the HIV-
seronegative individuals (n=72) from this study cohort (Table 5). Disease progression
was unknown for the Black African female with mutation 54A~G, classified with class I
disease stage after approximately one year of HIV-infection. This missense mutation
was not detected in the Coloured study cohort including 94 HIV-seropositive and 62 HIV-
seronegative individuals. Further, 54A~G was detected in only one of 92 (1.1%) African
HIV-seronegative individuals from the North West Province, and absent in 69 HIV-
seropositive individuals from this population. Similarly, mutation 54A~G was absent in
10 Black African HIV-seropositive individuals recruited from the Gauteng Province and
present in 5 of 120 (4.2%) HIV-seronegative individuals recruited at the same time in this
region. Statistical analysis did not reveal any significant associations between HIV
infection and the 54A~G mutation. Combined genotypes for all African individuals to
increase the statistical power also failed to show any significant association for either
genotype distribution (P=0.148) or allele frequencies (P=0.168) for HIV-seropositive
individuals (n=197), compared with HIV-seronegative individuals (n=284).
Application of the ESEfinder program
The possible significance of the mutations identified in the South African population was
further assessed by using the web-based ESEfinder release 2.0 (ESE - Exonic Splice
Element) computer program (Cartegni et al. 2003). Figure 1 shows differences observed
with regard to disruption or creation of binding sites for the four splice factors analysed
by this program (SF2ASF, SC35, SRp40 and SRp55), based on theoretical threshold
values. The previously identified mutations 77C~G and 59C~A, with a well-established
effect on CD45 expression due to alternative splicing (Jacobson et al. 2000, 2002), was
first tested to determine the usefulness of theoretical predictions using this program. In
both cases, presence of the mutant alleles abolished known binding sites for the splicing
factors as shown in Table 6. The results obtained for the 54A~G missense mutation
suggest that binding sites for SRp40 and SRp55 would be abolished in the presence of
the mutated g-allele, with no new binding sites created for any other splice factors.
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Table 5. Distribution of the CD45 (PTPRC) exon 4 54A~G SNP in South African populations of
African ethnicity and Mixed Ancestry, per geographical region
HIV+ HIV- P
n=291 n=346
Western Cape Province
African Genotype n=118 n=72
n=190 aa 117 (0.992) 72 (1.00) 0.434
ag 1 (0.008) 0
Alleles n=236 n=144
a 235 (0.996) 144 (1.00) 0.434
g 1 (0.004) 0
Mixed Ancestry Genotype n=94 n=62
n=156 aa 94 (1.00) 62 (1.00)
ag 0 0
Alleles n=190 n=124
a 188 (1.00) 124 (1.0)
g 0 0
North West Province
African Genotype n=69 n=92
n=161 aa 69 (1.000) 91 (0.989) 0.385
ag 0 1 (0.011)
Alleles n=138 n=184
a 138 (1.00) 183 (0.995) 0.386
g 0 1 (0.005)
Gauteng Province
African Genotype n=10 n=120
n=130 aa 10(1.00) 115 (0.958) 0.510
ag 0 5 (0.042)
Alleles n=20 n=240
a 20 (1.00) 235 (0.979) 0.514
g 0 5 (0.021)
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This may generate aberrant mRNAs that are either unstable or code for defective or
deleterious protein isoforms. In the case of mutation 32A~G, no evidence of disruption
of any of the binding sites analysed were obtained.
Flow Gytometry (FAGs) analysis
Since assessment of the 32A~G mutation revealed no apparent splicing effect utilising
the ESEfinder program, FACs analysis was performed to determine whether this
mutation (observed predominantly in slow progressors compared to fast progressors)
affects CD45 expression. The results obtained, as represented by Figure 2, suggested
that this silent mutation might potentially affect expression of GD45. Figure 2A shows
FACs profiles from two individuals with the 32A~G mutation, and a control without this
mutation. All three individuals were HIV-seropositive. Peripheral blood mononuclear cells
(PBMCs) were gated on CD4+ helper or CD8+ cytotoxic T-cells and CD45RA and
CD45RO expression was analysed. Striking differences in the proportions of CD4+
subsets in 32A~G individuals were observed, however these could possibly be due to
differences in the stage of disease of the three individuals since HIV is known to infect
CD4+ T-cells. The two individuals with the 32A~G mutation showed a significantly
reduced number of CD45RA- CD45RO+ cells in the CD8+ subset (9.8% and 16.6%
versus 40.6% of CD8+ cells), which might indicate altered splicing in CD8+ T-cells.
Interestingly, the effect of the well-characterised 77C~G mutation on splicing (Figure
2B) appears to be more pronounced in CD8+ than CD4+ cells. Differences in
proportions of both CD4+ and CD8+ subsets were obvious in the case of the 32A~G
mutation.
The likelihood that the differences observed with FACs analysis (as seen in Figure 2)
could be due to differences in the stage of disease or viral load in the individuals studied
has to be considered, since viral infections generally affect the phenotype of CD8+ T-
cells (Appay et al. 2002).
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D. 32A~G*
104
Splice factors:
-SF2/AS
-SC35
-SR040
c::JSRo55
C. 59C~A
E. 54A~G
* unknown whether other splice factors may be involved,
as ESEfinder analvses for solice factors as indicated
Figure 1. Theoretical predictions for creation or abolishment of binding sites for splice factors
SF2ASF, SC35, SRp40 and SRp55 in the exonic splicing silencer element 1 (ESS-1) of the CD45
gene, according to the ESEfinder program. Panel A shows the wild type (wt) nucleotide
sequence. Panels Band C show the known mutations 77C~G and 59C~G respectively,
previously associated with alternative splicing. Panels D and E show the novel mutations 32A~G
and 54A~G, respectively. Splice factors are as indicated by different colours.
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Table 6. ESEfinder results obtained for abolishing binding or creation of new binding sites for splicing factors due to nucleotide sequence
alterations in the CD45 ESS-1 gene sequence. Nucleotide sequences for recognition sites of respective splicing factors are as indicated for the
wild type (wt.) and mutant (mut.) sequences (bold and underlined). Nucleotide positions (nt.) are based on the nucleotide sequence as indicated in
the footnote, used in determination of binding sites for splicing factors, and representing a portion of the PCR-fragment used in mutation analysis
for CD45 exon 4.
Binding site abolished
77 C-4Ga SF2IASF caccgcaq 57 -64
New binding site created
Splice factor(s) for Recognition Nucleotide
mut. sequence nt. sequence (wt) (nt.) position #
SF2/ASF ctcaccg 55 -61
SF2IASF caccgc 57-62
SF2IASF cgcagca 60-66
SRp55 cgcagc 60-65
SRp40 tcaccgca 56-63
SRp40 tca_!!acc 40-46
SC35 _!!accactg 43-50
Mutation Splice factor(s) Recognition Nucleotide
for wt. sequence nt. sequence (wt) (nt.) position #
32 A-4G b
SC35 caccgcaqc 57 - 65
SRp40 ccgcaqc 59 - 65
SRp40 tcagacc 40 -46
SF2/ASF cagacca 41 - 47
SC35 £accact 43 -49
--
SRp40 tacctg 33 - 39
SRp55 ct_!!ctca 36 -42
none *
none
59 C-4A a
54 A-4G b
none
none *
a known mutations causing alternative splicing of CD45 b novel mutations identified by the present study
* unknown whether other splice factors may be involved, as ESEfinder analyses for four splice factors only: SF2IASF, SC35, SRp40, SRp55
# Nucleotide sequence for ESEfinder analysis (wild type): GATGCCCAGT GTTCCACTTT CAAGTGACCC CTTACCTACT CACACCACTG CATTCTCACC- - -
£CAGCACCTT TGAAAGAGAA AATGACTTCT CAGA (94 bases, nt. 1-94)
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Disease progression status for the two HIV-seropositive individuals with mutation 32A~G
was reported to be asymptomatic for HIV125 (Coloured female) and unknown for HIV118
(Black African female), while both were of class I WHO disease classification. Further,
HIV118 has not received any antiretroviral therapy with a CD4+ count of 283 x 106 cells/I,
whereas HIV125 received antiretroviral therapy for at least three years and maintained a
CD4+ count of 980 x 106 cells/I.
HIV disease progression was uncertain in the HIV-seropositive control individual
(HIV087/100) without mutation 32A~G who was included for comparison. However, WHO
classification was reported to be class I at initial blood sampling, whereas follow-up clinical
data approximately two years later reported class II disease classification, and CD4+
counts of 251 x 106 cells/I with no antiretroviral therapy.
Discussion
Analysis of exon 4 and the proposed promoter area (located between exons 1 and 2) of
the CD45 gene in South African populations from different ethnic backgrounds were
performed in this study, with the aid of PCR-based mutation detection methods. The data
obtained in this study confirmed the absence of the 77C~G mutation in exon 4 of the
CD45 gene in Africans, as previously reported (Tchilian et al. 2002). This mutation was
however observed in one individual of Mixed Ancestry in our study population, suggesting
inheritance due to Caucasian admixture. This mutation has been identified in individuals of
Caucasian origin, but appears to be absent in Africans (Jacobson et al. 2000, Tchilian et
al. 2001 b, 2002). The frequency of 77C~G varies considerably between different ethnic
groups and allele frequencies in healthy control groups have been reported to be 1.8% in
individuals from the USA (Jacobson et al. 2000), whereas it could be as high as 6.7% in
Pamiris from Central Asia (Tchilian et al. 2002). While this polymorphism was virtually
absent in the populations investigated in our study, association of this mutation with HIV-
infection or disease progression (Tchilian et al. 2001a) needs to be confirmed in different
populations of large sample size.
Mutations 32A~G and 54A~G identified in exon 4 of the CD45 gene have not previously
been detected in the Caucasian population of South Africa (JNP de Villiers, unpublished
data) and are therefore considered to be African-specific polymorphisms. Both mutations
are present in the ESS-1 element of exon 4, located between nucleotides 29 and 88 of
CD45 (Lynch and Weiss 2001).
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Figure 2. Variant expression of the CD45 protein in relation to the 32 A~G mutation. FACs
analysis profiles of 32A ~G, indicating markedly reduced CD8+ cells (figure 2A), compared with a
wild type control, 32A. Isolates presenting with the 32A~G polymorphismwere compared to both a
non-HIV control isolate and an isolate presenting with the 77C~G mutation (figure 28).
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Mutations in ESS1 have been associated with alternatively spliced isoforms of CD45
(Jacobsen et al. 2000, Lynch and Weiss 2001). Similar to the previously documented
77C~G and 59C~A substitutions, both the 32A~G and 54A~G transitions is therefore
likely to contribute to alternative splicing.
Application of the ESEfinder program predicted alternative splicing in the presence of
mutation 54A~G, due to abolishment of known binding sites for factors that are essential
for normal gene splicing. The creation of new binding sites were not indicated by this
program, as was the case for two well-characterised mutations in the CD45 gene, 77C~G
and 59C~A where known binding sites were abolished and new ones were predicted.
Further, in addition to being situated within the ESS1, the 54A~G mutation causes an
amino acid substitution, T18A, which may alter the CD45 protein structure. In the case of
mutation 32A~G, no indicationwas obtained that this sequence change is likely to abolish
or create binding sites for the splicing factors analysed. It is however possible that this
mutation has a favourable effect on immune function, or occurs in linkage disequilibrium
with another functional mutation, which may be associated with differential expression.
Based on the results obtained using FACs analysis, the likelihood that mutation 32A~G
affects splicing of the CD45 protein cannot be excluded, since clear differences in
proportions of both CD4+ and CD8+ subsets were observed in individuals with this
mutation compared with the control individual. However, since HIV is known to infect CD4+
T-cells, these differences might also be due to differences in the stage of disease. The
disease status of the two HIV-seropositive 32A~G heterozygotes included for FACS
analysis was both classified as WHO class I. However, the HIV-seropositive control
individual without the 32A~G mutation had much reduced CD4+ counts. Further,
according to clinical data this individual progressed from class I to II within two years from
seroconversion, and could be classified as a rapid progressor. The individual with mutation
32A~G for whom clinical data was available has remained asymptomatic for more than
four years since HIV-1 disease diagnosis.
Analysis of clinical data of three more individuals with mutation 32A~G (all class I disease
status and either normal or long-term non-progressors, LTNP), raise the possibility that this
mutation is associated with protection against progression to AIDS following HIV infection,
especially since none of the 22 rapid progressors subjected to mutation screening tested
positive for this mutation.
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This was exemplified by the fact that none of the slow progressors or LTNPs with mutation
32A~G and with known progression status received antiretroviral therapy. Rather, they
remained relatively healthy and maintained relatively stable or high CD4+ counts for
extended periods of 9-11 years since seroconversion.
Since our data does not provide conclusive proof that the 32A~G mutation affects CD45
splicing, FACs analysis on healthy HIV-seronegative individuals with the mutation is
required to clarify the possible phenotypic effect of this mutation. Differences in the stage
of disease or viral load in the HIV-seropositive patients analysed may be responsible for
the differences observed between patients and controls, since the phenotype of CD8+ T-
cells are affected due to viral infections (Appay et al. 2002). RNA studies or analysis of
possible splicing effects using minigenes (Zilch et al. 1998) containing the mutation could
clarify the potential role of mutation 32A~G on expression of the CD45 gene.
In this study we have provided evidence that the apparently African-specific
polymorphisms, 32A~G and 54A~G identified in the CD45 gene, may affect protein
expression. Final elucidation of the functional significance of these mutations would
contribute to our understanding of the involvement of CD45 in immune disorders and
modification of risk for HIV/AIDS in the African context. Increased understanding of the role
of CD45 in host immunity may provide potential targets for intervention strategies aimed at
slowing disease progression in affected individuals.
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D. Assessment of HLA-B27 genotypes in South African HIV-seropositive individuals
with slow versus rapid progression to AIDS in relation to predetermined
genotypes of the CCR5, SLC11A1, HFE and CD45 genes
Objectives: The potential protective effect of HLA type B27 was investigated in relation to
combined genotypes determined for several candidate susceptibility genes in HIV-
seropositive individuals. The objective of this study was to identify genetic markers that,
alone or in combination with other mutations, might explain differences in rate of disease
progression from stage I to IV according to WHO criteria in South African patients.
Study Design: Thirty-six HIV-seropositive individuals classified according to disease
status were selected for HLA-B27 genotyping. These individuals have previously been
screened for genetic polymorphisms in the CCR5, SLC11A1, HFE and CD45 genes, and
formed part of a cohort attending an infectious diseases clinic in the Western Cape
Province of South Africa.
Methods: The study population included 15 Xhosa, 17 Coloured and 4 Caucasian HIV-
seropositive individuals. HLA-B27 genotyping was performed by using a real-time
polymerase chain reaction (PCR)-based mutation detection method.
Results: Two individuals tested positive for HLA-B27, and remained to be classified as
WHO stage I after more than 5 years of infection. No predominant co-existence with any of
the mutations screened for in the CCR5, SLC11A1, HFE and CD45 genes were detected
in these individuals.
Conclusions: Although only two of 36 individuals analysed tested positive for HLA-B27, the
clinical features of the HIV-seropositive individuals with this allele is in accordance with the
protective effect previously ascribed to this allele occurring in individuals of Caucasian
origin. Our findings provide support for a multifactorial basis for the development of AIDS
in HIV-1 infected individuals.
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Introduction
The multifactorial nature of HIV disease pathogenesis is reflected by the highly variable
rates of disease progression in HIV-infected individuals and between populations.
Significant differences in the rate of HIV-1 disease progression have been observed in
longitudinally followed HIV-infected persons since the beginning of the HIV epidemic.
Although most infected individuals develop AIDS symptoms within ten years, a small
number remains relatively healthy for periods longer than fifteen years, whereas others
progress to full-blown disease within the first three years after infection (Phair et al. 1992,
Munoz et al. 1997). Some individuals however resist infection or have the ability to
eliminate the virus.
Various studies have indicated that susceptibility to many infectious diseases, including
HIV/AIDS and tuberculosis, may be under host genetic control (Bellamy et al. 1998, Liu et
al. 1996, Samson et al. 1996a,b,c). Modulation of the rate of disease progression can be
influenced by host factors that can be either intrinsic or acquired, and most host genetic
mechanisms contributing to HIV/AIDS susceptibility have been shown to influence the
immune defence system. Genetic variants contributing to resistance to infection have been
identified in persons who were persistently exposed to HIV-1 but remained uninfected
(Rowland-Jones and McMichael 1995, Liu et al. 1996, Paxton et al. 1996). Although a 32-
bp deletion of the eeR5 gene, CCR5~32, was shown to be associated with resistance to
HIV-1 infection in several studies (Liu et al. 1996, Samson et al. 1996a,b,c, Biti et al.
1997), this mutation is not responsible for a protective effect in all cases (Balotta et al.
1997, O'Brien eta/. 1997, Theodorou eta/. 1997). This also appears to be true in the Black
South African population (Williamson et al. 2000, Petersen et al. 2001), since the deletion-
mutation is virtually absent in Africans. Several reports have indicated that the
mechanisms underlying HIV/AIDS susceptibility differ amongst most risk groups and
between populations (Costello et al. 1999, Geczy et al. 2000, Roe et al. 2000, Gao et al.
2001).
Resistance or susceptibility to HIV infection and disease progression has been ascribed
largely to mutations in chemokine co-receptors and the presence of certain alleles of the
major histocompatibility complex (MHC) (Liu et al. 1996, Laumbacher and Wank 1998,
Magierowska et al. 1999).
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Speculation of polygenic control of infectious disease susceptibility has been confirmed by
identification of several genetic regions containing genes that determine susceptibility to
infection (Roberts et al. 1997a). For HIV-1 disease, it was shown that combinations of
genetic variants might contribute significantly to susceptibility patterns and disease
progression (Magierowska et al. 1999, Geczy et al. 2000). Strong association for a number
of alleles from the HLA system, including HLA-B27, have furthermore been associated with
slow HIV disease progression and even non-progression, whereas others favoured rapid
progression (Hendel et al. 1996, 1999; Malkovsky 1996, Kaslow et al. 1996, McNeil et al.
1996, Roger 1998, Scorza Smeraldi et al. 1986, Cruse et al. 1991). Although alleles of the
HLA system were shown to function independently from other host susceptibility genetic
variants (Flores-Villanueva et al. 2001), a combination of protective alleles from the HLA
system and chemokines was suggested to be responsible for slow disease progression in
a large proportion of individuals studied (Magierowska et al. 1999).
In addition to immunological factors and host genetic variants implicated in susceptibility to
HIV/AIDS, environmental and viral factors contribute significantly to the complexity of
disease pathogenesis (Klein and Miedema 1995, Bollinger et al. 1996, Haynes et al.
1996). Assessment of the importance of host genetic involvement in disease development
has however been complicated by the complexity of environmental factors and nutritional
requirements that can be modulated by genetic mechanisms, which might further affect
microbial transmission. Furthermore, the variation of disease outcome between individuals
has been speculated to be due to combination effects of host genes and proteins
controlling the quality and possibly quantity of host-parasite interaction and human immune
responses. Genetic variants often have subtle but significant consequences on gene
expression or protein function. A delicate balance among these factors most likely
determines the net rate of viral replication in HIV-infected individuals.
Recently, Carrington and co-workers (2001) suggested an approach that may assist to
clarify the influence of genetic mechanisms involved in microbial disease pathogenesis.
However, due to the complexity of host-pathogen interaction no standard practice exists
for prediction of the disease outcome based in part on the genetic profile of HIV-
seropositive individuals.
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In this study we investigated the potential protective effect of HLA type B27 in relation to
combined genotypes determined for several candidate susceptibility genes in HIV-
seropositive individuals, including the CCR5, SLC11A1, HFE and CD45 (PTPRC) genes.
The objective was to identify genetic markers that, alone or in combination with other
mutations, might explain differences in rate of disease progression from WHO stage I to
IV in South African patients. Discovery of host genetic mechanisms associated with
infectious disease pathology, and defining the involvement of environmental factors
interacting with genetic mechanisms underlying acquisition of infectious disease, may aid
in development of novel targets for vaccines or chemotherapy.
Materials and Methods
Study Population
Ethical approval for the study was obtained from the Ethics Review Committee of the
University of Stellenbosch. Venous blood samples were obtained with informed consent
from all the study participants and the DNA was extracted using standard methods. Thirty
six HIV-seropositive individuals with known disease progression status and WHO
classification (Table 1) were selected for HLA-B27 genotyping from a cohort of HIV-
seropositive individuals attending the Infectious Diseases Clinic at Tygerberg Hospital in
Cape Town, South Africa. This study group has previously been subjected to mutation
analysis of the CCR5, SLC11A 1, HFE and CD45 (PTPRC) genes (see sections A, Band C
of this chapter), and included 15 Black Africans (12 female, 3 male) of Xhosa origin, 17
Coloured individuals of mixed ancestry (13 females, 4 males) and 4 Caucasian males. The
Coloured individuals of mixed ancestry are of San, Khoi, African, Madagascar, Javanese
and European origin. Estimated date of infection and HIV-1 disease-associated
complication data were recorded for the majority of individuals included in the study, and
ages of all study participants were calculated based on date of blood sampling. Data on
HIV disease status was denoted according to WHO clinical disease classification (classes
I-IV, http://who.int), and HIV-seropositive individuals were classified as normal progressors
when progressive loss in CD4 cell counts were associated with development of AIDS-
related symptoms within 10 years after HIV-1 infection, as rapid progressors when
progression to full-blown AIDS occurred within 2-3 years from seroconversion, and as slow
progressors when they remained unaffected after 8-10 years from seroconversion.
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Table 1. Clinical data of 36 HIV-seropositive South African individuals in relation to genotypes determined for HLA-B27 and the SLC11 A 1, HFE, CD45 and CCR5 genes.
Clinical data Genetic Data
Classification Age (y.o.) CD4+ count Clinical SLC11A1 HFE HLA CD45 CCR5
HIVNo. Progr. WHO & Gender X106 ceUs/ml Symptoms ARV 5'[GT]n IVS3-48c/g -827 Exon2 P35 .1.32
Black African
Population (n=11)
HIV54 S,9y I 31 F 585 As + 3,3 - - 32A~G
HIV116 N,6y II 52 F 216 As + 3,3 +
HIV118 unk. I 45 F 293 unk. + 3,3 - - 32A~G
HIV122 N,5y II 26F 672,874 Seb + 3,3
HIV155 R IV 28 F 47 TB - 3,3
HIV200 R II 20F 207 Seb, Hb10 unk. 2,3
H IV202 R IV 43 M unk. PTB,O thr unk. 3,3 - - - +
HIV209 R,6y III 35 F 113 TB + 3,3 +
HIV215 LTNP,2y I 28M 1106, >1000 As unk. 3,3
HIV245 LTNP,11y I 19 F unk. HIV-as poliade, PTB - 3,3 - - 32A~G
HIV257 N IV 34M <50 OcTB,O thr,Per Neu + 3,3 +
HIV262124 LTNP,>10y I 46F 325,350 Lymphadenopathy - 2,3 + - 32A~G
HIV267 unk. I 26F unk. unk. - 3,3 - - 54A~G
HIV272 S I 28 F 727 As unk. 2,3
HIV273 S,6y II 37 F 239 Foil - 3,3
Coloured Populat/on
(n=16)
HIV93 N,9y II 32 F unk. Seb + 3,3
HIV98 Asymp,>3y I 49 F 400,175 As - 2,3
HIV111 R,>4y II 27 F 250, 291, 319 Seb + 3,3
HIV113 N unk. 46M 120,658 unk. + 3,3 - - - NR 32bp
HIV125 N,>4y I 43 F 980 As + 2,3 - - 32A~G
HIV137 N,>5y I 39M 305 Dia Mel + 2,3 - +
.... .Ieont.
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Table 1 cont.
Clinical data Genetic Data
Classification Age (y.o.) CD4+ count Clinical SLC11A1 HFE HLA CD45 CCR5
HIVNo. Progr. WHO & Gender X108 cells/ml Symptoms ARV 5'[GT]n IVS3-48c/g -B27 Exon2 P35 ó32
HIV142 N III 25 F unk. PTB - 3,3
HIV163 N III 49 F unk. unk unk. 3,3
HIV171 R IV 25 F 20 PerTB, HSV + 3,3
HIV174 S IV 29 F 804,909 TB unk. 3,3
HIV180 S II 32 F 609 Seb, Fe30 unk. 2,3 +
HIV195 unk. IV 41 F unk. Crypt men, TB + 3,3 - - 77C--)G
HIV206 N IV 44M 748 TB unk. 2,3
HIV231 N,>6y II 37 F 444 Seb unk. 2,3 +
HIV232 LTNP II 29F 288,415 Seb unk. 3,3 NR
HIV252 R,4y II 35M 244,112,55 p24 unk. 2,3
HIV255 R,>2y IV 29 F 128 PTB - 3,3
Caucasian population
(n=4)
HIV109 (Homo) N,6y I 33M unk. unk. + 3,3 - +
HIV183 LTNP,4y I 36M 650,658,473 As unk. 3,3 NR - 77C--)G NR
HIV266 R I 32M 21 unk. unk. 2,3
HIV277 (Homo) R,2y IV 26M unk. Oes Ca,Can unk. 2,3 NR
Abbreviations: y.o. = years old, ó32 = 32 bp deletion, Progr. = Progression, ARV = anti-retroviral therapy, N = normal, R = rapid, S = slow, LTNP = long term non-progressor, As = asympto-
matic, Seb = seborrhoea, TB = tuberculosis, Hb = haemoglobin, Foil = folliculitis, PTB, pulmonary tuberculosis, 0 thr = oral thrush, oe TB, occult tuberculosis, Per Neu =
pericardiaI neuropathy, HIV-as poliade = HIV-associated polyadenitis, HSV = herpes simplex virus, Crypt men = cryptococcal meningitis, Fe = ferritin, Dia Mel = Diabetes
mellitus, p24 = persistent HIV p24 antigen, Homo = homosexual, Des Ca = oesophageal cancer, Can = candida, unk. = unknown, NR = no result
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HLA-B27 genotyping
HLA-B27 genotyping was initially performed using the commercially available HLA-B27
Gene Detection Assay (ViennaLab, Austria). The assay procedure was followed as
specified by the manufacturers, which is based on a reverse-hybridisation procedure with
horseradish peroxidase staining. Briefly, HLA-B gene exon 2 sequences were PCR-
amplified and terminally labelled with a reporter molecule (included in the assay
procedure) before hybridisation to group-specific oligonucleotide probes (either HLA-B27
or control, CTL). Horseradish peroxidase-labelled antibody was added to the reporter
molecule and colour substrates. CTL was included as an indicator of successful PCR
amplification. Positive samples were observed visually, although a micro plate reader (not
available) is recommended for visualisation of HLA-B27 positive samples. Confirmation of
positive signals obtained with the HLA-B27 Gene Detection Assay was performed by real-
time PCR on a Roche LightCycler as described by Tiemann et al. (2001). I3-Globin-specific
PCR oligonucleotide primers were used as an internal control for this procedure. The
oligonucleotide primers, PCR conditions and mutation detection methods previously used
for mutation detection in the study population are summarised in Table 2, together with
that applied for HLA-B27 genotyping performed additionally in this study.
Results and Discussion
Clinical and mutation data of 36 HIV-seropositive individuals selected for this study based
on disease stage classified according to the WHO criteria, is summarised in Table 1. The
mutation detection methods previously used for genotyping of polymorph isms in the
CCR5, SLC11A 1, HFE and CD45 genes in these individuals are given in Table 2. Figure 1
illustrates genotype results obtained for HLA-B27, using the commercially available HLA-
B27 Gene Detection Assay (A), followed by confirmation of positive signals using real-time
PCR (B). All samples observed to be positive with the HLA-B27 Gene Detection Assay
(both light blue and strong dark blue staining wells) were subjected to real-time PCR using
LightCycier technology.
Only the two strongest positive signals representing the DNA samples of individuals
HIV137 and HIV109 (wells A7/AB and A11/A12, respectively), were confirmed as HLA-B27
positive following analysis by real-time PCR. According to disease progression status and
WHO disease classification, both individuals HIV137 and HIV109 had normal progression
status and were of WHO class I status.
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Table 2. Oligonucleotide primers and condition used for PCR-based mutation detection in the South African study population.
Gene & variation peR Primer nucleotide sequences (5'~3') TA1/A2 (0C) Size (bp) DNA Analysis
SLC11A1 (NRAMP1)
5'[GT]n promoter variant F CCCCAGAACCTTGAGGTCTA
R CCCACACCAGTACCCCAT
65/60 116 Rsa I RE digestion
HFE a
IVS3-48c~g F AGTGAAAGTTCCAGTCTTCC
R CTCACTGCCATAATTACCTC
55 202 Bsa J1 RE digestion
CD45 (PTPRC)
Exon 2 F CCGAATCTGACATCATCACC
R CCTTGTACTTACCTGTCACAA
60/55 324 Hex-SSCP analysis
CCR5b
P35
CCR5tJ.32
F ATTATACATCGGAGCCCTGC
R AGCATAGTGAGCCCAGAAGG
F CTGGCCATCTCTGACCTGTT
R GATGATTCCTGGGAGAGACG
60/55 280 Hex-SSCP analysis
65/60 332 12% PAGE (3.4% C)
HLA-B C
HLA-B27 F GGGTCTCACACCCTCCAGAAT
R CGGCGGTCCAGGAGCT
65/60 250 Real-time PCR (with [3-globin
primers# as internal standard
TAannealing temperature, bp base pair, F forward, R reverse, RE restriction enzyme, Hex-SSCP heteroduplex single-stranded conformation polymorphism
• [3-globinspecific primers BG1: CAACTTCATCCACGTTCACC, BG2: GAAGAGCCAAGGACAGGTAC
• Beutler et al. 2000, b Petersen et al. 2001, C Tiemann et al. 2001. These references refer to the first description of the mutation analysed, or the method
of mutation detection used.
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Figure 1. HLA-B27 genotyping using the commercially available HLA-B27 Gene Detection Assay (A) and
real-time PCR using the Roche LightGycler (B). A. Exon 2 of the HLA-B gene was PCR-
amplified and terminally labelled with a reporter molecule before hybridisation to a group-
specific HLA-B27 and generic control (GTl) oligonucleotide probes in alternating cavities of a
microweIl plate. Bound sequences are detected by addition of horse-radish peroxidase-
labelled antibody to the reporter molecule(s) and colour substrates. Positive signals are
indicated in wells A7/AB (HIV137) and A11/A12 (HIV139), respectively. B. The two strongest
signals observed by using the HLA-B27 Gene Detection Assay were confirmed as being
positive by real-time PGR on the Roche LightGycler. Sample numbers H137 and H109 is
indicated in red and black respectively, while the positive and negative controls are indicated
by blue and green respectively.
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HIV137, a Coloured male individual, has been HIV-seropositive for more than 5 years with
no clinical symptoms related to HIV-1 infection. This individual also had a diagnosis of
Diabetes Mellitus. HIV109, a Caucasian male, seroconverted 6 years prior to entry into the
study and was classified as stage I disease at the time. No additional clinical data was
available for this individual. Although only a limited number of gene mutations were
analysed in the study population, none of these individuals showed any predominant
association with a combination of gene variations in the GGR5, GD45, HFE and SLG11A1
genes. It therefore seems likely that the presence of the HLA-B27 allele could contribute to
the health status of the two mutation-positive individuals considered to be relatively good.
Although this could also be ascribed to antiretroviral therapy recorded for both individuals,
our findings are in accordance with a protective role of HLA-B27 against progression to
AIDS, seeing that none of the rapid progressors had this allele. Although HIV137 also
tested positive for allele 2 of the SLG 11A 1 5'[GT]n polymorphism, previously implicated as
a protective modifying factor in HIV-infected patients (Marquet et al. 1999), our earlier
studies (see section A of this chapter) could not confirm this association in the South
African population.
No possible gene-gene interactions were furthermore observed when LTNPs and
asymptomatic HIV-seropositive individuals without the HLA-B27 allele were assessed for
combinations of any of the other genes analysed in the same study cohort. Predominance
of mutation 32A~G in HIV-seropositive individuals classified as WHO class I and slow
progression compared with its absence in HIV-seropositive patients with rapid disease
progression (see section C of this chapter), suggests a positive link with slower disease
progression irrespective of interaction with any of the other genes studied. Two of the five
individuals with mutation 32A~G included in this study were classified as LTNPs, two
remained asymptomatic after several years of infection, and progression status was
unknown in the remaining individual.
The African-specific polymorphism IVS3-48c/g of the HFE gene involved in iron overload
was identified in the LTNP HIV262/24. This polymorphism occurs at a position in intron 3
of the gene that closely resembles a splice site nucleotide sequence, but further studies
did not demonstrate a functional role for this variant (Beutler and Gelbart 2000). Our
analysis of this variant (D Pretorius 2003a, section B of this chapter), although not
significantly associated with HIV-1 disease, indicated that the HFE IVS3-48c/g variant was
markedly associated with reduced haemoglobin levels (P=0.004).
Stellenbosch University http://scholar.sun.ac.za
120
This observation appears to be related to linkage disequilibrium with a functional mutation
in another gene in close association with the HFE gene. The combination of these two
genetic variants, together with SLC11A 1 genotype 2,3 in the same individual, raise the
possibility of gene-interaction between the SLC11A1, CD45 and HFE genes resulting in
the LTNP phenotype. However, co-existence of these mutations in the same individual
may also be due to chance, especially since no preferential association of the IVS3-48c--+g
mutation with disease status or progression was observed in individuals with this HFE
mutation.
Although one HIV-seropositive Coloured male, HIV113, tested positive for the CCR5t.32
deletion known to be associated with slow disease progression, this individual was
classified with normal disease progression and unknown WHO disease status, while
receiving antiretroviral therapy. CD4+ counts improved from 120 to 658 between two
clinical follow-up events.
Conclusions
In view of our results within the context of published data, it seems likely that susceptibility
to HIV/AIDS following exposure to HIV-1 infection may to a large extent be determined by
non-MHC genes such as CCR5 and SLC11A 1 amongst others, while severity of the
condition is determined by modulation of T-cell responses to particular antigens. This can
be supported by the proposed role of CD45 (Tchilian et al. 2001a,b,c), known to be
essential for the activation of T-cells, which is also implicated in this process and probably
forms part of the polygenic nature of HIV/AIDS susceptibility. Iron status appears to be
central to this process, since sufficient availability of iron is required for development of T-
cells, which in tum appears to regulate iron metabolism perhaps through interactions with
HFE (Bowlus 2002) encoding a non-classical major histocompatibility gene.
Our results are in accordance with the notion that HIV-1 disease susceptibility and
progression are regulated by polygenic control mechanisms, in addition to the influence
of environmental factors that are of vital importance in the regulation of cellular activities
and the recruitment of cells of the innate immune response. Investigating various host
genetic changes in the same population as performed in this study, could be important
for the development of a screening procedure to predict clinical outcome of HIV/AIDS.
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This may further aid in understanding the involvement of host factors in host immunity,
which may provide potential targets for intervention strategies aimed at slowing disease
progression in affected individuals.
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Prior to the initiation of this study very limited genetic analysis had been performed in the
South African population with regard to susceptibility to HIV/AIDS. The overall objective
was therefore to identify host genetic variants that may contribute to modified risk of HIV-1
infection and/or progression to AIDS, particularly in the non-Caucasian South African
population. It was anticipated that possible phenotypic effects of relevant mutations
investigated for their potential involvement in HIV-disease might provide an improved
understanding of the importance of host genetic mechanisms in the African context. The
elucidation of disease mechanisms may ultimately increase the predictive ratio of disease
evolution, thereby providing an opportunity to refine the ongoing evaluation of therapeutic
or preventive measures, or contribute to the development of novel therapeutic strategies.
Host genetic factors found to be involved in HIV/AIDS may have prognostic value and may
serve, in addition to CD4+ counts and viral load, as decision-making tools in clinical
management of HIV-infected individuals. The observations made in this study were
considered in the context of the variety of genetic mechanisms previously implicated in
susceptibility to HIV-1 infection and disease progression, in order to evaluate the potential
impact of our findings in relation to current knowledge.
It is known from the literature that various host genetic factors may be associated with
HIV-1 disease acquisition or progression to full-blown AIDS. The most extensively studied
factors associated with HIV-1 disease are summarised in table 1. Susceptibility to HIV-1
disease has mainly been attributed to variation of the chemokine and chemokine co-
receptor genes and alleles of the major histocompatibility complex (MHC). For example,
various mutations in the chemokine co-receptor genes, CCR5 and CCR2, may protect
against HIV-1 infection or are associated with slow disease progression. Alleles of the
MHC system are however more varied with regard to their involvement in HIV/AIDS. Some
alleles are associated with slow disease progression and others with rapid progression,
while the specific alleles involved also differ between Caucasian and African population
groups. Alleles of the MBL gene appear to be protective to HIV-1 infection, although not
against progression to AIDS. Once an individual has been infected, progression to AIDS
may occur rapidly irrespective of the MBL genotype. The proposed HIV/AIDS susceptibility
mechanisms and gene variations vary considerably between individuals, and in some a
combination of mutations in chemokine receptors together with specific HLA alleles are
responsible for diverse clinical outcomes (Magierowska et al. 1999).
Stellenbosch University http://scholar.sun.ac.za
123
Table 1. Genetic mutations (alleles and haplotypes) implicated with modified risk to HIV-1 infection and the rate of disease progression.
Gene Reference
H/V H/V-Progression
Allele/Haplotype Protection Infection LTNP Slow Normal Rapid
CCR5 CCR51132(Cau) ./ (hom) Liu et al. 1996; Samson et al. 1996;
Garred 1996; Biti et al. 1997; Eugen-
Olsen et al. 1997; Meyer. 1997;
Michael et al. 1997
Ouillent et al. 1998
Ouillent et al. 1998
Sriwanthana et al. 2001
Ouillent et al. 1998
Martin et al. 1998
./ (het)
-59353T/C - - ./
-59029G/A - - - ./
-50402AIG (CSWa) - - - ./
Hap/otype M330/CCR51132 (Cau) ./
-59353T1C I - - - ./
-50402AIG
CCR2 V641 - - - ./
(incl. CSW b)
SDF-1
MBL
SLC11A1
Hp
CD45
Smith et al. 1997, Anzala et al. 1998 c
Kostrikis et al. 1998, Mummidi et al.
1998, Rizzardi et al. 1998,Mangano
et al. 2000
SDF1-3'A - - ./
A, B, C (hom) ./
5'[GT]n Allele 2, ./
274CIT,469+GIT
823CIT - ./
Hp2-2 (phenotype) - ./
C77G - ./
Winkler et al. 1998, van Rij et al. 1998,
Brambilla et al. 2000
./ Nielsen et al. 1995, Garred et al. 1997,
Maas et al. 1998
Marquet et al. 1999
Marquet et al. 1999
./ Sanchez-Madrid et al. 1983, Valentin
et al. 1990, Delanghe et al. 1998
Tchilian et al. 2001
.... .Ieont.
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Table 1/cont.
HIV HIV-Progression
ReferenceGene Aliele/Haplotype Protection Infection LTNP Slow Normal Rapid
HLA A26, B14,B27
B57, C8, C14,
DR11
~
A2,A28, B18 ~
(Afr, CSW b)
A23 (Afr, CSW b)
Bw4
Bw6, B35
B5703 (Afr)
DQB1*0603 (Cau)
DOB1*03032 (Cau) ~
DOB1*04 (Cau)
DOB1*0201 (Afr)
A*0202, A*0205,
A*0214, A*6082
DRB1*0102
(Afr, CSWa)
Hap/otype A1-B8-DR3
A1-Cw7-B8,
Cw4-B35
A1-Cw7-B8-
DR3-D02
~
~
~
~
~
~
~
~
~
~
~
Hendel et al. 1996, 1999; Kaslow
et et. 1996, Malkovsky 1995, McNeil
et a/. 1996, Roger et a/. 1998, Scorza
Smeraldi et al. 1986
MacDonald et a/. 2000
MacDonald et el. 2000
Flores-Villanueva et a/. 2001
Flores-Villanueva et et, 2001,
Scorza Smeraldi et a/. 1986
Costello et el. 1999
Roe et et. 2000
Roe et et. 2000
Roe et a/. 2000
Roe et a/. 2000
MacDonald et a/. 2000
Steel et et. 1988, McNeill et a/. 1996,
Kaslow et et. 1990
Steel et et. 1988, Kaslow et a/. 1990,
Carrington et el, 1999, Keet et a/. 1999
Steel et et. 1988, Kaslow et el. 1990,
Carrington et a/. 1999, Keet et a/. 1999
LTNP, long-term non-progression; hom, homozygous; het, heterozygous; Afr, African; Cau, Caucasian; CSW, commercial sex workers; a Thailand; b Kenia
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Since mechanisms involving both the immune system and iron-related metabolic pathways
have been implicated in impaired antiviral responses, candidate genes considered to be of
importance in this context were selected for study. These included the iron-related genes
SLC11A and HFE, as well as the CD45 (PTPRC) gene involved in host immunity.
Although these genes have previously been investigated in relation to HIV disease, the
findings obtained have not yet been confirmed in follow-up studies. In fact, the HFE gene
has only been studied in a single HIV-infected individual, whilst the information provided
for the two other genes is mainly limited to Caucasian populations. This study represents
the first to investigate genetic variations of these candidate genes for their involvement in
HIV/AIDS in predominantly Black and Coloured South African populations. The selected
genes were studied to determine possible independent effects in relation to HIV disease,
and were also evaluated together with HLA-B27 to assess the likelihood that a
combination of any of the variants studied could explain diverse clinical outcomes in
patient subgroups.
SLC11A1
Variant alleles of the functional 5'[GT]n polymorphism present in the regulatory promoter
region of the SLC11A 1 gene, have previously been associated with susceptibility to
autoimmune disorders and infectious disease, in addition to regulating gene expression
(Blackwell and Searle 1999). Allele 2 [t(gt)sac(gt)sac(gt)10ggcaga(g)6] is associated with
susceptibility to infectious disease (Bellamy et al. 1998, Marquet et al. 1999), whereas
allele 3 [t(gt)sac(gt)sac(gt)9ggcaga(g)6] has been associated with susceptibility to
autoimmune disorders (Shaw et al. 1996, Kotze et al. 2001). The SLC11A 1 protein is
predominantly expressed in immune cells and functions in iron homeostasis (Atkinson and
Barton 1998). Differential expression of SLC11A 1 due to the functional 5'[GT]n
polymorphism may therefore yield altered iron homeostasis, which could contribute to
altered susceptibility to immune disorders.
Although allelic variation in the SC11A1 gene has previously been implicated in HIV/AIDS
susceptibility (Marquet et al. 1999), genotype and allele frequencies did not differ
significantly between' HIV-seropositive and HIV-seronegative individuals in the South
African population. Analysis of a 9 base-pair deletion of exon 2, previously associated with
modified risk to HIV-1 infection in Africans (Ramaley et al. 2000) also did not provide
evidence for association with HIV-1 disease in our study population. These results
suggested that allelic variation of SLC11A 1 could be population-specific.
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Furthermore, phenotypic effects of functional SLC11A 1 gene variants in HIV-1
pathogenesis appear to be mediated by complex gene-environment interaction, in the
context of the genetic background of an individual.
HFE
It has been speculated that molecules of the major histocompatibility complex (MHC) may
play a role in iron metabolism (Salter-Cid et al. 2000). The non-classical MHC
haemochromatosis (HFE) gene, known for its significant role in iron loading (Feder et al.
1996), was recently studied in the context of HIV infection. Although only described in an
isolated case, the presence of the iron-loading mutation C282Y was reported in relation to
HIV-1 disease progression (Nielsen et al. 1999). Molecular investigation of the HFE gene
was therefore deemed important in a population-based study, to investigate the potential
involvement of this gene in HIV/AIDS. The mutations identified in exons 2 and 4 of the
HFE gene (H63D, C282Y, S65C and V53M) were rare in the study population, which was
in accordance with a previous finding in Black Africans recruited from the general
population (De Villiers et al. 1999). However, genotype-phenotype correlation studies
indicated a possible direct effect of HIV-1 infection on iron metabolism. The African-
specific and apparently non-functional intron 3 polymorphism IVS3-48C--+G (Beutler and
Gelbart 2000), showed a significant association with reduced haemoglobin levels in HIV-
seropositive (P=0.004) and HIV-seronegative (P=0.02) Black Africans. The sample size
was similar in both these groups, which further emphasised the more pronounced effect of
the mutation on haemoglobin levels upon HIV infection. Although a linkage disequilibrium
effect cannot be excluded, it became clear that genetic variation might differentially affect
the degree of an acute phase response that could most likely alter disease susceptibility or
clinical outcome.
CD45
Molecules directly involved in immune activation, for example CD45, may contribute to the
multifactorial nature of HIV/AIDS susceptibility (Tchilian et al. 2001a). Activation of
lymphocytes is facilitated by CD45 upon antigen stimulation (Byth et al. 1996, Thomas and
Brown 1999). However, HIV-1 infected individuals show several immunological alterations,
some of which may be attributed to disease progression, including increased susceptibility
to cell death and a significant reduction in the number of CD4+ T-Iymphocytes (Gougeon
and Montagnier 1993, Hellerstein et al. 1999).
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A lack of CD45 as a consequence of the lack of circulating T-cells and impaired immune
responses often results in immunodeficiency. It is also known that CD45 is differentially
expressed on different cell types, dependent on the state of activation and differentiation of
haemopoietic cells (Hathcock et al. 1992, Craig et al. 1994). Genetic variation of the CD45
gene could therefore alter CD45 function, which may contribute to immunodeficiency or
impaired anti-viral responses (Tchilian et al. 2001 a,b). Functional mutations of CD45, for
example 77C~G, have been identified for their involvement in differential expression of
CD45, and may be associated with a modified risk for HIV-1 infection (Jacobsen et al.
2000,2002, Tchilian et al. 2001a). The CD45 mutation 77C~G was however shown to be
absent in African populations that were sampled (Tchilian et al. 2002). Identification of
functional mutations of CD45 in relation to HIV-1 disease in different populations may
therefore be important in understanding the involvement of genetic variation of this
molecule in immunodeficiency.
Investigation of the CD45 gene in this study identified two African-specific polymorphisms,
32A~G and 54A~G, in the exonic splicing silencer element 1 (ESS-1) located in exon 4.
Although modified risk to HIV-1 infection was not demonstrated, the silent 32A~G
mutation appears to predominate in slow disease progressors in the HIV-seropositive
individuals studied, while the missense mutation 54A~G (T18A) was predicted to affect
differential expression of CD45. Functional studies of 32A~G by flow cytometry (FACs)
analysis showed a reduced number of CD45RA- CD45RO+ cells in the CD8+ subset in two
HIV-seropositive individuals (9.8% and 16.6%) selected for further study, compared with a
control without the mutation (40.6%), which may be due to differences in disease status.
Although numbers were small, assessment of the clinical data of these individuals and
HIV-seropositive individuals with WHO Class I disease status and presenting with 32A~G
(5/14, 35.7%), suggested a possible protective effect in disease progression, compared
with 22 rapid progressing HIV-seropositive individuals without the mutation.
HLA-B27 and combined genotypes
In view of the multitude of environmental factors that contribute to HIV-1 disease outcome,
compounded by the differing effects of individual or combinations of genetic variations,
alleles of the highly polymorphic MHC system are crucial in immune activation in response
to infectious agents. HLA molecules function by binding and presenting antigens to class 1-
restricted CD8+ cytotoxic T-Iymphocytes (CTLs), thereby recruiting other cells involved in
the immune response.
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The polymorphic nature of HLA determines expression of CTL epitopes on the surface of
infected cells, and HLA alleles encoded by this system are known to differ significantly
between geographical populations. However, certain alleles have probably been
maintained within individual population groups as a consequence of natural selection, and
may be responsible for protection against certain infections. Although combinations of
certain HLA alleles with other functional disease-associated mutations, for example
CCR5~32 and CCR2-641, have been shown to significantly modulate the course of HIV-1
infection, these alleles contribute independently to HIV-1 infection or disease progression.
Class I HLA type B27 has also been implicated independently with slow disease
progression (Hendel et al. 1999), and can also function as part of the protective
mechanism when present on the same haplotype as other HLA alleles (Magierowska et al.
1999).
The potential protective effect of HLA type B27 was therefore analysed in our study
population, in relation to possible combined genotypes determined for the above-
mentioned candidate susceptibility genes in HIV-seropositive individuals. This was done to
identify genetic markers that might, independently or in combination with other mutations,
explain differences in the rate of disease progression in the population investigated. From
a selected group of 36 HIV-seropositive individuals with known progression status and
attending a clinic for the management of HIV-disease, two individuals who remained
relatively healthy after more than 5 years of HIV-1 infection tested positive for HLA-B27.
Absence of this allele in the Black Africans studied was in line with the previous
association of HLA-B27 with protection from HIV-1 disease progression in individuals of
Caucasian origin. Since no predominant co-existence with any of the mutations screened
for in the SLC11A 1, HFE, eD45 and eeR5 genes were detected in this study group, it was
concluded that HLA-B27 might independently contribute to the clinical features observed in
these individuals.
An attempt was made to establish whether gene-gene interactions might have contributed
to specific disease outcomes in the study population. Although a limited number of HIV-
seropositive individuals presented with combinations of genetic mutations identified during
this study, comparison of HIV-seropositive individuals with known progression status did
not indicate a distinct possibility for gene-gene interaction with regard to the gene
variations studied.
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However, in view of the diversity of host genetic mechanisms previously described for their
involvement in HIV/AIDS, these mutations may possibly in combination with other
mutations, have a significant impact on disease outcome in the South African population.
Future Prospects
In view of the data obtained by this study, the following aspects were identified for further
investigation.
Since the findings are not in agreement with the proposed HIV-1 protective role for allele 2
of the SLC11A 1 gene 5'-[GT]n promoter polymorphism, further studies are warranted to
clarify the effect of this polymorphism in HIV/AIDS susceptibility. It seems possible that the
differential allelic effects of this polymorphism on transcriptional activity observed in the
presence and absence of the nearby polymorphism -237C~ T (M. Zaahl PhD study,
submitted), may affect the outcome of case-control studies. When the -237 t-allele occurs
in combination with allele 3 of 5'[GT]n, expression of SLC11A 1 is down-regulated, similar
to the allelic effect associated with allele 2. Reassessment of allelic associations based on
expression profiles as demonstrated by these in vitro studies involving different SLC11A 1
promoter constructs, therefore needs to be performed in our study population. It seems
likely that the inability to replicate disease associations previously reported in relation to
SLC11A1 in different populations may be due to a linkage disequilibrium effect, and
therefore analysis of haplotypes rather than single mutations could be more appropriate.
Indications that the intronic polymorphism IVS3-48c~g in the HFE gene, which correlates
significantly with altered haemoglobin levels, may occur in linkage disequilibrium with a
functional mutation in a nearby gene raised an important question. Is it possible that
genetic variation in another gene on chromosome 6 results in differential immune
responses upon HIV-infection? The association between the presence of this mutation and
reduced haemoglobin levels appears to be more pronounced in HIV-seropositive
individuals than in HIV-seronegative individuals. This finding provides support for the
notion that genetic variation in any of the host molecules involved in response to infection
could influence HIV-infectivity and consequently clinical outcome in affected individuals. A
direct role of the HFE gene in this process cannot be excluded, since the HFE protein has
both structural and potential functional similarities with the immune-associated molecules
encoded by the MHC genetic region.
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Therefore, haplotype studies in conjunction with mutation studies, may prove useful to
investigate the likelihood that genetic variation in a nearby gene may be responsible for
the phenotypic effects observed in this study, in relation to the HFE mutation IVS3-48c~g.
The genetic alterations identified in the CD45 gene appear to affect expression of the
resulting protein, although further studies are required to confirm these findings. Due to the
fact that HIV-1 infection and disease status may influence expression of CD45, mutation
32A~G needs to be screened for in a population of healthy individuals who are
contactable for follow-up investigations, once this mutation is detected. Due to ethical
constraints, the control individuals testing positive for mutations in the CD45 gene in this
study, could not be contacted to obtain tissue samples for functional studies. Furthermore,
screening of additional HIV-seropositive individuals with diverse clinical features for
mutation 32A~G, is of great importance to confirm or exclude the possibility that this
mutation protects against disease progression following HIV-1 infection. Confirmation of
the proposed role of genetic variation in the CD45 gene with the rate of progression to
AIDS may possibly provide a novel molecular target for immune intervention, aimed at
slowing disease progression in affected individuals.
Other genes of interest for future studies in the context of HIV/AIDS are those involved in
drug response, in light of the clinical impact that pharmacogenetic testing may have on
patient management. These include genes encoding drug transporter proteins, which may
also alter the risk of immune disorders and infectious disease (Lee et al. 2000). Genetic
variation of the MDR1 gene, encoding the multidrug-resistant transporter MDR1/P-
glycoprotein, possibly contributes to HIV-1 susceptibility (Lee et al. 2000). Over-expression
of MDR1 has been associated with reduced HIV-1 viral production, and the MDR1
genotype was suggested to contribute to this observation. Furthermore, since antiretroviral
drugs are substrates for MDR1, it is likely that the therapeutic outcome could also depend
on the MDR1 genotype (reviewed by Sakaeda et al. 2002). MDR1 may be fundamental in
immune function (Adams et al. 1998, Johnstone et al. 2000) as it is expressed on cells of
the innate immune system (Chong et al. 1993, Klimecki et al. 1994, Randolph et al. 1998).
Expression of MDR1 is however affected by genetic variation of the MDR1 gene. A silent
mutation at position 3435 in exon 26, C3435T, appears to be important in both MOR 1
expression and pharmacokinetics, and occurs in significantly higher frequencies in
Africans compared with other populatious (Ameyaw et al. 2001, Schaeffeier et al. 2001).
Stellenbosch University http://scholar.sun.ac.za
131
Although the function of this mutation has not been clearly defined, linkage with another
SNP may possibly affect the function of this molecule. The possibility of treatment and
disease diagnosis based on MDR1 genotyping was highlighted by the observation that
MDR1 may be important in susceptibility to for example HIV-1 infection, in addition to
being vital in drug delivery. However, since the expression pattern of MDR1 appears to
differ between populations and in different cell types, intensive study of this gene is
required before any attempts can be made to use genetic information for the design of
gene-based therapeutic agents against HIV/AIDS.
Limitations of this study included the relatively small sample size of the study population in
relation to the complexity of the condition studied, as well as a lack of clinical information
for the majority of individuals subjected to mutation screening. Furthermore, although it
was shown that the HFE gene IVS3-48c~g mutation is associated with reduced
haemoglobin levels, future studies will require assessment of iron status in all individuals
included, especially those with known disease status. Other limiting factors that need to be
considered are that of cost and time. For HLA genotyping only HLA-B27 was analysed,
since commercially available screening kits that can be used for complete genotyping and
for haplotype analysis of the HLA region, are very expensive.
During this study it became clear that both host genetic factors and immunological
responses might contribute significantly to HIV-1 disease susceptibility. The complexity of
disease pathogenesis may furthermore be compounded by nutritional insufficiencies,
environmental influences and viral characteristics. Investigation of all these factors in large
population samples would therefore be essential to provide conclusive answers to the
many questions raised during this study. Given the absence of therapeutic or preventive
vaccines at present, findings of relevant genetic differences in or between populations may
provide the basis for future development of intervention-based HIV therapeutic or
prevention strategies, focussing on the interaction of HIV-1 with host factors.
This study has contributed to a better understanding of the influence of host genetics on
susceptibility to HIV-1 disease in the South African population. The effect of HIV-1 on iron
metabolism in the context of immune response was demonstrated for the first time at the
DNA level, as indicated by the differences in haemoglobin levels observed in relation to
the presence of the HFE mutation.
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Although no direct support was provided for a multifactorial basis for genetic susceptibility
to HIV/AIDS, sufficient data in the literature suggests that combined effects of different
genes determine the clinical outcome in some individuals, while single genetic factors
may be sufficient to produce diverse clinical outcomes in others, in conjunction with
relevant environmental factors.
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APPENDICES: DETAILED EXPERIMENTAL PROCEDURES AND PROTOCOLS
1. Genomic DNA Extraction
Long term storage, high yield - long salt-extraction procedure
Reference: SA Miller, DD Dykes, HF Polesky. A simple salting out procedure for extracting DNA
from human nucleated cells. 1988 Nucleic Acid Research 16:1215
Day 1:
1. Place EDTA blood ca. 10 ml in 50 ml Falcon tube
2. Add 30 ml cold lysis buffer. Place 15-20 min on ice with gentle agitation every 5 min.
3. Centrifuge 10 min at 1500 rpm
4. Carefully decant supernatant and keep pellet
5. Rinse with 10-15 ml Phosphate-buffered saline (PBS)
6. Centrifuge 10 min at 1500 rpm
7.
8.
Carefully decant supernatant and keep pellet
Dissolve pellet in: 3 ml Nucleus Lysis Buffer
30 III Proteinase K
300 1l110% SDS
Mix well and incubate overnight at 55°C
Day2:
1. Add 1ml 6M NaCI and shake vigorously for 1 minute
2. Centrifuge 15 min at 2500 rpm
3. Transfer supernatant to new 50 ml Falcon tube (taking care not to transfer
foam and pellet)
4. Add 2 volumes ice cold 100% Ethanol and precipitate DNA
5. Wash DNA in 70% Ethanol (room temp.)
6. Air dry for 20-30 min
7. Dissolve DNA in 200-800 III sterile dH20 or TE buffer, depending on pellet size
8. Store tube at 4 °C
...... ./(cont.)
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Genomic DNA Extraction (cont.)
Buffer Solutions: DNA Extraction
Per 1000 ml 5000 ml
1. Gold Lysis Buffer
0.01 M Tris-GI
O.4M NaGI
0.002M EDTA
Mr=121.1
Mr=58.44
Mr=292.2
1.211 9
23.4 9
0.6 9
6.055 9
117.0 9
3.0 9
Set pH8.2 with concentrated HGI
2. Nucleus Lysis Buffer
0.155M NH4GI
0.01M KHG03
0.001M EDTA
Mr=53.49
Mr=100.12
Mr=292.9
8.3 9
1.1 9
0.03 9
3. PBS Dissolve 10 pellets in 1 litre dH20
(phosphate-
buffered saline)
4. Proteinase K Add 10 ml sterile dH20 per 10mg vial and dissolve at room
temperature. Decant in 1.5 ml Eppendorf tubes and freeze
(-20°C) for long term preservation
5. 10% SOS Dissolve 10 9 SOS in 100 ml dH20
6. 6M NaGI Add 350 9 NaGI to 1 litre dH20 and mix well. Allow salt to
settle out prior to use
...... ./(cont.)
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Precipitation of DNA
Precipitation:
1. Add 1 volume Phenol-chlorophorm to DNA
2. Centrifuge -10 min
3. Keep top phase
4. Add. 1 volume chlorophorm
5. Centrifuge -10 min
6. Keep top phase
7. Add 2 volumes ice-cold 100% Ethanol, stand at room temperature for 30 min
8. Centrifuge 1 minute @ RT
9. Discard supernatant and air-dry pellet
10. Dissolve in dH20 or TE Buffer
Ethanol Precipitation:
1. Add 1/10 volume 3M Sodium Acetate
2. Put in freezer for 20 minutes
4. Centrifuge 10 minutes
5. Discard supernatant
6. Wash with 2 volumes 70% Ethanol (room temperature)
7. Vortex and leave 5 minutes @ RT
8. Centrifuge 1 minute @ RT
9. Discard supernatant and air-dry pellet 5-10 minutes at room temperature
10. Dissolve in dH20 or TE Buffer (pH7.4)
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PAA (poly-acrylamide) Gel Matrices:
Mix all ingredients, except TEMED. Add TEMED immediately before pouring, mix well
and pour immediately (takes about 6 minutes to polymerise at room temperature)
2.1. Combined Heteroduplex-SSCP (Hex-SSCA analvsis:
Volumes are 60 ml per gel (Hex-SSCP analysis slab gels), although the required
volume is 40 ml per 18cm x 32cm (0.75mm thickness), in case of leakage
A. 10% Urea gel
7.5% Urea
5 x TBE buffer
dH20
1%C (40% stock)
10% Ammonium persulphate 800 1-11
(APS - freshly prepared)
TEMED
Use 1.5 x TBE running buffer
B. 10% Glycerol gel
Glycerol
5 x TBE buffer
dH20
1%C (40% stock)
10% Ammonium persulphate
(APS - freshly prepared)
TEMED
Use 0.5 x TBE running buffer
4.5 g
18 ml
26ml
15 ml
801-11
3ml
6ml
36ml
15 ml
8001-11
2.2. Restriction Enzvme analvsis: Volumes - 20 ml
A. 12% PAA - 5% C gel
5 x TBE buffer 1 ml
dH20 4ml
5%C (40% stock) solution 6 ml
10% Ammonium persulphate 160 1-11
(APS - freshly prepared)
TEMED 80~
Use 1.5 x TBE running buffer
...... ./(cont.)
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Restriction Enzyme analysis (cont.)
B. 12% PAA - 3.4% C gel
5 x TBE buffer 4 ml
dH20 9 ml
3.4%C (30% stock) solution 7 ml
10% Ammonium persulphate 160 J.11
(APS - freshly prepared)
TEMED 80~
Use 1.5 x TBE running buffer
PAA Gel matrix stock solutions:
1. Hex-SSCP:
1% Cross-link (1% C), 40% Stock
Acrylamide
Bis-acrylamide
per 100ml
39.6 g
0.4 g
Mix well and keep refrigerated until needed
2. Restriction Enzyme analysis and general:
A. 3.4% Cross-link (3.4% C), 30% Stock
per 100ml
29 g
1 g
Acrylamide
Bis-acrylamide
Mix well and refrigerate until needed
B. 5% Crosslink (5% C), 40% stock
per 100ml
38 g
2g
Acrylamide
Bisacrylamide
...... ./(cont.)
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5x TBE (Stock): Storage - Room Temperature
0.445M Tris·HCI
0.445M Boric Acid
0.11M EDTA
(pH -8.0)
Gel loading:
Mr
121.1 gIl
61.83 glmol
292.2 gIl
Gel Loading Buffer: Storage - Room Temperature
0.25% Bromo Phenol Blue (w/v)
0.25% Xylene Cyanol (w/v)
15% Ficoll (Type 400) (w/v)
in dH20
per 1000 ml
54.5 g
27.5 g
2.9 g
Denaturing Gel Loading Buffer: Storage - Room Temperature
50 mM Tris·HCI
1 mM EDTA
0.1% Bromophenol Blue
0.1% Xylene Cyanol
80% Formamide (deionized)
Mr
121.1 gIl
292.2 gIl
w/v
w/v
v/v
per200 ml
121.10 mg
7.44 mg
200 mg
200 mg
160 ml
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3. Flow Cytometry (FACS) Analysis of CD45 mutant cells:
1. Isolation of peripheral blood mononuclear cells:
Venous blood was collected in heparinised syringes via 19G x 1 inch needles (Terumo
Europe, Belgium), diluted in an equal volume of phosphate buffered saline a (PBSa) and
slowly layered onto Ficoll Paque (Amersham Pharmacia, UK) in 50ml Falcon tubes. Blood
was centrifuged at 500 x g, 30 mins at room temperature (RT) without brake. Cells were
removed from the interface and washed twice in RPMI 1640 10% Human serum (R10H) or
sterile PBSa at 350-400 x g and resuspended at the required concentration.
2. Cell viability test:
Cell viability was tested using the trypan blue exclusion method. Cells were diluted in an
equal volume of trypan blue solution (Sigma, UK) and live cells, determined by exclusion
of trypan blue, were counted on a haemocytometer (improved Neubauer chamber) viewed
under a light microscope (Leica). The number of cells in the suspension is calculated by
the formula:
No. viable cells in 25 squares x 2 (dilution factor) x 104 = No. cells per ml
3. Cyropreservation of cells
Excess cells were frozen in 90% foetal calf serum (FCS)(PAA Laboratories, Austria), 10%
dimethyl sulphoxide (DMSQ) (Sigma, UK) at -BO°C overnight in a polystyrene box then
transferred to liquid nitrogen for long term storage.
4. Flow cytometric analysis
Flow cytometric analysis of CD45 variant splicing was performed as previously described
(ref). Briefly, 2x105 PBMC were stained with either APC-conjugated CD4 (S3.3, Caltag,
Silverstone, UK) or CD8-APC (clone RPAIT8, Pharmingen, San Diego, CA) along with
FITC-conjugated CD45RA (clone H110, Pharmingen) and PE-conjugated CD45RO (clone
UCHL 1, Pharmingen) mAbs in a single step at 4°C for 20 minutes and washed with PBS,
containing 0.2% BSA. Isotype matched mAbs were used as controls. 10,000 events per
sample were collected on a FACSCalibur (Becton Dickinson, Mountain View, CA) and
analysed using WinMOl software.
Reference: Tchilian EZ, Wallace DL, Imami N et al. The exon A (C77G) mutation is a common
cause of abnormal CD45 splicing in humans. 2001 J ImmunoI166:6144-148.
Stellenbosch University http://scholar.sun.ac.za
182
4. Iron Parameters: Reference values for analyses of volunteer isolates recruited from
the Northwest Province
Parameter Reference value
Serum Iron 10 - 30 Ilmol/L
nee 55 +- 5 urnol/l,
TS% 35+- 5%
Ferritin >8.5 Ilmol/L
Hb females: 12-15 g/dL
males : 14-17 g/dL
TIBC, total iron binding capacity; TS, serum transferrin; Hb, haemoglobin
Reference: Mahan KL, Escott-Stump SE. 2000. Krause's Food, nutrition & diet therapy. io" ed.
W.B. Saunders, London p 1194.
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5. Selection criteria for Xhosa Control samples from the University of Transkei
(UNITRA):
Control subjects were randomly selected from volunteers who responded to the
advertisement:
Healthy people, men or women between the ages of 18 - 45 with no history of TB (now or
before), diabetes, hypertension and psychiatric disorders.
Informed consent was obtained from all volunteers who participated in the study.
HIV status was assessed first by a screening test and positives were confirmed using the
confirmatory test.
1. Screening: Primary screening of blood sample was done by Enzymun-Test, HIV combi
(Roche Immunodiagnostics cat. No. 1877631)
Test principle: ELiSA/2-step sandwich assay, aided by Streptavidin technology
2. Confirmation: Positive samples were confirmed, using IMX HIV-1/HIV-2 111 plus
(Abbot Diagnostic division)
Test principle: Micropartiele Enzyme Immuno assay (MElA) technology
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6. Modified CDC Classification system of HIV infection (similar to WHO classification):
GROUP CRITERIA
Initial infection
2 Chronic asymptomatic
infection
3 Persistent generalized
lymphadenopathy
4 Other diseases:
Subgroup 4 A
Constitutional disease
Subgroup 4 B
Neurologic disease
Subgroup 4 C
Secondary infectious
diseases
Subgroup 40
Secondary cancers
Subgroup 4 E
Other conditions
Patients in this group may be designated as symptomatic seroconversion
or asymptomatic seroconversion. Symptomatic infection may include a
mononucleosis-like syndrome, aseptic meningitis, rash, musculoskeletal
complaints, and haematological abnormalities as well as other clinical and
laboratory findings. Asymptomatic infection may occur with or without
haematological abnormalities.
Patients in this group may be designated as having normal laboratory eva-
luation, specified laboratory abnormalities, or laboratory evaluation
pending or incomplete. Laboratory abnormalities associated with HIV
infection include anaemia, leukopenia, lymphopenia, decreased T-helper
lymphocyte count, thrombocytopenia, hypergammaglobinemia, and
cutaneous anergy.
Patients in this group may be designated on the basis of laboratory evalu-
ation in the same manner as those in Group 2.
Medical evaluation must exclude the presence of other intercurrent illness-
ses that could explain the symptoms.
Patients in this group may be designated as having more than 1 month in-
voluntary weight loss greater than 10% of baseline body weight, diarrhea
lasting more than 1 month, or any combination of these.
Category 1: Central nervous system disorders, including a) dementia,
b) cute atypical meningitis (occurring after infection), and c) myelopathy.
Category 2: Peripheral nervous system disorders, including a) painful
sensory neuropathy, and b) inflammatory demyelinating polyneuropathy.
Category 1: Patients in this group may be designated as having one or
more of the following: Pneumocystis carinii pneumonia, chronic crypto-
sporidiosis, toxoplasmosis, extraintestinal strongyloidiasis, isosporiasis,
candidiasis (esophageal, bronchial or pulmonary), cryptococcosis,
disseminated histoplasmosis, mycobacterial infection with M. avium
complex or M. kansasii, disseminated cytomegalovirus infection, chronic
mucocutaneous or disseminated herpes simplex virus infection, and
progressive multifocalleukoencephalopathy.
Category 2: Patients in this group may be designated as having one or
more of the following: oral hairy leukoplakia, multidermatomal herpes
zoster, recurrent Salmonella bacteremia, nocardiosis, tuberculosis, or oral
candidiasis (thrush).
Patients in this group may be designated as having one of the following:
Kaposi's sarcoma, non-Hodgkin's lymphoma (small, noncleaved
lymphoma or immunoblastic sarcoma), or primary lymphoma of the brain.
Includes patients with clinical findings or diseases not classifiable above,
that may be attributed to HIV infection and/or that may be indicative of a
defect in cell-mediated immunity. Patients in this group may be designated
on the basis of the types of clinical findings or diseases diagnosed, e.g.
chronic lymphoid interstitial pneumonitis.
Reference: Michael NL, Burke OS. Natural Human Immunodeficiency Virus Infection. 1991 Dermatol Clin
9:429-44.
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